luminec corporation - Luminec Life Sciences

Transcription

LUMINEC CORPORATION
A Private Holding Company
__________________________________________
Amnion Animal Sciences Corp. / Luminec Life Sciences Corp.
Bio Veritas Cosmetics Corp. / Amnion FulviGro., Ltd.
Luminec UV Laser Corp. / Luminec Dante Group, Ltd.
Luminec Life Sciences Health & Wellness Clinics / Amnion Animal Health & Wellness Clinics
Chairman & Board of Directors
“For many years the one main goal in my life has been to drive infectious diseases off the face
of this planet.” Steven R. Schutt August 20, 2011
L U M I N E C C O R P O R A T I O N 2014
Amnion Animal Sciences Corp. / Luminec Life Sciences Corp. / Bio Veritas Cosmetics Corp.
Amnion FulviGro., Ltd. / Luminec UV Laser Corp. / Luminec Dante Group, Ltd.
Luminec Life Sciences Health & Wellness Clinics/ Amnion Animal Heath& Wellness Clinics
Bernard William Downs
Chairman Luminec Corporation
Dr. Steven Kushner
CEO Luminec Corporation
Rick Episcopo
Founder, EVP of Luminec Corp., CEO Luminec Life Sciences Corp.
Steven R. Schutt
Founder, Chairman Emeritus of Luminec Corporation
Sallie M. Cassel
Exec. Advisor, International Product Development & Sales
Kristin Comella
Director of Science and Development
Daniel C. Masters, Esq.
Corporate Attorney, Finance & Securities
Thomas J. Kenan, Esq.
Founder
Dr. Robert Weinacker
Director, Business Development Health Care -Military
Dr. Stephen Nickerson
Founder, Dir., Scientific Development Animal Health Care
Dr. Thomas Beatrous
Founder, Dir., Scientific Development Human Health Care
William LoBell
Founder, CEO – Amnion Animal Sciences Corp.
Preston Brawn
Founder, Executive Advisor, International Products & Development CEO
Bruno Bruckner
Founder, Luminec Dante Group, Ltd. , Director
Gary N. Sater
Founder & Director, CFO - (Chief Financial Officer) Luminec Corporation
Albrecht W. Meyer
Founder, Director, International Investment Banking (Germany)
Frank Zhang, Esq.
Founder, Director of Product Distribution – all of Asia, Director
Denis Schinck
International Development & Advisor of Formulations International
Lord Michael Sandberg
Advisor - World Banking
Michael Sandberg, Jr.
Sandberg Family Directorship
Dr. Randall Davis
CEO Luminec Life Sciences Health & Wellness Clinics
Dr. Kenneth Blum – Executive Advisor
Dr. Walter F. Smith - Mr. Gaetano Gravina, SR. CSM.- Maggi Cary, PT, NASM-PES
2015
LUMINEC CORPORATION
Bernard William Downs
Chairman
Luminec Corp.
LUMINEC CORPORATION
Dr. Steven Kushner
CEO Luminec Corporation
Steve Kushner
Resume
Born: 3-7-61 Cleveland, Ohio
Current Residence: Pinellas County, FL - since 1975
Occupation: Nutrition Consultant – includes research and product development
Education
* Graduated Clearwater High School – 1979
* Awarded Doctorate Degree in Nutrition, Donsbach University – 1983
* Dissertation work on Protomorphogen Therapy
* Received license in Massage Therapy – Tampa, FL – 1984
*Studied under Dr. Hazel Parcells in Albuquerque, NM and utilize Dr. Parcells concepts
from 1985 through the present. Dr. Parcells was a nutritional pioneer in the U.S. and
revolutionized nutrition therapy from the 1930’s through the 1990’s when she passed
away at the age of 106.
Healing Modalities
Natural Healing
Whole Food Therapy
Energy Healing
Vitamins, Minerals, Trace Minerals
Herbology
Homeopathy and Cell Salt Therapy
Protomorphogen Therapy
Nano-Technology
Professional Experience
*Product Research and Development since 1982
*Massage Therapist from 1984-1992. Clients have included Congressman Bill Young
and Vice-President George Bush – 1986
*Owned and operated Natural Food Stores, 1986-1990
*Developed line of sublingual bodybuilding products marketed in over 500 GNC’s and
other stores
*Worked with Pyramid Power Products from 1991 to present as consultant. Developed
several food and nutrition products for PPP which have been used in several countries.
*Worked with TrimFast Group from 1998-2001 as a consultant in developing health
products which were sold nationwide in health and chain stores.
*Worked with Genetix Nutriceuticals from 2000 to 2005 as a consultant. Developed
sports nutrition supplements for sale in gyms, health food stores, and on-line.
*Worked part time as a Youth Director with Skycrest Methodist Church from 1998-2005.
Areas of focus included Bible study, religious education, and mission work.
*Work for Nutralab, Inc from early 2005 through 2007 as Vice-President of Research and
Development. Areas of focus included developing unique and innovative supplements
for mass market distribution.
*Work for Iasun, Inc from early 2005 through 2007 as President. Areas of focus include
research and development on specialty cosmeceutical products for both retail and
professional markets domestically and internationally.
*Work for E-Food Safety/Nuvilex from 2006 through 2010 as consultant. Areas of work
include R & D, product development, product design, manufacturing, marketing, and
management. Product development includes both ingestible and topical, including OTC.
*Own and operate ALM R & D, Inc from 2008 through present. Specialize in full
service consulting to companies in the nutriceutical and cosmeceutical industry. Services
provided include R & D, formulation, raw material procurement, manufacturing,
packaging and design, marketing assistance, and technical support.
*Part owner and head of R & D for PuriCorp Labs-2010 through present, specializing in
nutriceutical kits for addiction cessation
*Head of R & D for Euphorix Beverage Company 2011 through present
.
Original Products from Steve Kushner
Mega-Cuts, Mega-Mass: Sublingual bodybuilding formulas
Come Alive: Nutrient dense comprehensive nutritional supplement from whole foods
Super Stay Alive: Anti-oxidant, immune, and energy enhancer
Cygnus Explosion: Carbonated beverage with herbs and protein
Trimfast Energy Bars: Nutrient rich energy bars endorsed by WCW wrestlers
Leptolean: Non-stimulant metabolic enhancer for weight loss
Cortigen: Anti-anxiety, cortisol blocking supplement for weight loss
DEXL-10 Hoodia Thermo: Supplement for weight loss to suppress appetite and increase
metabolism and digestion. Sold in GNC nationwide.
Cinnergen: Liquid whole food supplement for balancing blood sugar. Sold via direct
marketing and mass market retail by promotion on national TV and radio. Cinnergen has
been available in such chains as GNC, Vitamin Shoppe, Kroger’s and Rite Aid.
Fulvium: Unique multi-mineral/trace mineral supplement employing a rare deposit of
Fulvic Compounds to enhance absorption.
Talsyn-CI: Clinically proven organic based scar cream sold nationally and
internationally. Talsyn-CI is sold through professional offices
Talsyn Skin Care: Includes ageless cream, cleanser, moisturizers, and toners
Arnica Mist: Topical solution with proprietary technology for alleviating bruising and
trauma to skin.
PuriDone Multi-Vitamin-Mineral Liquid Supplement: Utilizes nano-technology to
deliver essential vitamins, minerals, and herbal foods for maximum benefits. Clinically
researched to provide benefits for withdrawal from drugs. Available on-line through a
national advertising campaign, and soon to be available in Canada and EU.
Launching in Jan. 2013 is the next kit in the line for alcohol cessation and will be sold
domestically and abroad via internet direct sales.
Euphorix-Single shot beverage/supplement to improve mood and mental energy
List of Notable People who have used or are using products from Steve Kushner
Please note: These names are not paid endorsements and cannot be used for any
promotion. They are listed here for informational purposes only. In relaying this to
anyone else, the reference must be stated as “pro athletes”, “celebrities”, “heads of
state”
Shaquille O’Neal
Dominique Wilkins
Scottie Pippin
Terry Cummings
Hakeem Olajuwon
Craig Hodges
Sean Elliot
Charles Smith
Khaliah Ali
Serena Williams
Venus Williams
Butch Reynolds
John Mackey
Roy Disney
Michael Milken
Rupert Murdoch
Several Heads of State from the Middle East and Africa
Sinbad
LUM IN EC CORPORATION
Amnion Animal Science Corp. / Luminec Life Sciences Corp. / Bio Veritas Cosmetics Corp.
Amnion Health & Wellness Clinics / Amnion Animal Heath & Wellness Clinics
LUMINEC CORPORATION
Mr. Rick Episcopo, Founder
Executive VP Luminec Corp.
CEO Luminec Life Sciences Corp.
Luminec Corporation
Mr. Rick Episcopo
Executive VP Luminec
LUMINEC CORPORATION
Steven R. Schutt
Founder
Chairman Emeritus Luminec Corporation
Developer/Biochemist/Patentee & Creator of
Tri-Amino and Tri-Amino Fulvate (TAFA400) Formulas
and
Ultraviolet Blood Irradiation
LUMINEC CORPORATION
Sallie M. Cassel
Executive Advisor, International Product Development & Sales
SALLIE M. CASSEL
Escondido, CA, 92026, Cell: 858-382-1697
[email protected]
Energetic and versatile marketing professional with a strong track record of launching products in new/emerging
markets and successfully driving teams forward with an infectious, positive ‘can do’ attitude that thrives on new
challenges. Expertise in:
•
Genomics, Proteomics and Epigentics
•
•
Capital Equipment, reagents, software and services
•
Developing and implementing worldwide sales
training programs for both reps as well as distributors
Change Management
•
Product commercialization/launch strategies for
hardware, reagents, software and services
•
Developing execution oriented teams
EXPERIENCE:
SKINCENTIAL SCIENCES, San Diego, CA
2013 - 2014
Start-up biotech focused on commercializing novel technology for the skincare market. Product roadmap encompasses
multiple market sectors including: medical device, cosmetic as well as diagnostic.
Sr. Director of Marketing / Corporate Secretary
Joined the company as part of the initial core team with primary focus on the rapid commercialization of a skincare
product for the treatment of seborrheic keratoses. Complete commercialization plans including: market needs, product
definition, clinical trials, manufacturing and sales/marketing strategy were all developed prior to launch.
•
•
•
•
•
•
•
Spearheaded product commercialization strategy to align with FDA regulatory requirements for a cosmetic product
and successfully achieved 1st product launch in 12 months.
Developed a comprehensive marketing plan that included corporate brand and product brand strategy as well as
product launch plans to both physicians as well as consumer.
Defined product line strategy through competitor analysis and direct customer interviews that created customer
segmentation, product positioning, price points and product packaging options.
Managed key vendor relationships – eg, 3rd party manufacturers.
Responsible for developing and delivering Investor presentations.
Responsible for finances, budget oversight and Corporation needs.
Provide corporate oversight to funding activities.
MERCK (EMD) MILLIPORE CORPORATION, MA
2006 – 2012
Life science leader providing cutting edge technologies, tools and services for bioscience research and biopharmaceutical
manufacturing and a strategic partner to customers who confront challenging human health issues.
New Business Initiative Leader, Epigenetics, (2011 – 2012)
Selected to lead the first “New Business Initiative” for EMD Millipore.
•
•
•
•
•
•
Developed a 5 year strategy that focused on growth through strategic product line extensions, cancer diagnostic
development and leapfrog solutions that repositioned the business for larger, higher growth markets.
Member of the AACR Cancer Epigenome Taskforce
Established and managed a Scientific Advisory Board developed from key thought leaders across Epigenetics
Working with Worldwide sales developed a campaign that reversed a prior year trend of losses in new/small
accounts. This campaign generated a growth in 3Qs of $500K sales vs a PY loss of $300K.
Doubled the number of sales leads generated in prior years through cost effective, activities including:
o Revamping of HTML titles that resulted in 40% increase in products landing on 1-3 pages of search results.
This improved organic search enabled a 20% spend reduction in paid search terms.
o Effective and targeted email campaigns that routinely led the Reagents division with highest CTR
and open rate.
Provided monthly Marketing forecasts for Supply Chain S&OP activities.
Director of Antibodies and Immunoassays, (2006 – 2011)
Recruited to develop business practices/strategies/teams to enable sustainable business growth from the Antibody and
Immunoassay portfolio which consisted of >10K PNs and revenues between $50-100M. Areas of focus included
Neuroscience, Stem Cell, Cancer, Cell Structure and Epigenetics
•
•
•
Introduced new segmentation and processes to the portfolio that increased sales success of new products by over
25%.
Drove awareness and innovation in the key area of Epigenetics that resulted in the Frost and Sullivan Epigenetics
Market Share Leadership Award in 2010.
Refined current OEM/Bulk selling strategy to maximize revenue and minimize inventory risks to achieve a growth in
excess of 50%.
•
Launched a multi-stage gated Product Development Process with defined deliverables, timelines and Product
Guidelines that condensed the average product launch cycle by >30%.
•
Redefined product rationalization business rules to provide consistent/sustainable maintenance by the organization
and to minimize historical BO issues.
•
Partnered with R&D to develop a process to define 5 market-leading segments (Epigenetics, Signaling,
Neuroscience, Cancer and Cell Structure) and created 3-5 year product roadmaps for each segment.
•
Created a sustainable process to effectively evaluate hundreds of scientific leads that increased first year revenue
sales of products by 30%.
•
Developed a highly productive and aligned R&D/Marketing team of 50 people that consistently met new product
launch goals of >700 PNs/year for 3 years running.
•
Strengthened the marketing team through the development of mentoring program for junior staff members in which
they were exposed to different managers and facets of the business for 1-2 years.
•
Selected Temecula Site Leader by senior management to lead a cross-function leadership team to drive change
initiatives,
LIFE TECHNOLOGIES (IVGN) Carlsbad CA
2004-2006
Named 9th most innovative company in the world with biotechnology tools solutions in the areas of research, applied
and medical sciences and >$3B worldwide sales
Business Area Manager (Director of Marketing)
Joined IVGN to scope and develop product strategies around the newly emerging field of Epigenetics that would enable
IVGN to be a dominant market player. Responsibilities grew to include other market sectors as well as OEM and
Corporate Development roles.
•
Epigenetics (2004-2006)
o Accessed market potential for epigenetic cancer diagnostics and accessed market determined unmet needs,
size, growth and competitive landscape.
o Coordinated activities across multiple business sectors (i.e. Stem Cell, Toxicology, Gene Expression, ect…)
o Rapid execution and launch of first miRNA array in less than 1 year.
o Established collaborations with key thought leaders and corporations.
•
Oligonucleotides (2005-2006)
o Launched new product offering, plate based oligos, for Life Technologies that enabled further expansion into
high throughput genomic labs.
o Developed a market strategy to drive sales of a commoditized product that resulted in a 100% volume growth
over PY quarter.
o Revitalized the sales force through the generation of an Oligo Newsletter and targeted training program.
o Launched a Preferred Oligo Provider Program that included necessary sales tools and customer
communications that enabled the consolidation of customer spend across a site to effectively lock out
competitor penetration.
•
Mammalian Expression Products (2005)
o Utilizing low cost web channels and targeted field messaging was able to grow the revenue 124% worldwide
over prior year.
•
Gene Expression OEM and Corporate Development (2006)
o Drove growth of OEM sales for the Gene Expression products in both bioresearch as well as diagnostic
markets.
o Defined key market trends, customer targets and establishment of sales force operating processes.
o Support and drove the execution of large customer projects through a cross-functional team comprised of
members from research, manufacturing, regulatory and marketing.
SEQUENOM, San Diego CA
2000- 2004
A molecular diagnostics testing and genetics analysis company with >$50M in worldwide sales, 150 employees. Was
acknowledged by Deloitte and Touche's "Technology Fast 50 Program" as the second- fastest growing company in San
Diego in terms of revenues.
Sr. Product Marketing Manager / WW Customer Relations Manager
Exercised primary responsibility for all customer communications, support and feedback for product needs. Drove
development, product management and customer support of a rapidly growing product line with instrument prices
ranging from $320K to $1.2M. Worked in partnership with worldwide sales and customer support to achieve revenue
goals. Supported key strategic thought leaders, international customers and distributors that included Francis Collins,
Samsung Hospital as well Hitachi distribution.
Marketing and Marketing Communications Manager
• Successfully drove and launched 9 new products to market (5 of which were completed in 8 months) through the
introduction of a product commercialization process with a multi-functional team approach.
• In partnership with Sales, developed and implemented a worldwide strategic and tactical plan for the
commercialization of the entire Sequenom product line - instrumentation, consumables and software.
• Created and managed marketing activities to budget.
• Developed product branding and positioning, launch plans and necessary sales literature and tools.
• Monitored market trends, competitive product activities and defined future product needs.
• Coordinated support for both international and domestic customers, field organization, distributors and commercial
collaborations.
• Maintained product inventory and prepared sales forecast.
Worldwide Customer Relations Manager
• Full P&L responsibility.
• Successfully developed/executed a plan to convert Customer Support to a Profit Center through the establishment
of Service Contract Processes and Pricing Strategies.
• Captured an additional 3% per customer through the introduction of a sales commission and bonus plan to the
Customer Support Team.
• Established new WW processes that included a Product Champions program to ensure product training of support
staff, identification and feedback of product issues as well as to enable performance goals and metrics for
Customer Support staff.
• Succeeded in improving Customer Support Response times through implementation of an extensive Six Sigma
project.
• Managed high profile customer accounts to ensure satisfaction, system utilization and renewal of service contracts.
• Supervised a group of 26 scientists and field service engineers in multiple offices around the world.
Beckman – Coulter Inc., Fullerton, CA
1997- 2000
Wholly owned subsidiary of Danaher, that develops, manufactures and markets products that simplify, automate and
innovate complex biomedical testing with >$3B in worldwide sales
Project Manager/Research Scientist
Recruited to launch and market a new Genetic Analysis Product line that included: multicapillary DNA sequencer,
biorobotics for Genetic Analysis applications, Differential Display for Gene Expression and DNA synthesis.
•
•
•
•
•
Created and implement product launch plans for Beckman’s first genetic analysis product, a DNA capillary
sequencer targeted at genome sequencing.
Financial responsibilities to maximize product line profitability through price setting and promotion establishment.
Generated annual sales volume, unit budgets and current forecast outlooks.
Directed sales support activities including: generation of sales tools, competitive analysis, competitive strategy
implementation, pricing, product training and coaching.
Developed instrument leasing program to provide profitable alternatives to instrument purchases.
R&D EXPERIENCE
GENETIC BIOSYSTEMS, (Formerly AMBIS, Inc ) San Diego, CA
Venture capital funded company focused on the development of an ultra-thin, personal DNA Microsequencer
Molecular Biology Research Manager
Research Scientist
Recruited to lead development of a near IR analytical instrument for the high-speed separation of DNA sequencing
fragments in ultra-thin polyacrylamide micro-gels and innovative applications for near IR fluorescence detection of
DNAs. Successfully took the company from a capability concept to actual working beta units.
•
•
•
Collaborated with outside companies to develop ancillary reagents for the product line.
Interacted with potential customers to identify customer needs and to identify product improvement opportunities.
Developed and maintained research budget to align critical R&D developmental milestones with corporate financial
goals.
HOLOGIC, (Formerly Gen Probe) San Diego, CA
Gen-Probe, Inc., a subsidiary of Hologic Medical Devices, is a leader in the area of diagnostic DNA probe kits with
>$500M in worldwide sales
Senior Research Associate
• Conducted a study of various cloning techniques to identify method that would provide the highest efficiency when
used with specific types of targets.
MOLECULAR BIOSYSTEMS, San Diego, CA
Molecular Biosystems, Inc., a subsidiary of Alliance Pharmaceutical, focused on diagnostic DNA probe kits and
intravenous, echocardiographic imaging devices
Research Associate II
• Conducted protein conformational studies on AlbunexTM for 510K device submission.
• Development of short DNA probe diagnostic assays for HPV, CMV HBV and HSV.
• Development of an internal HPV assay control system that enabled non-PCR target amplification.
EDUCATION
Bachelor of Science, Biology, San Diego State University, San Diego CA.
Leadership Breakthrough Training – Rapport Leadership International
Leadership and Teamwork – Center for Creative Leadership
Communication with Diplomacy and Tact – Padgett Thomson
Managing the Difficult Business Conversation – Harvard Negotiation Program
Crucial Conversations - Traci Chevraux
Advanced Selling Skills – Brian Tracy
Strategic Conceptual Selling – Miller Heiman
World Class Sales Skills for Sales Pros – C.E.O Training Int.
Consultative Selling Skills (SPIN) – Huthwaite
Product Management – Univ. of Wisconsin, Madison
How to Develop a Workable Marketing Plan – Univ, of Wisconsin, Madison
Tactical Marketing Skills and Implementation – Univ. of Wisconsin, Madison
Pricing Strategies and Tactics – Univ. of Wisconsin, Madison
PUBLICATIONS, PRESENTATIONS and PATENTS
PUBLICATIONS AND PRESENTATIONS
Rice S.M., Jones D.O., Browning C.K., Cunningham L.A., and Guttman A.. "New Advances in Separation of DNA
Using Ultra-Thin Gels." Presented at the Seventh Fredericks Conferance on Capillary Electrophoresis. Frederick,
Maryland (1996).
MacDonell M.T., Rice S.M., and Roszak D. "Minimization of Pore Diameter in Polyacrylamide by Cross-linker
Concentration Is Temperature Dependent." Advances in Life Sciences: Molecular Biology 12:47-48 (1993).
Marich J1, Pontsler A.V1., Rice S.M1., McGraw K.A., and Dubensky T.W. "The Phylogenic Relationship and Complete
Nucleotide Sequence of Human Papillomavirus Type 35." Virology 186:770 (1992).
Dubensky T.W., Lauderdale V.R., Marich J.E., Podell S., Pontsler A.V., Rice S.M., Ruth J.R. and Jablonski E.G..
"Application of Non-isotopic Oligonucleotide Probes." Clinical Chemistry (37)611-612 (1991)
Dubensky T.W., Lauderdale V., Marich J., Podell S, Pontsler A.V., Rice S.M., Ruth J.L., and Jablonski E.G.
"Application of Non-isotopic Oligonucleotide Probes: Presented at the Fifth San Diego Conference on Nucleic Acids:
New Frontiers, 1990.
Barnhart J., Levene H., Villapando E., Maniquis J., Fernandez J., Rice S., Jablonski E., Gjoen T., and Tolleshaug H.
"Characteristics of Albunex: AirFilled Albumin Microspheres for Echocardiography Contrast Enhancement:
Investigative Radiology 25 (Supplement1), 1990.
1
Equal Contributors
ABSTRACTS
Rice S.M., Burke J, and Guttman A." Novel Sample Loading with Ultra-thin Gels." (1997) Fourth International
Conference on Automation in Mapping and DNA Sequencing, Heidleburg, Germany.
Rice S.M., Burke J., and Guttman A. "DNA Microsequencer. The Challenge of Sample Loading." (1996)
ILMAC/MicroTAS Basel, Switzerland.
Marich J., Pontsler A.V., Rice S.M., McGraw K.A., Clark P.R., Fleurbaaij G.A., and Dubensky T.W. "Sequence Analysis
and Propagation in Cells of Human Papillomavirus Type 35 DNA." (1991) Papillomavirus Workshop, Seattle,
Washington.
Pontsler A.V., Clark P.R., Rice S.M. Lauderdale V.R., Dubensky T.W., and Marich J. "The Specific Detection and
Typing of Human Papilloma Virus (HPV) in Cervical Smears Using and Automated in situ Hybridization Format and
Non-isotopic Oligonucleotide Probes." (1990) Papillomavirus Workshop, Germany.
Barnhart J., Levene H., Villapando E., Maniquis J., Fernandez J., Rice S., Jablonski E., Gjoen T., and Tolleshaug H.
"Characteristics of Albunex: Air Filled Albumin Microspheres for Echocardiography Contrast Enhancement." (1989)
Presented at Contrast Media Research Symposium, Sydney, New South Wales, and Hamilton Island, Australia.
Barnhart J., Rice S., Smeltzer D., Cerny C., Bakan G., and Jablonski E. "Characteristics of Albunex: Air-Filled Albumin
Microspheres for Echocardiography Contrast Enhancement: (1989) American College of Cardiology, Anaheim,
California.
Photomicrographs. Biotechniques 5:212 (1987).
PATENTS AND DISCLOSURES
"System for PH-Neutral Stable Electrophoresis Gel"
Updyke T., Englehorn S., Rice S., Moi M., Raab R., Alpenfels W.
US patent filed
"Membrane Loader for Gel Electrophoresis."
Rice S., Browning C., Burke J., Nguyen L.
US patent 5,972,188
"A Novel Method for Gel Electrophoresis Loading"
Rice S.
US patent disclosure
"Replicative DNA Sequencing"
Rice S.
US patent disclosure
"A Simple Enzymatic Method for Sequencing Double-Stranded DNA"
ASSOCIATIONS
Healthcare Business Women’s Association (HBA)
Diagnostic Marketing Association (DxMA)
LUMINEC CORPORATION
Dr. Kristin Comella
Chief Scientific Officer and Board
Member of Bioheart, Inc.
Ms. Comella has over 15 years’ experience in corporate entities with expertise in
regenerative medicine. She was recently named number 24 according to Terrapin’s list
of the Top 50 Global Stem Cell Influencers. Ms. Comella has pioneered a variety of
stem cell therapies including cord blood derived cells, bone marrow cells, muscle cells
and adipose cells for use in many different applications. She has developed a wide
range of regenerative products and techniques that have been successfully
implemented into the clinic. She also led the team that gained the first ever FDA
approval for clinical trials using a combined cell and gene therapy product.
Ms. Comella has been a member of the Bioheart Inc. senior management team since
2004 and is currently serving as the Chief Scientific Officer and board member.
Bioheart is a publically traded company focusing on the discovery, development and
commercialization of autologous cell therapies for the treatment of degenerative
diseases.
Since joining Bioheart, she has played a major role in managing the product
development, manufacturing and quality systems of cellular products. In addition,
Ms. Comella is currently and actively serving on multiple boards in the stem cell arena.
She was co-founder and Chief Executive Officer of Stemlogix, LLC for veterinary
medicine.
Ms. Comella has years of cell culturing experience including building and managing
the stem cell laboratory at Tulane University's Center for Gene Therapy. Previously,
she worked as a research engineer for Osiris Therapeutics developing stem cell
therapies for osteoarthritis.
Ms. Comella holds an M.S. in Chemical Engineering from Ohio State University and a
B.S. in Chemical Engineering from the University of South Florida.
LUMINEC CORPORATION
Kenneth Blum
Executive Advisor
CURRICULUM VITAE
NAME:
Kenneth Blum, Ph.D.
DATE OF BIRTH:
August 8, 1939
PLACE OF BIRTH:
Brooklyn, NY
ADDRESS:
Department of Pharmacology (retired Full Professor)
Chief Division of Substance Abuse
University of Texas Health Science Center
San Antonio, Texas, 78284
Department of Biological Sciences (Former-Research Professor Adjunct)
University of North Texas
Denton, Texas 76203
Department of Physiology & Pharmacology (Adjunct Full Research Professor)
Wake Forest University School of Medicine
Winston-Salem –North Carolina 27157
LifeGen Inc. (Co-Founder Chairman of Board & Chief Scientific Officer)
San Diego, California
Synaptamine Inc. (Founder and President)
Austin, Texas
Current:
Research Professor (Volunteer)
Department of Psychiatry
University of Florida
College of Medicine
McKnight Brain Institute
Gainesville, Florida
Research Professor (Adjunct)
Global Integrated Services Unit University of Vermont
Center for Clinical & Translational Science,
College of Medicine, Burlington, VT.
Chairman of the Board & Chief Scientific Officer
LifeGen, Inc. Lederach Pennsylvania
Managing Partner, Reward Deficiency Solutions, LLC
San Diego, California
Managing Partner, HapiGen, LLC San Diego, California
Dominion Ambassador of Molecular Neurobiology,
Dominion Diagnostics, LLC North Kingstown, Rhode Island
Chief Science Officer
G&G Health care Services LLC
North Miami Beach Florida
Scientific Director
Path Research Foundation
New York, New York
Emeritus Faculty
Center for Genomics and Applied Gene Technology,
Institute of Integrative Omics and Applied Biotechnology (IIOAB)
Nonakuri, Purba Medinipur, West Bengal, India.
HOME ADDRESS:
101 Colorado Street (#2503)
Austin, Texas, 78701
TELEPHONE
Office:
Foundation
E-mail :
[email protected]
EDUCATION:
Columbia University
B.S., Pharmacy (1961)
619- 890-2167
212- 213-0447
New Jersey College of Medicine
M.S., Medical Science (1965)
New York Medical College
Ph.D., Pharmacology (1968)
Southwest Foundation for Research and Education
Post-doctorate, Research in Psychopharmacology (19681970)
Irving Geller, Mentor
University of Colorado, College of Pharmacy, Boulder, Colorado
Pharmacogenetics Workshop
Gerald McClearn, Mentor Fellow, Summer of 1977
ACADEMIC APPOINTMENTS:
8’/2009 -present
Volunteer Full Professor
Department of Psychiatry
McKnight Brain Institute
University Of Florida
College Of Medicine
Gainesville, Florida.
10/2012-present
Research Professor (Adjunct)
Global Integrated Services Unit University of Vermont
Center for Clinical & Translational Science,
College of Medicine, Burlington, VT.
1/2005- 2009
Adjunct Full Research Professor
Department of Physiology & Pharmacology
Wake Forest University School of Medicine
Winston –Salem, North Carolina
6/96 - 6/97
Adjunct Professor, Department of Behavioral Science
School of Public Health,
University of Texas Health Science Center
Houston, Texas
9/96 - Present
Adjunct Professor, Department of Biological Sciences
University of North Texas, Denton, Texas
6/89-6/96
6/87- present
Full Professor, Department of Pharmacology
Chief, Division of Addictive Diseases
Director, Laboratory of Pharmacogenetics
The University of Texas Health Science Center at San Antonio
San Antonio, Texas
Path Research Foundation (Scientific Director and member of
Board)
New York, New York
9/75-5/83
Professor and Chief
Division of Substance and Alcohol Misuse
Department of Pharmacology
San Antonio, Texas
9/75-8/83
Associate Professor and Chief
Division of Substance and Alcohol Misuse
San Antonio, Texas
11/71-8/75
Assistant Professor
San Antonio, Texas
1/70-11/71
Assistant Foundation Scientist
Clinical Sciences Division
San Antonio, Texas
2/68-2/70
Associate Research Scientist
Division Biological Growth and Development
San Antonio, Texas
9/66-1/68
Graduate Student Instructor to Graduate Nurses
New York Medical College
New York, NY
9/64-9/65
Research Pharmacologist
Neuropharmacology Section
U.S. Vitamin and Pharmaceutical Corp.
Yonkers, NY
9/61-6/63
Laboratory Instructor
Columbia Univ. College of Pharmacy
New York, NY
ADMINISTRATIVE EXPERIENCE:
The University of Texas Health Science Center at San Antonio, San Antonio, TX
Chief, Division of Drug and Alcohol Abuse
Career teacher in drug abuse (sponsored by National Institute on Drug Abuse)
Course Coordinator for graduate students Advanced Pharmacology I (Basic
Principles) and Advanced Pharmacology II (Neuropsychopharmacology)
Course Section Leader for medical and dental students
Head, Graduate Dental Pharmacology
Seminar Program Director Pharmacology and Psychiatry Drug Abuse Lecture
Series
Course Director Neuropharmacology Course (1993)
Departments of Pharmacology and Anatomy
Chairman, Seminar Program
Neuro-Genesis Inc.
Chief Scientist
Executive Committee Member (owner of Stock current)
Antioch College/West, San Francisco, CA
Adjunct Clinical Supervisor Graduate Program in Psychology
Southwest Foundation for Research and Education, San Antonio, TX
Assistant Chief Pharmacology Laboratory
United States Vitamin and Pharmaceutical Corporation, Yonkers, NY
Assistant Head Neuropharmacology Laboratory
Pergamon Press of Oxford, England
CoFounder and EditorinChief Substance and Alcohol Actions/Misuse
International Society on Substance and Alcohol Abuse
Acting President and CoFounder (planning phase)
National Foundation on Addictive Diseases
President and CoFounder
Lexicon (Boulder, CO)
Chairman, Scientific Advisory Board
Universal Sales Corporation (Las Vegas, NV)
Scientific Advisory Board
Princeton Associates for Total Health
Scientific Director
Pharmavene Inc. (Gaithersburg, MD)
Scientific Consultant
Path Medical Foundation- Scientific Director
Excel Treatment Program – Scientific Director (resigned)
WorldNet Consultant
Named EDITOR in Chief Journal OF ADHD and Related Disorders (Marcel Decker) 2003 inactive
Editor-in-Chief of OMICS Group-Genetic Syndromes & Gene Therapy (2012-present)
C0-Editor-In-Chief IIOAB/BMC –Advances in Omics and Applied Bio-technology
(2012)
Editor-in-Chief Geentic Disease & Genetic reports (2012-present)
COMMITTEE EXPERIENCE:
APPOINTED:
Promotions Committee
Graduate Executive Committee
Laboratory Animal Care Utilization Committee
Ad Hoc Member, Special Committee on Drug and Alcohol Abuse
International Relations Committee
Texas Medical Association
Ad Hoc Member Special Committee on Drug and Alcohol Abuse
Bexar County Medical Society
Ad Hoc Member Disabled Physician Committee
Texas Research Society on Alcoholism
Chairman Hanging Bottle Research Project at San Antonio, TX
European Research Society –Grant Review Board
ELECTED:
Publication Committee Alcoholism: Clinical and Experimental Research
Nomination Committee Research Society on Alcoholism
Scientific Advisory Committee International Neurotoxicology Congress, Italy
Council Member Gordon Research Conferences
Chairman Steering Committee for Program on Gordon Research Conferences on
Alcohol (1978 & 1982)
Chairman, First International Congress on Neurogenetics of Alcoholism
Chairman, Fifth World Congress on Biological Psychiatry, Alcoholism, Florence, Italy
Chairman, Psychoneurogenetics, Gordon Research Conference
BUSINESS EXPERIENCE:
ZEPHRA CORPORATION- Vice President Research & Development
PHARMAGENE INC. - Chairman & Vice President Research & Development
MATRIX TECHNOLOGIES, INC. Chief Scientific Consultant
1899 LIMITED LIABILITY CORPORATION- Manager
CYBERPHARM INC. Chairman, President & CEO
PHARMABYTE INC. Chairman & President
PHARMACOGENOMICS INC - Chairman, President & CEO
NEURECOVERY INTERNATIONAL INC. CHAIRMAN & CEO
PSYCHIATRIC GENETICS CORPORATION - PRESIDENT & CEO
NUTRIGENOMICS,INC.- Chairman, President &CEO
ZIG ZIGLAR CORPORATION- Scientific Advisor
REXAL SHOWCASE INTERNATIONAL- Scientific Advisor
WEIDER INTERNATIONAL- Scientific Consultant
PHARMAVITE INC. – Scientific Consultant
BIOZONE LABORATORIES INC. Scientific Advisor
NUTRIGENOMICS INC.- President &CEO
DOCBLUM, INC. - Chairman
BASIC BOOKS PUBLISHING – Scientific Advisor
SALUGEN INC. Vice Chairman of Board and CSF (resigned)
LIFEGEN, INC. Chairman of Board
SYNAPTAMINE INC. President & CEO
G&G Health Care Services, LLC- Chief Science Officer
DOMINION DIAGNOSTICS- Scientific Advisor
MALIBU BEACH RECOVERY CENTER- Chief Neuroscience advisor
SYMPOSIA ORGANIZER:
INTERNATIONAL:
1979
Organizer and General Chairman, Gordon Research Conference "The Chemical
and Biological Mechanisms in Response to Alcohol" (Cochairmen: D. Lester and
E.P. Noble)
1979 Scientific Advisory Organizing Committee
"International Congress of
Neurotoxicity" Varese, Italy
1982 Organizer and General Chairman, Gordon Research Conference "The Chemical
and Biological Mechanisms in Response to Alcohol" (Cochairman: E. P. Noble)
1985 Organizer and General Chairman "First World Congress on Biogenetics of
Alcoholism" Republic of Germany (Planning phase). Cosponsored Germany
Council on Alcohol and Addictions
1989 Organizer and General Chairman "First International Congress on Neurogenetics
of Alcoholism" Italy
1990 Cochairman and organizer "Fifth World Congress on Biological Psychiatry/
Alcoholism" Florence, Italy
1991 Cochairman and organizer "Fourth Congress of Fachverband Sucht E.V."
Heidelberg, Germany
Cochairman and organizer "Sixth Annual Pacific Institute of Chemical
Dependency", Honolulu, Hawaii
Cochairman and organizer "Fifth World Congress of Biological Psychiatry
Symposium", Florence, Italy
1997- Chairman, “Molecular Psychiatry” Eleventh Congress of Biological Psychiatry
Symposium
Nice , France.
1999- Chairman “Molecular Genetics and Electrophysiological Aspects” AAPP Society
Meeting,
British Columbia
2001Key note address to SOS Euro Conference, Brussels
2001-2010 Over 50 talks worldwide.
2010 Plenary Talk at Foundations Conference on Addictions, San Diego, California ,
April 2012
2011- Keynote- Holistic Addiction Conference-Miami Beach Florida, March 2011.
2012- Plenary Speech at Summer of Love Conference, San Francisco CA June 2012
2012 Keynote – Omics-Addiction Research & Therapy Conference, Las Vegas
2012 Keynote- Omics –Genetic Syndromes & Gene Therapy Conference, San Antonio,
Texas
Pain
2012- “Best Abstract Award”- 11th Presented at America Society of Anesthesiology &
Meeting Miami Beach-November 16th, 2012.
NATIONAL:
1976 Organizer and Chairman "Neurochemical and Behavioral Mechanisms on
Alcohol and Opiate Dependence" National Drug Abuse Conference, NY
1977
1979
1990
1991
Organizer and Chairman "Symposium on Putative Role of Isoquinoline
Alkaloids in Alcoholism" San Diego, CA
Organizer and Chairman "Chemical Mechanisms of Drugs on Addiction"
National Drug Abuse Conference New Orleans, LA
Cochairman "A National Dialogue on the Intervention and Treatment of Drug
Abuse" Princeton, NJ (Cochairman: E. Braverman)
Chairman "New Jersey Conference and Cocaine Symposium" New Jersey
Chairman "Division of Addictive Disorders Research Symposium" New
Orleans, LA
Chairman "Annual Southwestern School for Behavioral Health Studies" Tucson,
AZ
Chairman "Virginia Association of Alcoholism of Drug Abuse Counselors
Annual Meeting " Virginia
Copresenter "American Society of Addiction Medicine" Washington, DC
Chairman "NIDAARC Seminar" Baltimore, MD
Grand Rounds "Veterans Affairs Medical Center" San Francisco, CA
Chairman "Neuroscience Society of New Orleans" New Orleans, LA
1980-1999 Numerous symposium and seminar presentations
2001
SYNDROME”
Chairman
of
the
first Conference
on
“REWARD
DEFICIENCY
San Francisco, Ca.
2001 National Association of Substance Abuse Counselors – Keynote –San Diego
LOCAL:
1969 Organizer and Chairman "San Antonio Conference on Drug Abuse" (Attracted
international and national speakers)
1971 Organizer and Chairman "San Antonio First Community Symposium on Drug
Abuse"
1975 Chairman and Organizer "San Antonio Drug Abuse Action Program, Resources
for Survival"
1979 Course Director and CoOrganizer Minisymposium on "Herbs, Consciousness
and Health" San Antonio, TX
1979 Course Director and CoOrganizer "International Herbal Conference" San
Antonio, TX
1979 CoOrganizer "Holistic Health Festival" San Antonio, TX
1982 Organizer and General Chairman "Biomedical Consequences of Alcohol Use
and Abuse" sponsored by March of Dimes and Texas Commission on
Alcoholism
1991 "American Group Psychotherapy Association Annual Meeting" San Antonio,
TX
1992 Seminar Trinity University San Antonio, TX
"Scientific Inquiry Class" Incarnate Word College San Antonio, TX
Seminar "Gulf Pines Hospital" Houston, TX
19832008 Numerous speaking engagements throughout the state
PEER REVIEWER EDITORIAL ADVISORY BOARDS (ELECTED):
1976 Present
1976 1983
Journal Psychoactive Drugs
Clinical Toxicology
1979 1985
1985 Present
1985 1987
1987 1991
1987 Present
2006-Present
2007- Present
2007-Present
2008-Present
2009-present
2009-present
2009- Present
2010-Present
2012-Present
2012-present2012-Present
2011 –Present
2012-Present
2013 Present
2013 –Present
2013 –Present
2012-Present
Founder and EditorinChief, Substance and Alcohol Actions/
Misuse (Elsevier)
Functional Neurology
Alcohol and Drug Research
Addictions, Alert News Letter
Biogenic Amines
Journal of Trends in Applied Sciences Research
Gene Therapy & Molecular Biology
Medical Genetics
Associate Editor of Research Notes (BMC)
Theoretical biology & Medical Modeling
Advances in Therapy
Journal Of Obesity (open access)
IIOAB Journal
IIPOAB Letters
Journal of Genetic Syndromes & Gene Therapy
Journal of Genetic Diseases and Genetic Reports
Functional Foods in Health and Chronic Diseases
World Class Cases
Behavioral Addictions
Journal of Addiction & Research Therapy
Frontiers in Neuroscience
Science Impact Journal
AD HOC REVIEWER FOR SCIENTIFIC JOURNALS:
Psychopharmacology
Life Sciences
Pharmacology, Biochemistry and Behavior
Alcoholism: Clinical and Experimental
Neuropharmacology
Science
Biochemical Pharmacology
European Journal of Pharmacology
American Journal on Drug and Alcohol Abuse
Clinical Toxicology, Special Guest Editor, Issue on Neurotoxicology, 1982
Journal of Pharmacy and Pharmacology
Journal Neuroscience
Research Communications in Chemical Pathology Pharmacology
Nature
Brain Research
Brain and Behavioral Science
Research Communication in Substance Abuse
Neuropsychopharmacology
Quarterly Journal Studies on Alcohol
Toxicology
Pharmacology
Alcoholism: Clinical and Experimental Research Alcohol (Publications Committee)
Drug and Alcohol Dependence
Alcohol and Drug Research
Alcohol
British Journal of Pharmacology
Journal American Medical Association (JAMA)
International Journal of Addictions
New England Journal of Medicine
Biological Psychiatry
Neuropsychogenetics
American Journal of Psychiatry
Archives of General Psychiatry
Pharmacogenetics
American Journal of Medical Genetics
Mammalian Genomics
Neuroendocrinolgy
Progress in Brain Research
Nutrition
AGE
Frontiers of science
Nursing and Neurobiology
Genetic Disease &Disorders & Genetic Information
PLOSONE
JAMA
AD HOC GRANT REVIEWER:
1979 1980
Ad Hoc Peer Reviewer, National Council on Alcoholism, Grants in Aid
Program
1980 1981
Ad Hoc Peer Reviewer, Veterans Administration, Washington, D.C.
1991 1992
Ad Hoc Reviewer, Australian Grant Administration
2007
Ad Hoc European Research Society
MEMBERSHIP IN PROFESSIONAL AND TECHNICAL SOCIETIES:
INTERNATIONAL:
1974
Brain Research Society of Great Britain (Honorary membership)
1977
International Platform Association
1981
International Biomedical Research Society on Alcoholism (Charter
member)
NATIONAL:
1965
1969
1970
1970
1973
1974
1975
1976
1976
1977
1978
1979
1979
American Foundation for Pharmaceutical Education (Fellow)
American Association for the Advancement of Science (AAAS)
Student Association for Hallucinogens
Research Society of America (RESA)
American Society of Pharmacology and Experimental Therapeutics
Neuroscience Society
American Society of University Professors
Academy of Medical Educators and Substance Abuse (AMESA) Charter
member
Society of Medicinal Chemistry
American College of Clinical Pharmacology (Fellow)
Research Society on Alcoholism
Committee of One Thousand (Health)
New York Academy of Science
1993
1993
Honorary Advisory Council Secular Organization of Sobriety (SOS)
Distinguished Advisory Council KidsatRisk Foundation
STATE:
1980Present
Texas Research Society on Alcoholism (Charter member)
LOCAL:
1968Present
1979Present
Bexar County Pharmaceutical Society (Honorary membership)
Holistic Health Association of San Antonio
Licensed Pharmacist New York and Texas (no longer licensed)
CONSULTATIONS:
INTERNATIONAL:
1980Present
Italian Drug Abuse Society
1980Present
World Federation of Clinical Toxicology
1980Present
FIDIA Laboratories
1982
Automobile Club of Italy Rome
1987Present
Baldacci Laboratories
1988Present
Alpha Pharmaceutical Company
1993Present
Secular Organization of Sobriety
NATIONAL:
1970 1972
Drug Consultant, Tennessee State Board of Education, Drug Education
Program
1970 1972
Pharmacology Consultant, Regional Center for Drug Education, The
University of Texas Pharmacy School at Austin and The University of
Texas Health Science Center at San Antonio, sponsored by the National
Office of Education
1971 1972
Drug Consultant, Missouri State Board of Education, Drug Education
Program
1971 1974
Pharmacology Consultant, Lackland Air Force Drug Rehabilitation
Center (Phase IV), Lackland Air Force Base, San Antonio, TX
1972 1974
Pharmacology Consultant, United States Office of Education, Drug
Education Training and Resource Center Region VII, Trinity University,
San Antonio, TX, sponsored by the National Office of Education
1973 1976
Pharmacology Consultant, Kelly Air Force Base, Social Action Office,
San Antonio, TX
1975 1977
Pharmacology Consultant, contract awarded to Southern California
Research Institute, "Evaluation of a Soberingup Pill," U.S. Department of
Highway Traffic Safety
1976
Speaker and Consultant, Drug Abuse Program, Special
Education, San Antonio Independent School District
1976Present
Consultant, Pyramid, Walnut Creek, CA
19771979
Consultant, National Drug Abuse Center
19791980
Scientific Advisor, Technology Resources, Inc., Washington, D.C.
1981
Scientific Advisor, National Alcohol Research Center, University of
California, School of Medicine, Irvine, CA
1982
Member Medical Scientific Advisory Board, MDI Industries, Laurel,
1982
19851989
1991Present
1992
1992
1992
1992-1993
MD
Scientific Advisor, National Alcohol Research Center, University of
California School of Medicine, Los Angeles, CA
Unipro Corporation, Sunnyvale, California (Scientific Advisory Board)
Chief Scientific Advisor, Neuro Therapy Institutes, Denver, Co
National spokesperson, CigARest
Scientific Advisor, Natural Alternative Inc., San Diego, CA
Board of Directors, Lexicor, Inc., Boulder, CO
Chairman of Board, Pharmagene
1992
Cochairman, Vice President and cofounder, American College of
Addictionology and Compulsive Disorders
1993
Chairman, Executive Advisory Board, Neurogenesis, Inc.
1993
Consultant, Health Projects United Information Systems, Inc.
2003- Present
Science Advisor- Electronic Waveform Labs, Huntington Beach
California
2009-Present Chief Science Officer– G&G Health care Services, NMBF
2011 -Present
Scientific Advisory Board, Dominion Diagnostics, LLC, North
Kingstown, RI
2012-Present
Ambassador of Molecular Neurobiology, Dominion Diagnostics, LLC,
NKRI
2012-Present Neuro-Science Advisor, Malibu Beach Recovery Center, Malibu Beach
CA,
2013 present Director of Science, PATH Foundation NY
STATE:
1979Present
1985Present
19881993
1995-Present
corporations
Texas Commission on Alcoholism
Chief, Scientific Affairs Consultant, Matrix Technologies, Inc., Houston,
TX
Chief Scientist, NeuroGenesis, Inc., Houston, TX
Chairman, President, CEO - NeuRecovery International, Inc.( See other
in Business section)
LOCAL (Texas):
19701996
Consultant Staff, Bexar County Teaching Hospital District, San Antonio,
TX
1971
Drug Consultant, Drug Abuse Central, San Antonio, TX
19761996
Consultant, The University of Texas Clinical Pharmacy, Drug
Information Center
19761981
Speaker and Consultant, Drug Abuse Program, Special Education, San
Antonio Independent School District
19831996
St. Mary's University Substance Abuse Program Advisory Board
1985- 1996
Board of Directors, San Antonio Council of Alcoholism Advisory Board
Member, Tommie Dahlmann and Associates
1990-1996
Honorary Advisor, San Antonio Council on Alcoholism and Drug
Dependence
COMMUNITY ACTIVITIES:
19691971
Director and Founder, Bexar County Pharmaceutical Speakers Bureau
19711980
Board of Directors, San Antonio Free Clinic
19721973
19721973
19731974
19731975
19781979
1979Present
19801981
19811982
1983Present
1986Present
VicePresident, Drug Institute of San Antonio
Board Member, San Antonio Committee on Dangerous Drugs
Board of Directors, Agudas Achim Synagogue
President, San Antonio Free Clinic
President, Job Power Now, Inc.
Member, San Antonio Holistic Health Association
Special Host, Cable TV Special on "Chemistry and the Mind," for series
entitled "Perspectives of Psychology"
Regular on "Good Morning San Antonio," KSAT TV
National Foundation for Addictive Diseases (Scientific Consultant
Director-CoFounder)
Consultant, Alamo Area Council of Government
HONORS AND AWARDS:
1974- NIDA Career Teachers Award
1978- Chairman and Award Gordon Research Conference on Alcohol
1982- Chairman and Award Gordon Research Conference on Alcohol
1988 Visiting Scientist, Douglas Hospital Research Centre, McGill University
1988 Finalist, Mind Science Foundation "Imagineer Award"
1990 John B. Sullivan Presidential Excellence Award for Treatment and Research
1990 Nursing Health Consultants Outstanding Achievement Award
1994 YMCA Achievement Award
2008 Elected to Who’s Who in America
2009- Who’s Who in the World
2011- Lifetime Achievement Award for Scientific Advancement of Addiction Medicine
-National Institutes of Addiction Studies.
2012 Best Abstract Award- American Society of Anesthesiology & Pain
2012 Keynote Award –Omics Conference on Addiction Research & Therapy
2012 Keynote Award –Omics Conference on Genetic Syndromes & Gene Therapy
2012 Organizing Program Member -2013 Addiction Research & Therapy Conference,
LV 2013
2013 “Epidemiology , Evolutionary Genetics, Orlando, Florida (Keynote)
2013 Addiction Research & Therapy (keynote) Las Vegas
2013 Behavioral Addictions conference in Budapest (Keynote)
2013 President’s Summit Conference Keynote in Kazakhstan
2013 Gala Celebrity Event –Scientific Achievement Award
2013 Speaker NADAC Conference in Anaheim
2014 Chairman Symposia World Congress of Psychiatry –Madrid Spain
INVITED SPEAKER:
Presented over 475 lectures on "Social Pharmacology" across approximately 44 states in
America, as well as Europe, Scandinavia, Mexico, Canada, USSR, Hungry, and the
Orient.
1974
1976
1976
Lecture Opener for Southwestern Teachers Commission on Drug Abuse,
Knoxville, TN
Program Speaker, Annual Meeting of the California Medical Association, San
Francisco, CA
Speaker and Workshop Coordinator, Anesthesiology Conference, University of
1976
1977
1979
1979
Kansas Medical Center, Kansas City, KS
Speaker, Ohio Drug Abuse Institute, Columbus, OH
Task Force Member, National Free Clinic, National Drug Abuse Conference, San
Francisco, CA
Speaker, Annual Texas Commission on Alcoholism Institute, Austin, TX
Speaker, Workshop on Drugs of Abuse, Big Springs, Texas Hospital
Scientific seminar on "Alcohol Research" presented to staff, Toxicology Branch, Food
and Drug Administration, Washington, D.C., Harvard Medical School, NIDAARC, as
well as over 200 research seminars to major universities in the U.S and abroad.
RESEARCH:
1974 Chairman, Behavioral Pharmacology, Session at ASPET Meeting in Montreal,
Canada
1976 Guest Speaker, Seventh Technical Review on Drug Interaction, National Institute
on Drug Abuse, Washington, D.C.
1977 Chairman, Alcohol Session, ASPET Meeting, Columbus, OH
1977 Chairman, Marijuana Session, National Drug Abuse Conference, San Francisco,
CA
1977 Task Force Member, Psychiatry Task Force, National Drug Abuse Conference,
San Francisco, CA
1977 Task Force Member, Research Task Force, National Drug Abuse Conference,
San Francisco, CA
1978 National Chairperson, Pharmacology and Research Task Force,
National Drug Abuse Conference
1979 General Chairman, Gordon Research Conference on Alcohol
1979 Chairman, International Congress of Neurotoxicology, "The Biological Basis for
Alcoholism," Varese, Italy
1979 Chairman, Pharmacology Alcohol Sessions Federation meetings, Dallas, TX
1982 General Chairman, Gordon Research Conference on Alcohol
1996
General Chairman, Gordon Research Conference on Psychoneurogenetics
Presented seminars on alcoholism research at major universities, governmental agencies
and sponsored societies including:
Selected as Scientific Leader of delegation to Union of the Soviet Union Socialist
Republic (Russia) (U.S. Professional Seminars, Inc.) on "Addictions," 1984.
Keynote Speaker "Genotype Theory of Alcohol Seeking Behavior." Current Research
Trends, San Francisco, CA, July, 1985.
Workshop Presenter "Alcoholism: Research into Biogenetics and Cure." Texas
Commission on Alcoholism, Austin, TX, Summer Alcohol Studies Institute, August,
1985.
Symposia Presenter "Animal and Human Evidence for the Genotype Theory in Alcohol
Seeking Behavior." International IV World Congress on Biological Psychiatry,"
Philadelphia, PA, September, 1985.
Invited Lecturer
October, 1985.
"Biogenetics of Alcoholism."
Friends Hospital, Philadelphia, PA,
Presenter "Alcoholism A Genotypic Disease." First World Congress on Drug and
Alcohol Abuse, Tel Aviv, Israel, December, 1985.
Scientific Leader U.S. Exchange Tour of China. Invited by the People’s Republic of
China. China Association for Science and Technology (sponsor), March 18 to April 5,
1986.
Grand Rounds "Alcoholism: Searching the Solution." University of Arkansas, College
of Medicine, Department of Psychiatry, Little Rock, AK, November, 1985.
Grand Rounds "Novel Neurochemical Approach to Alcoholism." The University of
Texas Health Science Center, Department of Psychiatry, Dallas, TX, November, 1986.
Keynote Speaker
November, 1986.
"Designer Drugs."
North Texas Psychiatric Society, Dallas, TX,
Scientific presentation Institute of Clinical Research of Montreal, Canada, April, 1987.
Seminar Douglas Hospital Research Centre, Montreal, Canada, April, 1987.
Seminar Addiction Research Foundation, Toronto and The University of Toronto,
Canada, April, 1987.
Chairman Neuotoxicology Congress, Alcoholism Session, Italy, June, 1987.
Invited Speaker SecondWest, "Assault on Alcoholism: A neurobiological Disease,"
Phoenix, AZ, March, 1988.
Seminar National Drug Research Centre and University of Malaysia, Dept. of
Pharmacology, March, 1988.
Selected Participant and Symposium Speaker
Germany, 1988.
XVI C.I.N.P. Congress, München,
One of six Americans lectured at the first SovietAmerican Conference on Alcoholism,
Moscow, 1989.
Cochairman on Alcoholism Session Fifth World Congress on Biological Psychiatry,
Italy, 1991.
Keynote Speaker, Pacific Chemical Dependency Institute, Hawaii, 1991.
Invited Speaker, National Academy of Science, East Berlin, 1991.
Chairman, C.I.N.P., XVII Molecular Genetics of Compulsive Diseases, Nice, 1992.
Plenary Speaker, 25th Anniversary Conference Haight Ashbury Medical Free Clinic,
1992.
Chairman, "International Congress on Amino Acid Therapy", Crete, Greece, 1993.
Chairman, World Congress in Psychiatry
Janeiro, June 613, 1993
Molecular Genetics Symposium, Rio de
European Society of Neuroscience, Biological Psychiatry Symposium, Vienna, Austria,
July 1994
Chairman, Molecular Genetic Symposium- Biological Psychiatry , Nice, France ,1996
American Society of Addiction Medicine,
Association for Applied Psychophysiology and Biofeedback until Present (2008)
Keynote CARA Conference on Brain Repair in Sacramento, California (2009)
Discussant, Food Addiction: The obesity epidemic connection, Bainbridge Island, WA
(2009)
Chairman –Omics Addiction Conference in Las Vegas, August 20-22
Chairman –Omics Conference on Gene Therapy-Genetic Syndromes Diagnosis
2012 November 22-24 San Antonio, Texas
Speaker- Foundations Conference on Freedom From RecoverySan Diego, California April 22-24 ,2012
Organizing Committee member –Functional Food Conference in Santa Barbara –
March 12-15th, 2012.
Best Abstract Award-Invited Speaker Luncheon, Fontainebleau Hotel, November 16th
2012, American Society of Anesthesiology & Pain
Grand Rounds – Department of Psychiatry & McKnight Brain Institute
Invited Lecture Quertero, Mexico University, Department of Chemistry
OTHER:
1961
19661968
1967
1969
1970
1970
19711972
1973
19741977
1975 & 1982
1976
1979
1979
1979
Bigelow Research Fellowship Award, Columbia University
American Foundation for Pharmaceutical Education Fellow Award, New
York Medical College
National Science Foundation Summer Fellowship Award, New York
Medical College
Personalities of the South, Listed
American Chemical Society Tour Speaker Plaque Award
National Association of Retail Druggist Citation of Honor
TwoThousand Men of Achievement, Listed
Intercontinental Biographical Association
Career Teachers Award in Substance Abuse NIDA
Who's Who in the South and Southwest
Personalities of the South, listed in Bicentennial Edition
National Free Clinic Council, Inc., Board of Directors, Southwest Region
Representative
Who's Who in the South and Southwest
Citation of Honor, Alamo Area Council of Governments (AACOG)
1979
1979
19791986
1979 & 1982
1981
1984 & 1985
1985
1985
1985present
1987
1987
1988
1989
1989
1990
1990
1992
1998
Certificate of Merit for Substance Abuse Service to the Community, St.
Mary's University, San Antonio, TX
Lions Club Speaking Service Award
American Men and Women in Science
Gordon Research Award
Humanitarian Award Columbian University (College of Pharmacy 20th
Year Reunion)
Who's Who in Frontiers of Science and Technology
Expert Drug Consultant for Scott Forseman, New Health Text
Distinguished Contributor to the Definition of Alcoholism for the World
Book Encyclopedia (To be published in 1989 edition)
Six scientific patents issued
U.S. Patent Office (Principal and
CoInventor), Two Canadian Patents, eleven European Patents issued,
One Japanese Patent pending, One PCT patent pending in 45 countries,
one USA patent Pending, One Provisional patent pending.
Contributor to 1987 Health and Medicine Annals World Book.
Selected Distinguished Speaker List Evaluation Research Associates,
Syracuse, NY
Issuance, USA Patent #4,701,421
Mind Science Foundation Award
Issuance, USA Patent #4,844,866 (see other patents).
Addictive’s Treatment Directory
Who's Who in American Inventors
Honorary Diplomat, Addictions Board of Certification, American
Academy of Addictionology & Compulsive Disorders
Honorary Doctorate in Humane Letters, St. Martin’s College, Milwaukee
2008
Who’s Who In America
2009
Who’s Who in The World.
2009
Editorial review board of Journal of Medical Genomics
2009
Editorial review board of Post Graduate Medicine Journal
2009 Associate Editor BMC Research Notes
2009 Associate Editor BMC Theoretical Biology and Medical Modeling
2007-2010 Editorial Review Board –Gene Therapy & Molecular Biology
2009 Editorial Board Medical Genetics and Genomics
2009 Editor Frontiers in Science (Obesity)
1970-2012 Editorial Review Board Journal Psycho Active Drugs
2007 -2010 Editorial Review Board Trends in Applied Science Research
2007 -2012 Editorial Review Board Advances in Therapy
2008-2012 Editorial Board the Physicians Sports Medicine Journal
2008-2012 International Journal of Obesity (Open Access Journal)
2010 Editorial Board Health Journal
2010 Editorial Board Member and Section Editor. International Journal of Omics and
Biotechnology
2010 Editorial Board Member and Executive Editor – Journal of Genetic Syndromes and
Gene Therapy
2012 Editor-in-Chief, Omics Journal of Genetic Syndromes & Gene Therapy
2012 Editorial Board Member, IIOAB Letters
2012 Editorial Board Genetic Diseases & Disorders& Genetic Information
2012 Editorial Board Science Impact Journal
PUBLICATIONS:
(Scientific articles, reviews, chapters in books, books, abstracts and scientific presentations)
•
Blum, K., Seifter, E. and Seifter, J. Muscle contraction by d and l carnitines and d and
lacetylcarnitines: Comparison with choline and acetylcholine. Pharmacologist 9:218, 1967.
(Abstract)
•
Blum, K., Seifter, E. and Seifter, J. The pharmacology of carnitines and acetylcarnitines:
Comparison with choline and acetylcholine. Pharmacologist 10:177, 1968. (Abstract)
•
Blum, K., Seifter, E. and Seifter, J. The pharmacology of carnitines (Ct) and acetylcarnitines
(ACt): Comparison with choline (Ch) and acetylcholine (ACh). ASPET Fall Meeting,
Minneapolis, Minn. August 1822, 1968.
•
Blum, K. The effect of dopamine and other catecholamines on neuromuscular transmission.
Arch. Int. Pharmacodyn. Ther. 181:297306, October, 1969.
•
Blum, K. and Geller, I. Facilitation of brain stimulation with parachlorphenylalanine. Fed.
Proc. 28:794, 1969. (Abstract)
•
Geller, I., Campbell, N. and Blum, K. Protection against acute alcoholic intoxication with
diethanolaminerutin. Pharmacologist II:246, 1969. (Abstract)
•
Blum, K. and Geller, I. Facilitation of brain stimulation with parachlorphenylanine (PPCA).
FASEB, 53rd Annual Meeting, Atlantic City, New Jersey, April 1318, 1969.
•
Geller, I., Campbell, N. and Blum, K. Protection against acute alcoholic intoxication with
diethanolaminerutin. ASPET Fall Meeting, Pittsburgh, Pennsylvania, August 2428, 1969.
•
Blum, K. Effects of chlordiazepoxide and pentobarbital on conflict behavior in rats.
Psychopharmacologia 17(5):3918, 1970.
•
Blum, K., Ryback, R.S. and Geller, I. Effects of vodka and bourbon on sleeping time in mice.
Q. J. Stud. Alcohol (Suppl) 5:626, May, 1970.
•
Geller, I. and Blum, K. The effects of 5HTP on parachlorphenylalanine (pCPA) attenuation
of "conflict" behavior. Eur. J. Pharmacol. 9(3):31924, March, 1970.
•
Geller, I., Campbell, N.D. and Blum, K. Protection against acute alcoholic intoxication with
diethanolamine rutin. Res. Commun. Chem. Pathol. Pharmacol. 1(3):38394, May, 1970.
•
Geller, I. and Blum, K. A comparison for the effects of nicotine analogues and
chlordiazepoxide on discrimination behavior of laboratory rats. Pharmacologist 12:206, 1970.
(Abstract)
•
Blum, K., Wallace, J.E., Ryback, R. and Geller, I. Augmentation of ethanol's effects in
laboratory rodents by pretreatment with pyrazole. Pharmacologist 12:276, 1970. (Abstract)
•
Hahn, J.W., Owen, R., Blum, K. and Geller, I. Ethanolinduced sleep time as a function of
alterations of brain monoamine levels in mice. Pharmacologist 12: 276, 1970. (Abstract)
•
Campbell, N., Blum, K. and Geller, I. Effect of tryptamine and indole3 acetic acid
derivations on leverpressing behavior in white mice. Pharmacologist 12:206, 1970.
(Abstract)
•
Ryback, R., Blum, K., Campbell, N. and Geller, I. Some pharmacologic and toxicologic
aspects of diethanolaminerutin. Pharmacologist 12:234, 1970. (Abstract)
•
Blum, K. and Geller, I. Nicotine effects on discrimination behavior: Mechanism of action
studies. Second Research Conference, Committee for Research on Tobacco and Health,
American Medical Association Education and Research Foundation, Scottsdale, Arizona,
May 6, 1970.
•
Blum, K., Wallace, J.E., Ryback, R. and Geller, I. Augmentation of ethanol's effects in
laboratory rats by pretreatment with pyrazole. ASPET Fall Meeting, Stanford, California,
August 2327, 1970.
•
Geller, I. and Blum, K. A comparison of the effects of nicotine analogues and
chlordiazepoxide on discrimination behavior in laboratory rats. ASPET Fall Meeting,
Stanford, California, August 2327, 1970.
•
Ryback, R., Blum, K., Campbell, N. and Geller, I. Some pharmacologic and toxicologic
aspects of diethanolaminerutin. ASPET Fall Meeting, Stanford, California, August 2327,
1970.
•
Hahn, J.W., Owen, R., Blum, K. and Geller, I. Ethanolinduced sleep time as a function of
alterations of brain monoamine levels in mice. ASPET Fall Meeting, Stanford, California,
August 2327, 1970.
•
Blum, K., Seifter, E. and Seifter, J. The pharmacology of d and 1choline and d and
1acetylcarnitine. Comparison with choline and acetylcholine. J. Pharmacol. Exp. Ther.
178(2):3318, August, 1971.
•
Blum, K., Geller, I. and Wallace, J.E. Interaction effects of ethanol and pyrazole in
laboratory rodents. Br. J. Pharmacol. 43(1):6773, September, 1971.
•
Geller, I., Hartmann, R. and Blum, K. Effects of nicotine, nicotine monomethiodide,
lobeline, chlordiazepoxide, meprobamate and caffeine on a discrimination task in laboratory
rats. Psychopharmacologia 20(4):35565, 1971.
•
Payte, J.T., Wallace, J.E. and Blum, K. Hydrolysis: A requisite for morphine detection in
urine. Curr. Ther. Res. 13(6):4126, June, 1971.
•
Payte, J.T., Wallace, J.E. and Blum, K. Acid hydrolysis: A requisite for morphine detection
in urine of opiatedependent patients. Presented at the 33rd Annual Scientific Meeting of the
Committee on Problems of Drug Dependence, National Academy of Sciences, Toronto,
Canada, 1:601, 1971.
•
Blum, K., Wallace, J.E. and Geller, I. Diethanolamine: A possible weak agonistantagonist
to ethanol. Presented at 33rd Annual Scientific Meeting of the Committee on Problems on
Drug Dependence, National Academy of Sciences, Toronto, Canada, 11:1532, 1971.
•
Blum, K. and Geller, I. Effects of 5hydroxytryptamine on levelpressing behavior of
laboratory rodents as a function of the animal's age: The bloodbrain barrier problem.
A.A.A.S. Meetings, Dallas, Texas, 1971.
•
Wallace, J.E. and Blum, K. Detection of psychoactive agent in body fluids. Drug Abuse
Symposium, 175th Annual Southwestern Psychological Association Meeting, San Antonio,
Texas, May, 1971.
•
Blum, K., Wallace, J.E. and Geller, I. Influence of chemical agents on the effects of ethanol:
Mechanism of action studies. Symposium on Alcoholism at American Psychological
Association Scientific Meeting, Washington, D.C., September, 1971.
•
Blum, K., Ryback, R.S. and Geller, I. Effects of vodka and bourbon on lever pressing
behavior of mice. Curr. Ther. Res. 14(2):958, February, 1972.
•
Blum, K., Wallace, J.E. and Geller, I. Synergy of ethanol and putative neurotransmitters:
Glycine and serine. Science 176(32):2924, April 21, 1972.
•
Blum, K., Merritt, J.H., Wallace, J.E., Owen, R., Hahn, J.W. and Geller, I. Effects of
catecholamine synthesis inhibition on ethanol narcosis in mice. Curr. Ther. Res. 14(6):3249,
June, 1972.
•
Blum, K., Huizenga, C.G., Ryback, R.S., Johnson, D.K. and Geller, I.
diethanolamine in mice. Toxicol. Appl. Pharmacol. 22(2):18585, June, 1972.
•
Blum, K., Wallace, J.E., Ryback, R.S. and Geller, I. Diethanolamine: A possible weak
agonist antagonist to ethanol. Eur. J. Pharmacol. 19(2):21822, August, 1972.
•
Geller, I., Hartmann, R.J. and Blum, K. The effects of lowdose combinations of
Damphetamine and cocaine on experimentally induced conflict in the rat. Curr. Ther. Res.
14(4):2204, April, 1972.
•
Wallace, J.E., Biggs, J.D. and Blum, K. Gasliquid and thinlayer chromatographic
determination of morphine in biologic specimens. Clin. Chem. Acta. 36(1):8591, January,
1972.
•
Wallace, J.E., Biggs, J.D., Merritt, J.H., Hamilton, H.E. and Blum, K. A sensitive thinlayer
chromatographic technique for determining morphine in urine. J. Chromatogr. 71(1):3540,
Toxicity of
August 23, 1972.
•
Wallace, J.E., Hamilton, H.E., Payte, J.T. and Blum, K. Sensitive spectrophotometric
method for determining methadone in biological specimens. J. Pharm. Sci. 61(9):1397400,
September, 1972.
•
Wallace, J.E., Ladd, S.L. and Blum, K. Determination of propoxyphene in biological
materials by ultraviolet spectrophotometry and gas chromatography. J. Forensic Sci.
17(1):16473, January, 1972.
•
Blum, K., Merritt, J.H. and Wallace, J.E. Serotonergic involvement in ethanolinduced
narcosis in mice. FASEB 56th Annual Meeting, Atlantic City, New Jersey, April 914, 1972.
•
Blum, K., Merritt, J.H., Sulkowski, T.S. and Wallace, J.E. Synergy of ethanol and
alcohollike metabolites: Tryptophol and 3,4Dihydroxyphenylethanol. 5th International
Congress on Pharmacology, San Francisco, California, July 2328, 1972.
•
Geller, I., Hartmann, R. and Blum, K. The effect of lowdose combinations of damphetamine
and cocaine on experimentallyinduced conflict in the rat. American Psychological
Association Meeting,
Honolulu, Hawaii, 1972.
•
•
Blum, K., Merritt, J.H., Reiter, R.J. and Wallace, J.E. A possible relationship between the
pineal gland and ethanol preference in the rat. Curr. Ther. Res. 15(1):2530, January, 1973.
•
Blum, K., Calhoun, W., Merritt, J. and Wallace J.E. LDOPA: Effect on ethanol narcosis and
brain amines in mice. Nature 242(397):4079, April 6, 1973.
•
Blum, K., Calhoun, W., Wallace, J.E., Merritt, J.H. and Geller, I. Soporific action of ethanol
in mice: Possible role of biogenic amines. Pharmacol. Biochem. Behav. 1(3):2716, MayJune,
1973.
•
Blum, K., Calhoun, W., Merritt, J.H. and Wallace, J.E. Synergy of ethanol and alcohollike
metabolites: Tryptophol and 3,4dihydroxyphenylethanol. Pharmacology 9(5):2949, 1973.
•
UV
Wallace, J.E., Biggs, J.D., Hamilton, H.E., Foster, L.L. and Blum, K.
spectrophotometric method for determination of phenacetin in biological specimens. J.
Pharm. Sci. 62(4):599601, April, 1973.
•
Reiter, R.J., Blum, K., Wallace, J.E. and Merritt, J.H. Effect of the pineal gland on alcohol
consumption by congenitally blind male rats. Q. J. Stud. Alcohol 34(3):9379, September,
1973.
•
Blum, K., Wiggins, B., Hudson, K., Friedman, R.N. and Wallace, J.E. Effects of biogenic
amine synthesis inhibitors and precursor amino acids on alcohol induced withdrawal
symptoms in mice. Pharmacologist 15:159, 1973. (Abstract)
•
Blum, K., Hudson, K. and Wallace, J.E. Tetrahydrocannabinol blockade of alcoholinduced
withdrawal symptoms in mice. 2nd International Symposium on Drug Addiction, New
Orleans, Louisiana, March 79, 1973.
•
Blum, K., Wiggins, B., Hudson, K., Friedman, R. N. and Wallace, J.E. Effects of biogenic
amine synthesis inhibitors and precursor amino acids on alcoholinduced withdrawal
symptoms in mice. ASPET Fall Meeting, East Lansing, Michigan, August 1923, 1973.
•
Blum, K., Reiter, J.J., Merritt, J.H., and Wallace, J.E. Ethanol preference as a function of the
pineal gland. 57th Annual FASEB Meeting, April 15, 1973.
•
Blum, K., Wiggins, B. and Wallace, J.E. Effects of centrifugation on ethanol induced
narcosis in mice. Annual Meeting of Aerospace, sponsored by U.S. Air Force, Colorado
Springs, Colorado, October 2426, 1973.
•
Blum, K., Eubanks, J.D., Wiggins, B., Tabor, R.G., Wallace, J.E. and Friedman, R.N. The
effects of acceleration on ethanolinduced narcosis in mide. IRCS 2:1468, 1974.
•
Blum, K., Wallace, J.E. and Eubanks, J.D. Effects of alanine and disulfiram on blood
acetaldehyde and ethanol in rats. IRCS 3:332, 1974.
•
Blum, K., Wallace, J.E. and Friedman, R.N. Reduction of acute alcoholic intoxication by
alpha amino acids: Glycine and serine. Life Sci. 14(3): 55765, February 1, 1974.
•
Blum, K. and Wallace, J.E. Effects of catecholamine synthesis inhibition on ethanolinduced
withdrawal symptoms in mice. Br. J. Pharmacol. 51(1):10911, May, 1974.
•
Blum, K., Wallace, J.E., Calhoun, W., Tabor, R.G. and Eubanks, J.D. Ethanol narcosis in
mice: Serotonergic involvement. Experientia 30(9):10534, September 15, 1974.
•
Blum, K., McDonald, L., Maddux, J. and Wallace, J.E. Production of "wetdog" shakes by
chronic administration of methadone in female rats. In: Singh, J.M., Lal, H., ed., Drug
Addiction. Vol. 4: New Aspects of Analytical and Clinical Toxicology, pp. 1236, 1974.
New York, Stratton.
•
Blum, K., Hudson, K.C., Friedman, R.N. and Wallace, J.E. Tetrahydrocannabinol:
Inhibition of alcoholinduced withdrawal symptoms in mice. In: Singh, J.M., Lal, H., ed.,
Drug Addiction. Vol. 3: Neurobiology and Influences on Behavior, pp. 3953, 1974. New
York, Stratton.
•
Hamilton, H.E., Wallace, J.E. and Blum, K.
Improved methods for quantitative
determination of methadone. J. Pharm. Sci. 63(5):7415, May, 1974.
•
Wallace, J.E., Hamilton, H.E., Riloff, J.A. and Blum, K. Spectrophotometric determination
of ethchlorvynol in biologic specimens. Clin. Chem. 20(2): 15962, February, 1974.
•
Wallace, J.E., Blum, K., Foster, K. and Eubanks, J.D. Drug identification: Spectroscopy,
colorimetry and flurometry. J. Pharmaceut. Sci. 63(2):741, 1974.
•
Wallace, J.E., Hamilton, H.E. and Blum, K. Microdetermination of dephenylhydantoin in
serum and plasma by ultraviolet spectrophotometry. J. Pharm. Sci. 63:1795, 1974.
•
Wallace, J.E., Hamilton, H.E., Farquhar, J.K., Everhart, B.E. and Blum, K. Comments on
the determination of dephenylhydantoin. Clin. Chem. 20:515, 1974.
•
Wallace, J.E., Hamilton, H.E., Blum, K. and Petty, C. Determination of morphine in
biologic fluids by electron capture gasliquid chromatography. Anal. Chem. 46(14):210711,
December, 1974.
•
Wallace, J.E., Blum, K. and Singh, J.M. Determination of drugs in biologic specimens
review. Clin. Toxicol. 7(5):47795, 1974.
•
Wallace, J.E., Blum, K. and Singh, J.M. The determination of drugs in biologic specimens:
A review. In Singh, J.M., Lal, H., ed., Drug Addiction. Vol. 4: New Aspects of Analytical
and Clinical Toxicology, pp. 17592, 1974. New York, Stratton.
•
Wallace, J.E., Blum, K. and Singh, J.M. The determination of drugs in biological specimens
-a review. In: Winek, C.L., ed., Toxicology Annual 1974, pp. 16785, 1975. New York,
Dekker.
•
Reiter, R.J., Blum, K., Wallace, J.E. and Merritt, J.H. Pineal gland: Evidence for an
influence on ethanol preference in male Syrian hamsters. Comp. Biochem. Physiol. (A)
47(1):116, January, 1974.
•
Blum, K., Eubanks, J.D., Wallace, J.E. and Tabor, R.G. Nonspontaneous convulsions in
mice elicited by some catecholamine releasers and 6,7dihy droxytetrahydroisoquinoline
(TIQ). Pharmacologist 16:263, 1974. (Abstract)
•
McDonald, L., Blum, K., Maddux, F. and Wallace, J.E. Effects of subchronic administration
of methadone on reproduction in rats. Annual Meeting of Society of Toxicology,
Washington, D.C., March 1014, 1974.
•
Blum, K., Eubanks, J.D., Wallace, J.E. and Tabor, R.G. Nonspontaneous convulsions in
mice elicited by some catecholamine releasers and 6,7dihydroxytetrahydroisoquinoline (TIQ).
ASPET Fall Meeting, Montreal, Canada, August 22, 1974.
•
Wallace, J.E., Blum, K. and Singh, J. Determination of drugs in biological specimens.
Toxicol. Annals 2:167, 1975.
•
McDonald, L.K., Maddux, J.F. and Blum, K. Fetal consequences of chronic methadone
administration to pregnant rats: Methodological problems. Curr. Ther. Res. 17(3):30817,
March, 1975.
•
Hamilton, H.E., Wallace, J.E. and Blum, K.
Spectrophotometric and gasliquid
chromatographic determination of amitriptyline. Anal. Chem. 47(7):113943, June, 1975.
•
Wallace, J.E., Hamilton, H.E., Goggin, L.K. and Blum, K. Determination of amitriptyline at
nanogram levels in serum by electron capture gasliquid chromatography. Anal. Chem.
47(9):15169, August, 1975.
•
Wallace, J.E., Hamilton, H.E., Schwertner, H., King, D.E., McNay, J.L. and Blum, K.
Thinlayer chromatographic analysis of cocaine and benzoylecgonine in urine. J. Chromatogr.
114(2):43341, November, 1975.
•
Blum, K., Wallace, J.E. and Eubanks, J.D. Effects of naloxone on ethanol withdrawal:
Preference and narcosis. Pharmacologist 17(197), 1975.
•
Blum, K., Eubanks, J.D., Wallace, J.E., Schwertner, H.A. and Morgan, W.W. Possible role
of tetrahydroisoquinoline alkaloids in post alcohol intoxication states. National Council on
Alcoholism Symposium, Milwaukee, Wisconsin, May, 1975.
•
Blum, K., Eubanks, J.D. and Wallace, J.E. Alcohol dependence and opiate dependence.
Evidence for a relationship in mice. 37th Annual Meeting of Committee on Problems of
Drug Dependence, National Academy of Science, Washington, D.C., May 21, 1975.
•
Blum, K., Wallace, J.E., Eubanks, J.D. and Schwertner, H.A. Effects of naloxone on ethanol
withdrawal, preference and narcosis. ASPET Fall Meeting, Davis, California, August 1721,
1975.
•
Blum, K., Wallace, J.E., Eubanks, J.D., Schwertner, H.A. and Morgan, W.W.
Amphetamineinduced excitation: Direct or indirect action. Society for Neuroscience 5th
Annual Meeting, New York, New York, November 26, 1975.
•
Blum, K., Eubanks, J.D., Wallace, J.E., Schwertner, H.A. and Futterman, S. Possible
rationale for differential chemotherapy of depression in humans: A review of the biogenic
amine hypothesis, Part I. J. Psychedelic Drugs, 8(3): 223234, 1976.
•
Blum, K. Depressive states induced by drugs of abuse: Clinical evidence, theoretical
mechanism(s) and proposed treatment, Part II. J. Psychedelic Drugs, 8(3): 235262, 1976.
•
Wallace, J.E., Hamilton, H.E., Goggin, K.K. and Blum, K. Determination of chlorprothixine
by electron capture gasliquid chromatography. J. Forensic Sci., 1976.
•
Blum, K., Eubanks, J.D., Wiggins, B. and Wallace, J.E. Morphine withdrawal reactions in
male and female mice. Am. J. Drug. Alcohol Abuse 3(2):3638, 1976.
•
Blum, K., Eubanks, J.D., Wallace, J.E., Schwertner, H. and Morgan, W.W. Possible role of
tetrahydroisoquinoline alkaloids in postalcohol intoxication states. Ann. NY Acad. Sci.
273:23446, 1976.
•
Enhancement of
Blum, K., Wallace, J.E., Schwertner, H.A. and Eubanks, J.D.
ethanolinduced withdrawal convulsions by blockade of 5hydroxytryptamine receptors. J.
Pharm. Pharmacol. 28(11):8325, November, 1976.
•
Blum, K., Eubanks, J.D., Wallace, J.E. and Hamilton, H. Enhancement of alcohol
withdrawal convulsions by haloperidol. Clin. Toxicol. 9(3):42734, 1976.
•
Blum, K., Eubanks, J.D., Wallace, J.E. and Schwertner, H.A.
withdrawal by dopamine. Experientia 32(4):4935, April 15, 1976.
•
Blum, K., Wallace, J.E., Schwertner, H.A. and Eubanks, J.D. Morphine suppression of
ethanol withdrawal in mice. Experientia 32(1):7982, January 15, 1976.
•
Blum, K., Meyer, E., Futterman, S., Wallace, J.E. and Schwertner, H.A. Possible
neurochemical mechanisms of ethanol dependence in mice. Pharmacologist 18:681, 1976.
Suppression of ethanol
•
Blum, K. A prescription for social pharmacology. Proc. Ohio Drug Inst. Stud., 1976.
•
Blum, K. Neurochemical and behavioral considerations on the relationship between ethanol
and opiate dependence. In: J.H. Lowinson (Ed.). Proc. of the National Drug Abuse
Conference. Marcel Dekker, New York, 1976.
•
Blum, K. Consideration on the neurochemical and behavioral relationship between alcohol
and opiate dependence. National Drug Abuse Conference, Symposium on Neurochemical
and Behavioral Mechanisms of Alcohol and Opiate Dependence, New York, March 21, 1976.
•
Blum, K., Feinglass, S.F., Wallace, J.E. and Briggs, A.H. Amphetamineinduced polyphasic
mortality: Differential strains, mechanism and polydrug effects. FASEB Annual Meeting,
Anaheim, California, April 1116, 1976.
•
Blum, K. Evidence for a relationship between alcohol and opiate dependence in mice. In:
Seventh Technical Review on Drug Interaction, M.C. Braude, Moderator, sponsored by
NIDA, May 6, 1976.
•
Blum, K., Eubanks, J.D., Wallace, J.E. and Schwertner, H.A. Ethanolinduced withdrawal
reactions: Effects of neurotransmitter substances and receptor blockers. National Council on
Alcoholism Symposium, Washington, D.C., May 7, 1976.
•
Blum, K., Meyer, E., Futterman, S., Wallace, J.E. and Schwertner, H.A. Possible
neurochemical mechanisms of ethanol dependence in mice. ASPET Fall Meeting, New
Orleans, Louisiana, August 1519, 1976.
•
Pollock, S.H., Blum, K., Dear, L.L., Futterman, S., Wallace, J.E. and Schwertner, H.A. A
stereospecific comparison of the enzymatic 6keto reduction of hydromorphine, naloxone,
hydrocodone and oxycodone. ASPET Fall Meeting, New Orleans, Louisiana, August 1519,
1976.
•
Hamilton, M.G., Marshall, A.M., Blum, K. and Hirst, M. Effects of salsolinol on the
fieldstimulated guinea pig ileum. ASPET Fall Meeting, New Orleans, Louisiana, August
1519, 1976.
•
Blum, K., Meyer, E., Wallace, J.E., Schwertner, H.A., Futterman, S., Hirst, M., Marshall, A.
and Hamilton, M. Effects of intracerebral administration of salsolinol on nociceptive
stimulation, narcotic antagonism and morphine analgesia in mice. 6th Annual Meeting,
Society of Neuroscience, Toronto, Ontario, Canada, November 711, 1976.
•
Blum, K. and Futterman, S.L. Drugs: Have it your way. J. Psychedelic Drugs 9(1):812,
1977.
•
Blum, K., Futterman, S.L. and Pascarosa, P. Peyote, a potential ethnopharmacologic agent
for alcoholism and other drug dependencies: Possible biochemical rationale. Clin. Toxicol.
11(4):45972, 1977.
•
Marshall, A., Hirst, M. and Blum, K. Analgesic effects of 3carboxysalsolinol alone and in
combination with morphine. Experientia 33(6):7545, June 15, 1977.
•
Schwertner, H.A., Blum, K., Wallace, J.E. and Eubanks, J.D.
Alterations in brain
electrolytes during acceleration in mice. Aviat. Space Environ. Med. 48(8):7057, August,
1977.
•
Blum, K., Wallace, J.E., Schwertner, H.A., Meyer, E. and Morgan, W.W. Central super
sensitivity to norepinephrine and amphetamine following brain chemical sympathectomy by
6hydroxydopamine. Life Sci. 20(10):170513, May 15, 1977.
•
Wallace, J.E., Hamilton, H.E., Shimek, E.L., Jr., Schwertner, H.A. and Blum, K.
Determination of primidone by electroncapture gas chromatography.
Anal. Chem.
49(7):9036, June, 1977.
•
Hamilton, M.G., Blum, K. and Hirst, M. Ethanol dependence: Modification by
administration of calcium gluconate and phenoxybenzamine alcoholism. Clin. and Exp. Res.
1(2):153, 1977.
•
Blum, K., Hamilton, M.G., Meyer, E.K., Hirst, M. and Marshall, A. Isoquinoline alkaloids
as possible regulators of alcohol addiction (Letter). Lancet 1(8015):799800, April 9, 1977.
•
Blum, K., Wallace, J.E., Meyer, E. and Schwertner, H.A.
Intensification of
amphetamineinduced excitation by methysergide, a sertonergic receptor blocker. Experientia
33(2):2135, February 15, 1977.
•
Blum, K. and Briggs, A.H. Effects of delta9 tetrahydrocannabinol (delta9THC) on
amphetamineaggregate toxicity in mice. Curr. Ther. Res. 21(2):2414, February, 1977.
•
Blum, K., Futterman, S., Wallace, J.E. and Schwertner, H.A. Naloxoneinduced inhibition of
ethanol dependence in mice. Nature 265(5589):4951, January 6, 1977.
•
Blum, K., Hamilton, M.G. and Wallace, J.E. Alcohol and Opiates: A Review of Common
Neurochemical and Behavioral Mechanisms. Editor: K. Blum. Academic Press, New York,
pp. 203, 1977.
•
Pollock, S.H. and Blum, K. Metabolic stereospecificity of opiate agonist and antagonist
drugs. In: Alcohol and Opiates: Neurochemical and Behavioral Mechanisms. Editor: K.
Blum. Academic Press, New York, pp. 359, 1977.
•
Alcohol and Opiates: Neurochemical and Behavioral Mechanisms; Symposium on Alcohol
and Opiates; Neurochemical and Behavioral Mechanisms of Alcohol and Opiate Dependence.
Edited by K. Blum, Associate Editors, Diana L. Bard and Murray G. Hamilton. Academic
Press, New York, pp. 403, 1977.
•
Blum, K., Newmeyer, J. Inaba, D. Whitehead, C., Smith, D.E. Acupuncture as a common
treatment modality in drug and alcohol dependence: Possible neurochemical rationale. J.
Psychedelic Drugs, 10: 105115, 1978.
•
Blum, K., Hamilton, M.G., Hirst, M. and Wallace, J.E. Putative role of isoquinoline
alkaloids in alcoholism: A link to opiates. Alcoholism: Clin. Exp. Res. (NY) 2(2):11320,
April, 1978.
•
Hamilton, M.G., Blum, K. and Hirst, M. Identification of an isoquinoline alkaloid after
chronic exposure to ethanol. Alcoholism: Clin. Exp. Res. (NY) 2(2):1337, April, 1978.
•
Carter, P., Wallace, J.E. and Blum, K. Improved ultraviolet spectrophotometry of serum
theophylline. Clin. Chem. 24(2):3601, February, 1978.
•
Schwertner, H.A., Wallace, J.E. and Blum, K. Improved ultraviolet spectrophotometry of
serum theophylline. Clin. Chem. 24:360361, 1978.
•
Hamilton, M.G., Hirst, M. and Blum K. Central formation of an abnormal amine metabolite
after chronic exposure to ethanol. Pharmacologist 19:138 (#61), 1978. (Abstract)
•
Blum, K., Hamilton, M.G., Meyer, E.K., Nardacci, N.J. and Hirst, M. Attenuation of ethanol
physical dependence development by cyclohexamide: A protein synthesis inhibitor.
Pharmacologist 19:138 (#65), 1978. (Abstract)
•
Blum, K. and Briggs, A.H. Blood transfer of ethanolinduced withdrawal convusions in mice.
Fed. Proc. 37:A174, 1978. (Abstract)
•
Blum, K. and Briggs, A.H. Withdrawal convulsion factor(s) induced by ethanol:
Characterization and localization studies. Pharmacologist 20:A70, 1978. (Abstract)
•
Cull, D.L., Blum, K. and Briggs, A.H. Studies on the transfer of phenobarbitalinduced
withdrawal convulsions in mice. Southwest Region Society of Experimental Biology,
November, 1978.
•
Inaba, D., Way, E.L., Blum, K. and Schnoll, S. Pharmacological and Toxicological
Perspectives on Commonly Abused Drugs. Medical Monograph, NIDA, 1978.
•
Hamilton, M.G., Hirst, M. and Blum, K. Opiatelike activity of salsolinol on the electrically
stimulated guinea pig ileum. Life Sci. 25(26):220510, December 24, 1979.
•
Verebey, K. and Blum, K. Alcohol euphoria: Possible mediation via endorphinergic
mechanisms. J. Psychedelic Drugs 11(4):30511, OctoberDecember, 1979.
•
Blum, K., DeLallo, L., Elston, S.F.A. and Briggs, A.H. Evidence for direct interaction of
ethanol on the opiate sensitive receptors of the vas deferens in inbred strains of mice.
Alcoholism: Clin. Exp. Res., 3:170, 1979. (Abstract)
•
Elston, S.F.A., Blum, K., DeLallo, L. and Briggs, A.H. Evaluation of ethanol intoxication as
a function of genotype dependent response(s) in three different strains of mice. Fed. Proc.
38:1029, 1979. (Abstract)
•
Blum, K., DeLallo, L., Briggs, A.H. and Elston, S.F.A. Comparative effects of alcohol on
the vas deferens in three inbred strains of mice. Fed. Proc. 38:1028, 1979. (Abstract)
•
Blum, K. and Briggs, A.H. Evidence for common receptor sites for alcohol and opiates:
Interaction effects with neuropeptides. "Chemical and biological mechanisms in response to
alcohol," Gordon Research Conference, Santa Barbara, California, February 59, 1979.
•
Briggs, A.H. and Blum, K. Localization and characterization. "Chemical and biological
mechanisms in response to alcohol," Gordon Research Conference, Santa Barbara, California,
February 59, 1979.
•
Blum, K. "Alcohol and Opiates: A review of its common mechanisms." "Advances in the
biology of alcoholism," International Congress of Neurotoxicity, Varese, Italy, September,
1979.
Blum, K., Ehrenpreis, S.H. and Briggs, A.H. Social Pharmacological Perspectives of Uppers
(Stimulants). STASH. Pamphlet publication, 1979.
•
•
Blum, K., Briggs, A.H., Elston, S.F. and DeLallo, L. Psychogenetics of drug seeking
behavior (Letter) Subst. Alcohol Actions Misuse 1(3):2557, 1980.
•
Blum, K., Cull, D.L., Briggs, A.H. An improved technique for the induction of barbiturate
dependence in mice. J. Pharmacol. Methods 3(1):8992, January, 1980.
•
Blum, K., Elston, S.F., Schwertner, H., DeLallo, L. and Briggs, A.H. A rapid method to
evaluate acute ethanol intoxication in mice. Pharmacol. Biochem. Behav. 14(6):8358, June,
1981.
•
Blum, K., Briggs, A.H., DeLallo, L. and Elston, S.F. Genotype dependent responses to
ethanol and normorphine on vas deferens of inbred strains of mice. Subst. Alcohol Actions
Misuse 1(56):45965, 1980.
•
Blum, K., Briggs, A.H., DeLallo, L., Elston, S.F. and Hirst, M. Naloxone antagonizes the
action of low ethanol concentrations on mouse vas deferens. Subst. Alcohol Actions Misuse
1(4):32734, 1980.
•
Dalterio, S., Blum, K., DeLallo, L., Sweeney, C., Briggs, A. and Bartke, A. Perinatal
exposure to delta 9THC in mice: Altered enkephalin and norepinephrine sensitivity in vas
deferens. Subst. Alcohol Actions Misuse 1(56): 46771, 1980.
•
Hamilton, M.G., Blum, K. and Hirst, M. In vivo formation of isoquinoline alkaloids: Effect
of time and route of administration of ethanol. Adv. Exp. Med. Biol. 126:7386, 1980.
•
Blum, K., Briggs, A.H., Elston, S.F.A., Hirst, M., Hamilton, M.G. and Vereby, K. Common
denominator theory for alcohol and opiate dependence: A review of similarities and
differences. In: Alcohol Tolerance and Dependence. Editors: H. Rigter and J. Crabbe.
ElsevierNetherlands, Chapter 15: 371396, 1980.
•
Blum, K., Briggs, A.H., Elston, S.F.A., DeLallo, L. and Hirst, M. Validation of central and
peripheral models to evaluate alcohol sensitivity and opiatemembrane interactions as function
of genotypedependent responses in three different strains of mice. Academic Press, NY, pp.
8491, 1980.
•
Blum, K. Alcohol and Opiates: A review of common mechanisms. Proc. Internat.
Neurotoxicology Congress, Pergamon Press, pp. 7190, 1980. Edited by Y. Lacasse, W. Levy
and L. Manzo.
•
Hamilton, M.G., Blum, K. and Hirst, M. In vivo formation of isoquinolines during chronic
exposure of rodents to ethanol. In: Alcoholism: A Perspective. Editors: F.S. Messiha and G.
Tyner. Spectrum Press, New York, pp. 373382, 1980.
•
•
•
Blum, K., Hamilton, M.G., Briggs, A.H. and Hirst, M.
Calcium gluconate and
Paradoxical modification of ethanol dependence in mice.
In:
phenotybenzamine:
Alcoholism: A Perspective. Editors: F.S. Messiha and G. Tyner. Spectrum Press, New
York, pp. 234246, 1980.
Blum, K. "The Psychogenetics of Drug Seeking Behavior." FIDIA Laboratories, Aldana,
Terne, Italy, June, 1980.
Blum, K. "Alcoholism and the Psychogenetic Theory." Traffic Medicine, World Health
Organization Symposium, Catholic University, Rome, Italy, November 6, 1980.
•
Blum, K., Eubanks, J.D., Elston, S.F.A. and Briggs, A.H. Differential brain receptor
stimulation by norepinephrine and serotonin: Possible rationale for differential chemotherapy
or depression in humans. Acupuncture and Electrotherapeutic Res. 4:18594, 1979.
•
Blum, K., Elston, S.F.A., DeLallo, L. and Briggs, A.H. A rapid method for the evaluation of
ethanol intoxication in mice. Pharmacol. Biochem. and Behavior, 14:8358, 1981.
•
Blum, K., Briggs, A.H., Elston, S.F. and DeLallo, L. Ethanol preference as a function of
genotypic levels of whole brain enkephalin in mice. Toxicol. Eur. Res. 3(5):2612, September,
1981.
•
Blum, K., Briggs, A.H. and Cull, J.G. Holism: A social pharmacological approach to
drugseeking behavior. J. Psychoactive Drugs 13(4):36971, OctoberDecember, 1981.
•
Dalterio, S., Bartke, A., Blum, K. and Sweeney, C. Marihuana and alcohol: Perinatal effects
on development of male reproductive functions in mice. Prog. Biochem. Pharmacol.
18:14354, 1981.
•
Hamilton, M.G., Blum, K. and Hirst, M. In vivo isoquinoline formation: Effect of time and
route of ethanol administration. In: Advances in Exp. Med. Biol., Plenum Press, New York,
pp. 7386, 1981.
•
Blum, K. and Tilton, J.E. Understanding the high mind. In: Folk Healing and Herbal
Medicine. Editors: G. Meyer, K. Blum, and J.G. Cull, Charles C. Thomas and Company,
261274, 1981.
•
Blum, K. Evidence for the psychogenetic theory of drug seeking behavior. Symposium:
Ethanol, Nucleic Acid and Protein Synthesis in Brain and Other Organs. Subs. Alco.
Act./Misuse 2(4):196, 1981.
•
Blum, K. "Opioid Reponses of Isoquinolines." International Research Workshop on
Isoquinoline Alkalines. Major speaker Satellite meeting to American College of
Neuropsychopharmacology, San Diego, California, December 18, 1981.
•
Folk Medicine and Herbal Healing, edited by G.G. Meyer, K. Blum and J.G. Cull.
Springfield, Ill. Thomas, 1981, pp. 356.
•
Blum, K., Briggs, A.H., DeLallo, L., Elston, S.F. and Ochoa, R. Whole Brain
methionineenkephalin of ethanolavoiding and ethanolpreferring C57BL mice. Experientia
38(12):146970, December 15, 1982.
•
Wallace, J.A. and Blum, K. An evaluation of the TRI dipstick test for the detection of drugs
of abuse in urine. Subst. Alcohol Actions Misuse 3(12): 12932, 1982.
•
Blum, K., Briggs, A.H. and DeLallo, L.. On the mechanism of methadoneinduced alcohol
consumption in humans (Letter). Subst. Alcohol Actions Misuse 3(12): 14, 1982.
•
Blum, K., DeLallo, L., Briggs, A.H. and Hamilton, M.G. Opioid responses of isoquinoline
alkaloids (TIQs). Prog. Clin. Biol. Res. 90:38798, 1982.
•
Blum, K., Briggs, A.H., Elston, S.F., DeLallo, L., Sheridan, P.J. and Sar, M. Reduced
leucineenkephalin──like immunoreactive substance in hamster basal ganglia after longterm
ethanol exposure. Science 216(4553):14257, June 25, 1982.
•
Elston, S.F., Blum, K., DeLallo, L. and Briggs, A.H. Ethanol intoxication as a function of
genotype dependent responses in three inbred mice strains. Pharmacol. Biochem. Behav.
16(1):135, January, 1982.
•
Blum, K. Neurophysical effects of ethanol. In: American Encyclopedia of Alcoholism.
Editors: E.M. Pattison and E. Kaufman. Gardner Press, New York, 1982.
•
Blum, K., Briggs, A.H. and Verebey, A.K. The pharmacology of addictive drugs:
Similarities and differences. In: Perspectives in Alcohol and Drug Abuse: Similarities and
Differences. Editor: J. Solomon, 1982.
•
Blum, K. "The Role of Neuropeptides on Ethanol Preference."
Conference on Alcoholism, Ventura, California, February 1519, 1982.
•
Blum, K. Special Guest Invitation of Correo Medico Magazine Conference on Drug
Dependence. "The Psychogenetic Theory of Drug Seeking Behavior," Milan, Italy, 1982.
•
Blum, K. and Manzo, L. Clinical Toxicology. Special editors, Marcel Dekker, New York,
1982 (3 issues).
Blum, K. Alcohol and central nervous system peptides. Subst. Alcohol Actions Misuse
4(23):7387, 1983.
•
•
Gordon Research
Blum, K., Elston, S.F., DeLallo, L., Briggs, A.H. and Wallace, J.E. Ethanol acceptance as a
function of genotype amounts of brain (Met)enkephalin. Proc. Natl. Acad. Sci. USA
80(21):65102, November, 1983.
•
Blum, K., Briggs, A.H. and DeLallo, L. Clonidine enhancement of ethanol withdrawal in
mice. Subst. Alcohol Actions Misuse 4(1):5963, 1983.
•
Blum, K., Dalterio, S., Briggs, A.H., DeLallo, L.J. and Hall, C.W. Supersensitivity to
norepinephrine induced by prenantal exposure to ethanol. Eur. J. Pharmacol. 106(2):4157,
November, 13, 1984.
•
Blum, K. Handbook of Abusable Drugs, Gardner Press, New York, 721 p., 1984.
•
Blum, K. "The Background For Abuse." In: Handbook of Abu sable Drugs, Gardner Press,
New York, pp. 116, 1984.
•
Blum, K. "Some General Social Pharmacologic Aspects of Substance Abuse."
Handbook of Abu sable Drugs, Gardner Press, New York, pp. 1728, 1984.
•
Blum, K. "Basic Pharmacological Considerations and Principles." In: Handbook of Abu
sable Drugs, Gardner Press, New York, pp. 2944, 1984.
•
Blum, K. "Classification of Psychoactive Drugs." In: Handbook of Abu sable Drugs,
Gardner Press, New York, pp. 4552, 1984.
•
Blum, K. "Narcotics." In: Handbook of Abu sable Drugs, Gardner Press, New York, pp.
5380, 1984.
•
Blum, K. "Pharmacology and Clinical Applications of Narcotic Antagonists."
Handbook of Abusable Drugs, Gardner Press, New York, pp. 91100, 1984.
•
Blum, K. "Methadone and Other Narcotic Maintenance Drugs: Pharmacologic Issues,
Myths and Realities." In: Handbook of Abusable Drugs, Gardner Press, New York, pp.
101144, 1984.
•
Blum, K. "Internal Opioids: A Look into the Future." In: Handbook of Abusable Drugs,
Gardner Press, New York, pp. 145164, 1984.
•
Blum, K. "CNS Depressants: Sedative, Hypnotics (Barbiturates and NonBarbiturates)." In:
•
Blum, K. "Solvent and Aerosol Inhalants ("Glue Sniffing")." In: Handbook of Abusable
Drugs, Gardner Press, New York, pp. 211236, 1984.
•
Blum, K. "Alcohol: The World's Most Devastating Drug." In: Handbook of Abusable
•
Blum, K. "Central Nervous System Stimulants ("The Uppers")." In: Handbook of Abusable
•
Blum, K. "Tranquiling Agents." In: Handbook of Abusable Drugs, Gardner Press, New
York, pp. 352376, 1984.
In:
In:
•
Blum, K. "Antidepressants and Antimania Drugs (Mood Elevators and Stabilizers)." In:
•
Blum, K. "Tobacco and Smoking Behavior." In: Handbook of Abusable Drugs, Gardner
•
Blum, K. "OvertheCounter (OTC) Drugs." In: Handbook of Abusable Drugs, Gardner
•
Blum, K. "Marihuana: Heaven or Hell." In: Handbook of Abusable Drugs, Gardner Press,
New York, pp. 447507, 1984.
•
Blum, K. "Psychedelics: Brave Old World." In: Handbook of Abusable Drugs, Gardner
•
Blum, K. "Psychotropic Drug Interactions." In: Handbook of Abusable Drugs, Gardner
•
Blum, K.
"Influence of Psychopharmacologic Agents on Sexual Function:
Psychopharmacosexology." In: Handbook of Abusable Drugs, Gardner Press, New York, pp.
645662, 1984.
•
Blum, K. "Drug Odyssey 2001." In: Handbook of Abusable Drugs, Gardner Press, New
York, pp. 663676, 1984.
•
Blum, K., Gaskill, H., DeLallo, L., Briggs, A.H. and Hall, W. Methionine enkephalin as a
possible neuromodulator of regional cerebral blood flow. Experientia 41(7):9323, July 15,
1985.
•
Manzo, L., Blum, K., Sabbioni, E. Neurotoxicity of Selected Metals. In: Neurotoxicology,
edited by Blum, K. and Manzo, L., Marcel Dekker, Inc., New York, 1985.
•
Blum, K. The cytogenetics of alcoholism: The role of opioid peptides. Substance Abuse,
AMERSA Publication, 1985.
•
Blum, K. Animal and human evidence for the importance of the "Genotype Theory" in
alcohol seeking behavior.
Proc. International Congress on Biological Psychiatry,
Elsevier/NorthHolland, Amsterdam, 1985.
•
Blum, K. Alcoholism: Research into the Biogenetics and Cure. Workshop presented at the
2nd Institute on Alcohol Studies, Texas Commission on Alcoholism, August, 1985.
•
Blum, K. The Role of Opioid Peptides in Alcohol Seeking Behavior. Invited participant in
"Alcoholism Bridging the Gap." Friends Hospital, October 910, 1985.
•
Blum, K. The "Genotype Theory" in Alcohol and Drug Seeking Behavior. Keynote address.
In "Currents in Alcohol and Drug Abuse Research." Youth Projects, Oakland, California,
July, 1985.
•
Blum, K. and Wallace, J.E. A commentary on the biochemical pathogenesis of
alcoholinduced depression. J. Psychoactive Drugs, 1985 18(2):1612, 1986.
•
Blum, K., Wallace, J.E., Briggs, A.H. and Trachtenberg, M.C. Evidence for the "Genotype"
theory in alcohol seeking behavior: A commentary. Alch. Drug Res. 6:45561, l986.
•
Blum, K., Trachtenberg, M.L. "Neurochemistry and Alcohol Craving."
Soc. Treat. Alc. Other Drug Dependence News 13(2):17, 1986.
•
Blum, K. Alcoholism: Scientific Basis and Chemotherapeutic Control. Dental School
Quarterly (UTHSC) 2(1):15, 1986.
•
Blum, K., Wallace, J.E., Briggs, A.H., DeLallo, L. and Trachtenberg, M.C. Enkephalinase
inhibition by thiorphan and subsequent response to ethanol, normorphine and enkephalins on
mouse vas deferens. Functional Neurology, 1:15664, 1986.
•
Blum, K., and Topel, H. Opioid peptides and alcoholism: Genetic deficiency and chemical
management. Func. Neurol. 1:7183, 1986.
•
Blum, K., Trachtenberg, M.C. New insights into the causes of alcoholism. Prof. Counselor
1(5):3336, 1987.
•
Blum., K., Trachtenberg, M.C. Addicts may lack some neurotransmitters. U.S. J. Drugs and
Alc. Dep., pp. 16, 1987.
•
Blum, K., DeLallo, L., Briggs, A.H. and
DAla2MeT5Enkephalinamide on guinea pig ileum:
interaction. Biogenic Amines 4(5):193198, 1987.
•
Blum, K., Briggs, A.H., Wallace, J.E., Hall, C.W., Trachtenberg, M.C. Regional brain
(MET) enkephalin in alcoholpreferring and nonalcoholpreferring inbred strains of mice.
Experientia 43:408410, 1987.
•
Blum, K., Wallace, J.E., Trachtenberg, M.C. Enkephalinase inhibition:
ethanol intake in genetically predisposed mice. Alcohol 4(6): 449456, 1987.
•
Trachtenberg, M.C., Blum, K. Alcohol and opioid peptides: Neuroparmacological rationale
for physical craving of alcohol. Am. J. Drug Abuse 13(3):365372, 1987.
•
Blum, K. Alcoholism and Drug Abuse (Closeup). World Book Encyclopedia Annals Health
and Medicine, pp. 217222, 1987.
•
Blum, K., Trachtenberg, M.C., Elliott, C.E., Dingler, M.L., Sexton, R.L., Samuels, A.I. and
Cataldie, L. Enkephalinase inhibition and precursor amino acid loading improves inpatient
treatment of alcohol and poly drug abusers: Doubleblind placebocontrolled study of the
nutritional adjunct SAAVE Alcohol 5:481493, 1988.
•
Blum, K. and Trachtenberg, M.C. Alcoholism: Scientific basis of a neuropsychogenetic
disease. Intl. J. Addict. 23:781796, 1988.
Calif.
Hall, C.W.
Salsolinol and
Possible opioid agonist/antagonist
Regulation of
•
Blum, K., Trachtenberg, M.C. and Ramsey, J.C. Improvement of inpatient treatment of the
alcoholic as a function of neurotransmitter restoration: A pilot study. Intl. J. Addict.
23:991998, 1988.
•
Trachtenberg, M.C. and Blum, K. Improvement of cocaineinduced neuromodulator deficits
by the neuronutrient Tropamine' J. of Psycho. Drugs 20:315331, 1988.
•
Blum, K. and Tractenberg, M.C. Neurogenetic deficits caused by alcoholism: Restoration
by SAAVETM, a neuronutrient intervention adjunct. J. of Psycho. Drugs 20:297313, 1988.
•
Blum, K. "Alcoholism." Worldbook Encyclopedia. Submitted as Invited Contributor, 1988.
•
Blum, K., Briggs, A.H.
Opioid peptides and genotypic responses to ethanol.
Biogenic Amines 5:527533, 1988.
•
Blum, K.
Narcotic antagonism of seizures induced
tetrahydroisoquinoline alkaloid. Experientia 44:751753, 1988.
•
Blum, K., Allison, D., Trachtenberg, M.C., Williams, R.W. and Loeblich, L.A. Reduction of
both drug hunger and withdrawal against advice rate of cocaine abusers in a 30day inpatient
treatment program by the neuronutrient Tropamine' Curr. Ther. Res. 43:12041214, 1988.
•
Sheridan, P.J., Blum, K. and Trachtenberg, M.C. A look to the future. In: Steroid Receptors
and Disease. Eds. P.J. Sheridan, K. Blum and M.C. Trachtenberg, Marcel Dekker, New
York and Basel, pp. VIIX, 1988.
•
Sheridan, P.J., Martin, P.M. and Blum, K. Steroid receptor dynamics: A function of cellular
equilibrium. In: Steroid Receptors and Disease. Eds. P.J. Sheridan, K. Blum and M.C.
Trachtenberg, pp. 4970, 1988.
•
Blum, K. The disease process in alcoholism. Alco. and Addic. May, 1988.
•
Blum, K. A commentary on ethanol neuromodulator mechanism: Theoretical and clinical
implications. In: Neurodegenerative Disorders: The Role Played by Endotoxins and
Xenobiotics. Ed. G. Nappi et al., Raven Press, New York, pp. 269285, 1988.
•
Sheridan, P.J., Blum, K. and Trachtenberg, M.C. Cancer, Autoimmune, Bone and
Circulatory Disorders. In: Steroid Receptors and Disease. Eds. P.J. Sheridan, K. Blum and
M.C. Trachtenberg, Marcel Dekker, New York, 1988.
•
Blum, K., Trachtenberg, M.C. and Kozlowski, G.P.
Cascade" link. Professional Counselor Jan., 1989.
•
Blum, K. A commentary on neurotransmitter restoration as a common mode of treatment for
alcohol, cocaine and opiate abuse. Integr. Psych. 6:199204, 1989.
•
Blum, K., Briggs, A.H., Trachtenberg, M.C. Ethanol ingestive behavior as a function of
central neurotransmission. (Review). Experientia 45:444452, 1989.
by
a
dopaminederived
Cocaine Therapy:
The "Reward
•
Blum, K. Multiauthored review on molecular basis of alcoholism. Molecular mechanism of
intracellular ethanol action. Experientia 45:406, (7 reviews), 1989.
•
Blum, K. Neuronutrition as an adjunct to therapy for addictive disease. The Nutrition
Report. I(6), 1989.
Blum, K., Briggs, A.H., Delallo, L., Hall, C.W., and Parvez, S.H. Potentiation of the
inhbibitory action of methionine enkephalamide by low ethanol concentrations on mouse vas
biferens. Biogenic Amines 7(3):249255, 1990
•
•
Blum, K., Trachtenberg, M.L., and Cook, D.W. Neuronutrient effects on weight loss in
carbohydrate bingers: An open clinical trial. Current Therapeutic Research. 48(2):217233,
1990.
•
Blum, K., Noble, E.P., Sheridan, P.J., Montgomery, A, Ritchie, T., Jagadeeswaran, P.,
Nosam, H., Briggs, A.H., and Cohn, J.B. Allelic Association of human dopamine D2 receptor
gene in alcoholism. JAMA. 263(15):20552060, 1990.
•
Blum, K. and Noble, E.P. Allelic association of human dopamine D2 receptor gene in
alcoholism (Reply). JAMA 264(14):18071809. (Letter)
•
Blum, K. and Kozlowski, G.P. Ethanol and neuromodulator interactions: A cascade model
of reward. Prog. Alcohol Res. 2 Ollat et al. (Eds), VSP, Utrecht, pp 131149, 1990.
•
Brown, R.J., Blum, K. and Trachtenberg, M.C. Neurodynamics of relapse prevention: A
neuronutrient approach to outpatient DUI offenders. J. Psychoactive Drugs. 22(2):173187,
1990.
•
Braverman, E.R., Blum, K., and Smayda, R.J. A commentary on brain mapping in 60
substance abusers: Can the potential for drug abuse be predicted and prevented by treatment.
Cur. Therap. Res. 48(4):569 585, 1990.
•
Braverman, E., Smith, R., Smayda, R., and Blum, K. Modification of P300 amplitude and
other e electrophysiological parameters of drug abuse by cranial electrical stimulation. Cur.
Therap. Res. 48(4):586596, 1990.
•
Blum, K., Rassner, M. and Payne, J.E. Neuronutrient therapy for compulsive disease:
Rationale and clinical evidence. Addiction and Recovery 10(2):1216, 1990.
•
Blum, K. The "Alcoholic" Gene, Professional Counselor. Sept/Oct 3947, 1990.
•
Blum, K. The background for abuse, Sixth Edition of the Psychiatric Knowledge and Skills
SelfAssessment Program VI. (PKSAP VI), pp 4359, 1990.
•
Blum, K. Some general social pharmacologic aspects of substance abuse. Sixth Edition of
the Psychiatric Knowledge and Skills SelfAssessment Program VI (PKSAP VI) pp 6171,
1990
•
Noble, E.P., Blum, K., Ritchie, T., Montgomery, A., and Sheridan, P.J. Allelic association of
the dopamine D2 receptor gene with receptor binding characteristics in alcoholism. Arch.
Gen. Psyc. 48:648654, 1991.
•
Noble, E.P. and Blum, K. Rebuttal Letter: Population and pedigree studies reveal a lack of
association between the dopamine D2 receptor gene with alcoholism.
JAMA
265(20):26672668. 1991.
•
Blum, K., Noble, E.P., Sheridan, P.J., Finley, O., Montgomery, A., Ritchie, T., Ozkaragoz, T.,
Fitch, R.J., Sadlack, F., Sheffield, D., Dahlmann, T., Halbardier, S., and Nogami, H.
Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism.
Alcohol 8, 1991.
•
Blum, K., Sheridan, P.J. and Noble, E.P. The A1 allele of the dopamine D2 receptor gene as
a genetic marker for risk of severe alcoholism. In: Biological Psychiatry (Racagnie, G.,
Brunello, N. and Fukudo, T.) 2:1417, Elsevier Science Publishers B.V., Amsterdam, 1991.
•
Blum, K., Noble, E.P. and Sheridan, P.J. Association of the A1 allele of the D2 dopamine
receptor gene with severe alcoholism. In: Biological Psychiatry (Racagni, R., Brunello, N.
and Fukuda, T.) 29(11S):711S, Elsevier Science Publisher B.V., Amsterdam, 1991.
•
Blum, K. (in collaboration with J.E. Payne). Alcohol and the Addictive Brain: New Hope
for Alcoholics from Biogenetic Research. McMillan (Free Press), New York, 1991. (Trade).
•
1992
•
Kaats, G.R., Wise, J.A., Blum, K., Morin, R.J., Adelman, J.A., Craig, J. and Croft, H.A. The
shortterm therapeutic efficacy of treating obesity with a plan of improved nutrition and
moderate caloric restriction. Cur. Thera. Res. 51:261274, 1992.
•
Noble, E.P., Blum, K., and Khalsa, H. Allelic association of the D2 dopamine receptor gene
in cocaine dependence. CINP XVII Congress, Oral Communication, Nice, June 30, 1992
(Abstract).
•
Blum, K., Noble, E.P. and Sheridan, P.J. Genetic predisposition to alcoholism: association
of the B1 allele of the DRD2 receptor gene in severe alcoholics. CINP XVII Congress, Oral
Communication, Nice, June 30, 1992 (Abstract).
•
Braverman, ER, Swartz, K., Blum, K., Moss, R, "Electrotherapy for Addictions," Addiction
and Recovery, May/June 1992, pp. 34-36.
•
Blum, K., Braverman, E., Loeblich, L., and Payne, J.D. Neurogenetics of compulsive
disease: neuronutrients as adjuncts to recovery. In: The Chemically Dependent: Phases of
Treatment and Recovery (B.C. Wallace, Ed). BrunnerMazel Inc., New York, N.Y. 1992.
•
Blum, K., Noble, E.P., Sheridan, P.J., Montgomery, A., Ritchie, T., Ozkaragoz, T., Fitch,
R.J., Wood, R., Finley, O. and Sadlack, F. Genetic predisposition in alcoholism: association
of the D2 dopamine receptor TaqI B1 RFLP with severe alcoholics. Alcohol 10:5967, 1993.
•
Noble, E.P., Blum, K., Khalsa, M.E., Ritchie, T., Montgomery, A., Wood, R.C., Fitch, R.J.,
Ozkaragoz, T., Sheridan, P.J., Anglin, D., Paredes, A., Treiman, L.J. and Sparkes, R.S.
Allelic association of the D2 dopamine receptor gene with cocaine dependence. Alcohol and
Drug Dependence 33:271-285, 1993.
•
Noble, E.P. and Blum, K. Alcoholism and the D2 dopamine receptor gene. Letter to JAMA
270:1547, 1993.
•
Blum, K. Braverman, E.R., Dinardo, M.J., Wood, R.C. and Sheridan, P.J., Prolonged P300
latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele,
Pharmacogenetics, 4:313-322, 1994.
•
Gejman, P.V., Ram, A., Gelernter, J., Friedman, E., Cao, Q., Pickar, D., Blum, K., Noble,
E.P., Kranzler, H.R., O'Malley, S., Hamer, D.H., Whitsitt, F., Rao, P., DeLisi, L.E.,
Virkkunien, M., Linnoila, M., Goldman, D. and Gershon, E.S. No structural mutation in the
dopamine D2 receptor gene in alcoholism or schizophrenia: Analysis using denaturing
gradient gel electrophoresis. JAMA 271: 204-208, 1994.
•
Blum, K., Sheridan, P.J., Wood, R. and Braverman. Utilization of Bayes' theorem to
estimate the predictive value of the A1 allele of the D2 dopamine receptor gene in
compulsive disease. Presented at 17th Annual Meeting of European Neuroscience
Association, September 1994, Vienna, Austria
•
Noble, E.P., Syndulko, K., Fitch, R.J., Ritchie, T., Bohlman, M.C., Guth, P., Sheridan, P.J.,
Montgomery, A., Heinzmann, C., Sparkes, R.S. and Blum, K., D2 dopamine receptor Taq I
alleles in medically ill alcoholic and nonalcoholic patients. Alcohol & Alcoholism, 29:729744, 1994.
•
Blum, K., Noble, E.P., Balducci, G., Pasculli, E. and Ceccanti, M. Psychoneurogenetic and
behavioral aspects of alcoholism. The cascade theory of reward and the role of tetrahydroisoquinoline (TIQs): the alcohol-opiate linkage, Alcologia 6: 89-98, 1994.
•
Gejman, P.V., Ram, A., Gelernter, J., Friedman, E., Cao, Q., Pickar, D., Blum, K., Noble,
E.P., O'Malley, S., Kranzler, H., Hamer, D.H., Whitsitt, F., Rao, P., DeLisi, L.E., Virkkunen,
M., Linnoila, M., Goldman, D., and Gershon, E.S. No structural mutation in the dopamine
D2 receptor gene in alcoholism or schizophrenia. JAMA 271:204-208, 1994.
•
Blum, K. and Noble, E.P. The sobering D2 story. Science, 265, 1346, 1994.
•
Blum K., Braverman ER, Dinardo M., Wood R., Sheridan P., “Prolonged P300 Latency in a
Neuropsychiatric Population with the D2 Dopamine Receptor A1 Allele," American
Psychiatric Electrophysiology Association, 2nd annual meeting, Philadelphia, PA., May 20,
1994. Pharmacogenetics, 1994; 4:313-322.
•
Defrance J., Hymel C., Trachtenberg M., Ginsberg L., Braverman ER, Blum K.,
“Enkephalinase-inhibition and Precursor Amino Acid Loading Enhances Attention
Processing and P300 in Healthy Humans," American Psychiatric Electrophysiology
Association, 2nd annual meeting, Philadelphia, PA., May 20, 1994.
•
Blum K, Sheridan P, Wood R, Braverman E, Chen T, Comings D. “Dopamine D2 receptor
gene variants association and linkage studies in impulsive-addictive-compulsive behavior.”
Chapman & Hall, Ltd, 1994.
•
Blum, K., Braverman, E.R., Wood, R., Sheridan, P.J. DRD2 A1 Allele and P300
abnormalities in obesity [Abstract]. Presented at the American Society of Human Genetics,
Montreal, Canada, October 8th, American Journal of Human Genetics, 1994.
•
Blum, K., Braverman, E.R., Wood, R.C. and Sheridan, P.J. Increased prevalence of the Taq
I A1 allele of the Dopamine D2 receptor gene in obesity with comorbid polysubstance abuse.
Pharmacogenetics 6, 297-305, 1995
•
Blum, K., Sheridan. P.J., Wood, R.C., Braverman, E.R., Chen, T.J.H.and Comings, D.E.
Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictivecompulsive behavior. Pharmacogenetics 5:121-141, 1995.
•
Blum, K., Sheridan, P.J., Wood, R. and Braverman, E.R. Dopamine D2 receptor gene
polymorphisms in Scandinavian chronic alcoholics: a reappraisal. Eur. Arch. Psychiatry Clin.
Neurosci 244: 50-52, 1995.
•
Blum, K., Wood, R.C., Braverman, E.P., Chen, T.J.H. and Sheridan, P.J. D2 dopamine
receptor gene as a predictor of compulsive disease: Bayes' theorem. Functional Neurology:
10(1):37-44, 1995.
•
Blum, K., Braverman, E.R., Wood, R.C., Sheridan, P.J., Chen, T.J.H., Cull, J.G. and
Comings, D.E. The D2 dopamine receptor gene as a predictor of "Reward Deficiency
Syndrome" (RDS). In: University of Pavia Seminar Series, Pavia, Italy, 1995.
•
Blum, K., Cull, J.G,. and Sheridan, P.J. Genetic screening: To be or not to be. Genetic
Engineering News. November 1995.
•
Blum, K., Sheridan, P.J., Wood, R. and Braverman, ER, “Dopamine D2 receptor gene
polymorphisms in Scandinavian chronic alcoholics: a reappraisal.” Eur. Arch. Psychiatry
Clin. Neuroscience 244:50-52, 1995.
•
Blum, K., Sheridan, P.J., Wood, R. C., Braverman, E.R., Chen, T.J.H., Cull, J.G. and
Comings, D.E. The D2 dopamine receptor gene as a predictor of impulsive-addictivecompulsive behavior: Bayes' theorem. J. Royal Society of Medicine 89, 396-400, 1996.
•
Blum, K., Cull, J.G. and Comings, E.D. Biogenetics of Reward Deficiency Syndrome.
American Scientist 84, 132-145, 1996.
•
Braverman, E.E. and Blum, K. Substance Use Disorder Exacerbates Brain
Electrophysiological Abnormalities in a psychiatrically-ill population. Clinical EEG suppl.
27(4), 5-28, 1996
•
Wise, J.A., Morin, R.J., Sanderson, R. and Blum, K. Changes in plasma Carotenoid, Alphatocopherol and lipid peroxide levels in response to supplementation with concentrated fruit
and vegetable extracts: a pilot study. Current Therapeutic Research 57)6), 446-462, 1996
•
Kaats, G.R., Blum, K., Fisher, J.A., Adelman, J.A. and Wood, R. Effects of chromium
picolinate supplementation on body composition: a randomized double blind placebo
controlled study. Current Therapeutic Research 57(10),747-756, 1996.
•
Braverman, E.R., Miller, D.S., Hollad, R., Johnson, D., and Blum, K. Myers-Briggs type
indicator relationships with the Millon Clinical Multiaxial Inventory Version II. Presented at
the 149th Annual Meeting of the American Psychiatric Association, May 7, 1996, NY.
Abstract # NR, pp 145, 1996.
•
Blum, K. Braverman, E.R., Cull, J.G., Gill, J., Chen, T.H.J., Eisenberg, A., Sherman, M.,
Wood, R. and Comings, D.E. Polymorphism of the dopamine D2 receptor gene associates
with brain electrophysiological abnormalities in humans: Exacerbation with Substance Use
Disorder . Clinical EEG.,1996.
•
Blum K., Braverman E. R., Cull J., Brenner B., Gill J., Zedar M., “Brain
Electrophysiological Abnormalities As a Function of the Dopamine D2 Receptor A1 Allele
and Comorbid Substance Use Disorder” Presented on 1996 Annual Meeting of American’s
Mental Health; 2132 May, 1996.
•
Braverman E., Blum K, Comorbid Psychiatric Disorders in a Holistic Health Clinic Society
of Medicine, Vol 89, 1996.
•
Blum, K. , Braverman, ER, Wu, S., Cull, JG., Wood, R. et al. Association of polymorphisms
of dopamine D2 receptor (DRD2 ) , and dopamine transporter (DAT1) genes with schizoid/
avoidant behaviors (SAB). Molecular Psychiatry 2 : 239-246, 1997.
•
Blum, K. Cull, JG. Chen TJH, Garcia-Swan Susan, Holder,JM, Wood,R. Braverman, ER,
Buci, LR., & Trachtenberg,MC. Clinical evidence For Effectiveness of PhencalTM in
maintaining weight loss in an open-label, controlled, 2-year study. Current Therapeutic
Research. 58 (10) 1997.
•
DeFrance, J.F., Hymel, C., Trachtenberg, M.C., Ginsberg, L.D., Schweitzer, F.C., Estes, S.,
Chen, T.J.H., Braverman, E.R., Cull, J.G. and Blum, K. Enhancement of attention
processing by Kantrol TM in healthy humans: A pilot study. Clinical EEG, 1997
•
Blum, K. Cull, J.G., Braverman, E.R., Chen, T.H.J. and Comings, D.E. Reward deficiency
syndrome: Neurobiological genetic aspects in Handbook of Psychiatric Genetics (Blum, K.,
and Noble, E.P., Eds), Chapter 18, pp 311-332, CRC Press, Boca Raton, Florida, 1997
•
Blum, K. Sheridan, Ph.J. Chen, THJ, Wood, R.C., Braverman, Cull, J.G. and Comings, D.E.
The dopamine d2 receptor gene locus in reward deficiency syndrome: Meta analyses. In:
Handbook of Psychiatric Genetics (Blum, K. and Noble, E.P., Eds) chapter 24, pp. 407-434,
CRC Press, Boca Raton, Florida 1997
•
Blum, K. and Noble, E.P. (Eds.) [Sparks, R. Cull, J.G., Chen, T.H.J. Associate Editors],
Handbook of Psychiatric Genetics, CRC Press, Boca Raton, Florida, 1997
•
Miller, D. and Blum, K. (in collaboration with J.E. Payne and M. Miller) Overload: Attention
Deficit Disorder and the Addictive Brain, Andrew McNeal, Kansas City, Missouri, January,
1997 (first printing, 1996)
•
Blum, K and Holder, J. (in collaboration with Cull, J.G., Chen, T.H.J., Braverman, E.R.)
Handbook of Abuse able Drugs: Amended Edition, Ameron Press, In press, 1997.
•
Ehrenpreis, S. Blum, K. Balagot R., Hyodo M., Cull, JG., Wood, R., 7 Wise, J. Open Label
studies Showing Analgesic and anti-inflammatory effects of D-Phenylalanine (DPA) in
Arthritis and chronic , Intractable Pain Patients : A preliminary Report. Submitted to Pain.
•
Blum, K. Cull, JG & Miller, M. To Binge and Not To Binge , Psychiatric Genetic Press , San
Antonio, Texas, 1999.
•
Cull, JG., Luck,R., Blum, K. Bingeing and Your addictive Brain: A life -Style Change
Program. A Cognitive Behavioral Approach to Overcoming Carbohydrate Bingeing.
Psychiatric genetic Press , San Antonio, Texas, 1999.
•
Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral
disorders.Prog Brain Res. 2000;126:325-41
•
Blum, K. and E.R. Braverman “Reward Deficiency Syndrome: A biogenetic Model for the
treatment of impulsive, addictive and compulsive behaviors. Journal Psychoactive Drugs, 32:
1-12. 2001.
•
Blum, K. and Noble, EP. First Conference on “Reward deficiency syndrome’: Genetic
Antecedents and Clinical Pathways. Molecular Psychiatry vol. 6 supplement Feb. 1 , 2001.
•
Blum,K. and Noble,EP Reward Deficiency Syndrome (RDS) : A biogenic model for the
diagnosis and treatment of impulsive , addictive, and compulsive behaviors. Molecular
Psychiatry 6: S2, 2001.
•
Blum, K. and Braverman, ER “Reward Deficiency Syndrome” : An emerging concept.
Molecular Psychiatry, 6: S3, 2001.
•
Braverman, ER , Blum, K. Lubar, J, Lubar, Jo, Lubar, and Comings, DE. Genetic
dopaminergic deficits: Clinical correlates to schizoid/avoidant personality, ADHD probands,
pathological violence. P300 event related potential and TOVA attention test. Molecular
psychiatry, 6: S5, 2001.
•
Holder, JM., Duncan, RC, Gissen, M., Miller,M., Braverman,ER and Blum, K. Increasing
retention rates among the chemically dependent in residential treatment: auriculotherapy and
subluxation-based chiropractic care. Molecular Psychiatry, 6 S8, 2001.
•
•
Braverman ER, Blum K. P300 (latency) event-related potential: an accurate predictor of
memory impairment. Clin Electroencephalogr. 2003 Jul; 34(3):124-39.
•
•
Braverman E, Blum K, Stanford M. “From Brain Science to Brain Based Medicine”, Medical
Hypotheses; 63(5):919-20, 2004.
•
Chen, T.J.H, Blum, K, Payte, James, T., Schoolfield, J, Hopper, D., Stanford, M, Braverman,
ER, “Narcotic Antagonists in Drug Dependence: Pilot Study Showing Enhancement of
Compliance with Amino Acid and Enkephalinase Inhibition Therapy”, Medical Hypotheses,
Feb. 25, 2004.
•
Chen J.H, T; Blum K, Mathews D, Fisher L, Schnautz N, Braverman ER, Schoolfield J,
Downs BW, Comings DE. Are dopaminergic genes involved in a predisposition to
pathological aggression? Hypothesizing the importance of “super normal controls” in
psychiatric genetic research of complex behavioral disorders. Medical hypotheses, volume 65,
Issue 4, 2005, pages 703-707
•
Comings DE, Chen TJ, Blum K, Mengucci JF, Blum SH, Meshkin B. Neurogenetic
interactions and aberrant behavioral co-morbidity of attention deficit hyperactivity disorder
(ADHD): dispelling myths.Theor Biol Med Model. 2005 Dec 23;2:50.
•
Blum K, Chen TJ, Ross BD. Innate properties of H-Wave device, a small fiber stimulator
provides the basis for a paradigm shift of electro-therapeutic treatment of pain with increased
functional restoration associated with human neuropathies by affecting tissue circulation: a
hypothesis.Med Hypotheses. 2005;64(5):1066-7
•
Braverman ER, Chen TJ, Schoolfield J, Martinez-Pons M, Arcuri V, Varshavskiy M, Gordon
CA, Mengucci J, Blum SH, Meshkin B, Downs BW, Blum K. Delayed P300 latency
correlates with abnormal Test of Variables of Attention (TOVA) in adults and predicts early
cognitive decline in a clinical setting. Adv Ther. 2006 Jul-Aug;23(4):582-600.
•
Blum K, Chen T, Meshkin B, Downs WB, Gorden C, Blum S, Braverman ER, Arcuri V.
Varshavskiy M, Deutsch R, Martinez-Pons M. Reward Deficiency Syndrome in Obesity: A
Preliminary Cross-Secontional Trail With a Genotrim Variant. Advances in Therapy. 23 (6)
1040-1051, 2006.
•
Blum K, Chen TJ, Martinez-Pons M, Dinubile NA, Waite RL, Schoolfield J, Blum SH,
Mengucci J, Downs BW, Meshkin B. The H-Wave small muscle fiber stimulator, a
nonpharmacologic alternative for the treatment of chronic soft-tissue injury and neuropathic
pain: an extended population observational study.Adv Ther. 2006 Sep-Oct;23(5):739-49.
•
Blum K, Chen TJH, Blum SH, Comings DE, Mengucci JF, Meshkin B, Downs BW,
Braverman ER. Reward Deficiency Syndrome (RDS): Neurogenetic Aspects of Aging and
Related Behavioral Disorders Specific To Dopaminergic Pathways. Anti-Aging Therapeutics,
8: 9-26 2006.
•
Blum K, DiNubile NA, Tekten T, Chen TJ, Waite RL, Schoolfield J, Martinez-Pons M,
Callahan MF, Smith TL, Mengucci J, Blum SH, Meshkin B. H-Wave, a nonpharmacologic
alternative for the treatment of patients with chronic soft tissue inflammation and neuropathic
pain: a preliminary statistical outcome study.Adv Ther. 2006 May-Jun;23(3):446-55.
•
Blum K, Meshkin B, Downs BW. DNA based customized nutraceutical "gene therapy"
utilizing a genoscore: a hypothesized paradigm shift of a novel approach to the diagnosis,
stratification, prognosis and treatment of inflammatory processes in the human. Med
Hypotheses. 2006;66(5):1008-18.
•
Blum K, Chen, TJ, Meshkin B, Downs WB, Gordon, CA, Blum S, Mengucci JF, Braverman
ER, Arcuri V, Deutch R, Martinez-Pons M. Genotrim a DNA-customized nutrigenomic
product, targets genetic factors of obesity: Hypothesizing a dopamine-glucose correlation
demonstrating reward deficiency syndrome (RDS). Medical Hypotheses, 2007, pages 68,
844-852
•
Meshkin B, Blum K. Folate nutrigenetics: a convergence of dietary folate metabolism, folic
acid supplementation, and folate antagonist pharmacogenetics.Drug Metab Lett. 2007
Jan;1(1):55-60.
•
Braverman ER, Chen T, Prihoda T, Sonntag W, Meshkin B, Downs W, Mengucci J, Blum S,
Notaro A, Arcuri V, Varshavskiy M, Blum K. Plasma Growth Hormones, P300 EventRelated Potential and Test of Variables of Attention (T.O.V.A) Are Important
Neuroendocrinological Predictors of Early Cognitive Decline in Clinical Setting: Evidence
supported by structural Equation Modeling Parameter Estimates. Age 2006 29(2-3):55-67.
•
Blum K, Chen T, Meshkin B, Blum S, Mengucci J, Notaro A, Arcuri V, Waite R, Braverman
ER. The PPAR-gamma Pro12Ala allele polymorphism of the Peroxisome ProliferatorActivated Receptor (gamma) Gene (PPARG2) Is a Risk Factor With a Self-Identified Obese
Dutch Population. Gene Therapy & Molecular Biology.11:37-42, 2007
•
Chen T, Blum K, Waite R, Meshkin B, Schoolfield J, Downs WB, Braverman ER, Arcuri V,
Varshavskiy M, Blum S, Mengucci, J Reuben C, Palomo T. Reward Deficiency Syndrome
(RDS) and Substance Use Disorder (S.U.D.): The Gene Narcotic Attenuation Program
(GNAP) including Haveos** (Synaptamine) Attenuates Addictive Related Behaviors.
Advances in Therapy. 2007 Mar-Apr; 24(2): 402-14
•
Chen T, Blum K, Kaats G, Braverman ER, Eisenberg A, Sherman M, Davis K, Comings D,
Wood R, Pullin D, Arcuri V, Varshavski M, Mengucci J, Blum S, Downs, B, Meskin B,
Waite R, Williams L, Schoolfield J, Prihoda T, White L. “Cromium Picolinate (CrP) a
putative anti-obesity nutrient induces changes in body composition as a function of the Taq1
dopamine D2 receptor polymorphisms in a randomized double-blind placebo controlled
study.” Gene Therapy and Molecular Biology Vol 11, 161-170, 2007
•
Blum K, Chen TJH, Meshkin B, Waite RL, Downs BW, Blum SH, Mengucci JF, Arcuri V,
Braverman ER, Palomo T. Manipulation of Catechol-O Methyl Transferase (COMT) Activity
to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency
Syndrome (RDS), is dependent upon gene polymorphisms: A hypothesis. Med Hypotheses.
69(50: 1054-1060, 2007.
•
Blum K, Chen TJH, Downs BW, Meshkin B, Blum SH, Martinez Pons M, Mengucci JF,
Waite RL, Arcuri V, Varshafski M, Braverman ER. Synaptamine (SG8839) An Amino-
Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of
Reward Deficiency Syndrome (RDS). Trends in Applied Sciences Research. 2(2): 132-138,
2007
•
Chen TJH, Blum K, Mathews D, Fisher L, Schnautz N, Braverman ER, Schoolfield J,
Downs BW, Blum SH, Mengucci J, Meskin B, Arcuri V, Bajaj A, Comings DE. Preliminary
Association Of Both the Dopamine D2 Receptor (DRD2) [Taq1 A1 Allele] And The
Dopamine Transporter (DAT1) [480 bp Allele] Genes With Pathological Aggressive
Behavior, A Clinical Subtype Of Reward Deficiency Sybdrome (RDS) in Adolescents. Gene
Ther Mol Biol. Volume 11, 93-112, 2007
•
Chen TJH, Blum K, Kaats G, Braverman ER, Pullin D, Downs BW, Martinez-Pons M, Blum
SH, Mengucci J, Bagchi D, Bagchi M, Robarge A, Meskin B, Arcuri V, Varshavsky M,
Notaro A, Comings DE, White L. Reviewing the role of putative candidate gebes in
“Neurobesigenics”, a clinical subtype of Reward Deficiency Sundrome (RDS). Gene Ther
Mol Biol. Volume 11, 61-74, 2007
•
Braverman ER, Chen TJH, Prihoda T, Sonntag W, Meshkin B, Downs BW, Mengucci J,
Blum SH, Notero A, Arcuri V, Varshavski M, Blum K. Plasma growth hormones, P300
event-related potential and test of variables of attention (TOVA) are important
neuroendocrinological predictors of early cognitive decline in a clinical setting: Evidence
supported by structural equation modeling (SEM) parameter estimates. Springer, American
Aging Association 2007.
•
Thomas JH Chen, Kenneth Blum, Daniel Mathews, Larry Fisher, Nancy Schnautz, Eric R.
Braverman, John Schoolfield, Bernard W. Downs, Seth H. Blum, Julie Mengucci, Brian
Meshkin, Vanessa Arcuri, Anish Bajaj, Roger L. Waite, David E. Comings. Preliminary
association of both the Dopamine D2 Receptor (DRD2) [Taq1 A1 Allele] and the Dopamine
Transporter (DAT1) [480 bp Allele] genes with pathological aggressive behavior, a clinical
subtype of Reward Deficiency Syndrome (RDS) in adolescents. Gene Therapy & Mol. Biol.
11; 93-112. 2007
•
Blum K, THJ Chen, B W Downs, Waite RL, Meshkin B, Braverman R. Nutrigenomics : A
Scientific Wonderland. Journal Of Social Sciences; Life Science issue 2007 (French Journal
National Academy Sciences of France).
•
Thomas JH Chen, Kenneth Blum, Gilbert Kaats, Eric R. Braverman, Arthur Eisenberg,
Mark Sherman, Katharine Davis, David E. Comings, Robert Wood, Dennis Pullin, Vanessa
Arcuri, Michael Varshavski, Julie F. Mengucci, Seth H. Blum, Bernard W. Downs, Brian
Meshkin, Roger L. Waite, Lonna Williams, John Schoolfield, Thomas J Prihoda, Lisa White.
Chromium Picolinate (CrP) a putative anti-obesity nutrient induces changes in body
composition as a function of the Taq1 dopamine D2 receptor polymorphisms in a randomized
double-blind placebo controlled study.Gene Therapy & mol. Biol. 11: 161-170, 2007.
•
Blum K, Chen AL, Braverman ER, Comings DE, Chen TJ, Arcuri V, Blum SH, Downs BW,
Waite RL, Notaro A, Lubar J, Williams L, Prihoda TJ, Palomo T, Oscar-Berman M.
Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis
Treat. 2008 Oct;4(5):893-918.
•
Oben JE, Ngondi JL, Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on
adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and upregulation of the adiponectin gene. Lipids Health Dis. 2008 Nov 13;7:44.
•
Blum K, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW,
Waite RL, Williams L, Prihoda TJ, Kerner MM, Palomo T, Comings DE, Tung H, Rhoades
P, Oscar-Berman M. Activation instead of blocking mesolimbic dopaminergic reward
circuitry is a preferred modality in the long term treatment of reward deficiency syndrome
(RDS): a commentary. Theor Biol Med Model. 2008 Nov 12;5:24.
•
Chen AL, Chen TJ, Braverman ER, Acuri V, Kemer M, Varshavskiy M, Braverman D,
Downs WB, Blum SH, Cassel K, Blum K. Hypothesizing that marijuana smokers are at a
significantly lower risk of carcinogenicity relative to tobacco-non-marijuana smokers:
evidenced based on statistical reevaluation of current literature. J Psychoactive Drugs. 2008
Sep;40(3):263-72.
•
Brian Meshkin, Thomas JH Chen, Amanda LC Chen, Thomas JH Prihoda, Hayley
Morrisette4, Eric R. Braverman, Seth H. Blum, Kimberly Cassel, Lonna Williams, Roger L.
Waite, B. Willliam Downs, Howard Tung, Patrick Rhoades, Kenneth Blum. Health
economics of nutrigenomics in weight management Gene Therapy & Mol. Boil. 12: 25-30.
2008.
•
Blum K, Chen AL, Chen TJ, Rhoades P, Prihoda TJ, Downs BW, Waite RL, Williams L,
Braverman ER, Braverman D, Arcuri V, Kerner M, Blum SH, Palomo T. LG839: anti-obesity
effects and polymorphic gene correlates of reward deficiency syndrome.Adv Ther. 2008
Sep;25(9):894-913.
•
Amanda LC Chen, Kenneth Blum, Thomas JH Chen, Jeffrey Reinking, Roger L Waite,
Bernard W. Downs, Eric R. Braverman, Vanassa Arcuri, Mallory Kerner, Alison Notaro,
Kimberly Cassel, Seth H. Blum, Debasis Bagchi, Manashi Bagchi, Ariel Robarge, Gilbert
Kaats, David E. Comings, Patrick Rhoades, Lonna Williams, Howard Tung. The impact of
biomics technology and DNA directed anti-obesity targeting of the brain reward circuitry.
Gene Therapy & Mol Bio. 12: 45-68, 2008.
•
Blum K, Chen AL, Chen TJ, Prihoda TJ, Schoolfield J, DiNubile N, Waite RL, Arcuri V,
Kerner M, Braverman ER, Rhoades P, Tung H. The H-Wave device is an effective and
safe non-pharmacological analgesic for chronic pain: a meta-analysis. Adv Ther. 2008
Jul;25(7):644-57.
•
Kenneth Blum, Thomas JH Chen, Amanda LC Chen, Patrick Rhoades, Thomas J Prihoda, B.
William Downs, Debasis Bagchi, Manashi Bagchi, Seth H. Blum, Lonna Williams, Eric R.
Braverman, Mallory Kerner, Roger L Waite, Brien Quirk, Lisa White, Jeffrey Reinking.
Dopamine D2 Receptor Taq A1 allele predicts treatment compliance of LG839 in a subset
analysis of pilot study in the Netherlands. Gene Therapy & Mol. Biol. 12: 129-140. 2008.
•
Kenneth Blum, Thomas JH Chen, Lonna Williams, Amanda LC Chen, William B. Downs,
Roger L. Waite, T. Huntington, Simon Sims, Thomas Prihoda, Patrick Rhoads, Jeffrey
Reinking, Dasha Braverman, Mallory Kerner, Seth H. Blum, Brien Quirk, Eric R Braverman.
A short term pilot open label study to evaluate efficacy and safety of LG839, a customized
DNA directed nutraceutical in obesity: Exploring Nutrigenomics. Gene Therapy & Mol. Boil.
12: 371-382. 2008
•
Blum K, Ho CK, Chen LC, Fulton M, Fulton B, Westcott WL, Reinl G, Braverman ER,
DiNubile N, Chen TJH. The H-Wave Device Induces No-Dependent Augmented
Microcirculation and Angiogenesis Providing Both Analgesia and Tissue Healing in Sports
Injuries. The Physician and Sports Medicine. 36 (1) : 103-115. .
•
Smith TL, Blum K, Callahan MF, Dinubile NA, Chen TJ, Waite RL H-Wave(R) induces
arteriolar vasodilation in rat striated muscle via nitric oxide-mediated mechanisms. J Orthop
Res. 2009 27(9):1248-51
•
Chen AL, Chen TJ, Waite RL, Reinking J, Tung HL, Rhoades P, Downs BW, Braverman E,
Braverman D, Kerner M, Blum SH, DiNubile N, Smith D, Oscar-Berman M, Prihoda TJ,
Floyd JB, O'Brien D, Liu HH, Blum K. Hypothesizing that brain reward circuitry genes are
genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment
targets for chronic pain conditions. Med Hypotheses. 2009 Jan;72(1):14-22.
•
•
•
Blum K, Chen AL, Oscar-Berman M, Chen TJ, Lubar J, White N, Lubar J, Bowirrat
A, Braverman E,Schoolfield J, Waite RL, Downs BW, Madigan M, Comings DE, Davis
C, Kerner MM, Knopf J, Palomo T,Giordano JJ, Morse SA, Fornari F, Barh D, Femino
J, Bailey JA. Generational association studies of dopaminergic genes in reward deficiency
syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors.
Int J Environ Res Public Health. 2011 Dec;8(12):4425-59. doi: 10.3390/ijerph8124425.
Blum K, Chen TJH, Meskin B, Downs BW, Waite RL, Braverman ER, Arvuri V, Notaro A,
Mengucci JF, Blum SH, Bagchi D, Bagchi M, Robarge A, Kaats G, Comings DE.
Pharmacogenomics & Nutrigenomic Aspects of Neurobesigenics, A Genetic Pleiotropic
Clinical Subtype of Reward Deficiency Syndrome (RDS). Current Pharmacogenomics (In
Press).
B. William Downs, Amanda LC Chen, Thomas JH Chen, Roger L. Waite, Eric R.
Braverman, Mallory Kerner, Dasha Braverman, Patrick Rhoades, Thomas J Prihoda, Tomas
Palomo, Marlene Oscar –Berman , Jeffrey Reinking, Seth H Blum , Nicholas A. DiNublie,
Kenneth Blum. Nutrigenomic targeting of carbohydrate craving behavior: Can we manage
obesity and aberrant craving behaviors with neurochemical pathway manipulation by
Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS)
Map? Medical Hypotheses (2009) 73(3):427-34. doi: 10.1016/j.mehy.2009.02.037.
•
Kenneth Blum, Amanda LC Chen, Thomas JH Chen, Roger L. Waite, Nicholas DiNubile, B.
William Downs, Mallory Kerner, Eric Braverman, Thomas J Prihoda, Howard Tung. Chronic
H-Wave® Device Stimulation and Program Induces Significant Increases in the Range of
Motion of Post- Operative Rotator Cuff Reconstruction in a Double-Blinded Randomized
Placebo Controlled Human Study. BMC Musculoskeletal Disorders.
10:132 doi:10.1186/1471-2474-10-132
•
Kenneth Blum, Amanda LH Chen, Thomas JH Chen, Roger L. Waite, B William Downs,
Eric R. Braverman, Mallory Kerner, Howard Tung. Healing Enhancement of Chronic Venous
Stasis Ulcers Utilizing H-Wave® Device Therapy: A Case Series. The Case Journal 2010
Feb 10;3:54. doi: 10.1186/1757-1626-3-54..
•
•
•
•
•
•
•
•
Braverman ER, Chen AL, Chen TJ, Schoolfield JD, Notaro A, Braverman D, Kerner M,
Blum SH, Arcuri V, Varshavskiy M, Damle U, Downs BW, Waite RL, Oscar-Berman M,
Giordano J, Blum K. Test of variables of attention (TOVA) as a predictor of early attention
complaints, an antecedent to dementia. Neuropsychiatr Dis Treat. 2010 Oct 15;6:681-90.
doi:
Kenneth Blum, Amanda LC Chen,Nicholas DiNubile,Thomas JH Chen,Thomas J Prihoda,
Ken Williams, William B. Downs, Gary Reinl ,Mallory Kerner John B. Floyd, David W.
O’Brien, Eric R. Braverman. The H-Wave device® is a non-addicting and safe analgesic for
chronic nonmalignant back pain: a bio-economic analysis. Adv. Ther.
Blum K, DiNubile NA, Tekten T, Chen TJ, Waite RL, Schoolfield J, Martinez-Pons M,
Callahan MF, Smith TL, Mengucci J, Blum SH, Meshkin B. H-Wave, a nonpharmacologic
alternative for the treatment of patients with chronic soft tissue inflammation and neuropathic
pain: a preliminary statistical outcome study. Adv Ther. 2006 May-Jun;23(3):446-55.
Westcott WL, Chen T, Neric FB, DiNubile N, Bowirrat A, Madigan M, Downs BW,
Giordano J, Morse S, LC Chen A, Bajaj A, Kerner M, Braverman E, Reinl G, Blakemore M,
Whitehead S, Sacks L, Blum K. The Marc ProTM Device Improves Muscle Performance and
Recovery from Concentric and Eccentric Exercise Induced Muscle Fatigue in Humans: A
Pilot Study. JEPonline 2011;14(2):55-67.
Thomas L. Smith, Kenneth Blum, Michael F. Callahan, Nicholas A. Dinubile, Thomas JH
Chen, John Schoolfield, Brian Meshkin, Roger L. Waite. H-Wave™ Treatment Induces
Angiogenesis and Increases Blood Flow in Microcirculatory Studies in Rats. Adv Orthoped
Research (in press)
Braverman ER, Chen TJ, Chen AL, Arcuri V, Kerner MM, Bajaj A, Carbajal J, Braverman D,
Downs BW,Blum K. Age-related increases in parathyroid hormone may be antecedent to both
osteoporosis and dementia. BMC Endocr Disord. 2009 Oct 13;9:21. doi: 10.1186/14726823-9-21.
Eric R. Braverman, Amanda LC Chen, Thomas JH. Chen, John Schoolfield, Mallory Kerner,
Roger L. Wait, Howard Tung, Kenneth Blum. Low Plasma Levels of Sex Hormones and
Human Growth Factor(s) Correlate to Cognitive Decline as a Function of Gender. BMCResearch Notes. 2009, 2:126 doi:10.1186/1756-0500-2-126
Blum K, Han D, Hauser M, Downs BW, Giordano J, Borten J, Winchell W, Simpatico T,
Barh D. Nrueogenetic impairments of brain reward circuitry links to Reward Deficiency
Syndrome(RDS) as evidenced by genetic addiction risk score(GARS): A case study. IIOAB
4(1): 4-9.
•
Blum K, Ho CK, Chen AL, Fulton M, Fulton B, Westcott WL, Reinl G, Braverman ER,
Dinubile N, Chen TJ. The Wave .Dependent Augmented Microcirculation and Angiogenesis,
Providing Both Analgesia and Tissue Healing in Sports Injuries. Phys Sportsmed. 2008
Dec;36(1):103-14.
Fritch D, Blum K, Nonnemacher S, Haggerty BJ, Sullivan MP, Cone EJ. Identification and
quantitation of amphetamines, cocaine, opiates, and phencyclidine in oral fluid by liquid
chromatography-tandem mass spectrometry.J Anal Toxicol. 2009 Nov-Dec;33(9):569-77.
• Braverman ER, Chen TJ, Chen AL, Kerner MM, Tung H, Waite RL, Schoolfield J, Blum K.
Preliminary investigation of plasma levels of sex hormones and human growth factor(s), and
P300 latency as correlates to cognitive decline as a function of gender. BMC Res Notes.
2009 Jul 7;2:126.
•
•
Downs BW, Chen AL, Chen TJ, Waite RL, Braverman ER, Kerner M, Braverman D,
Rhoades P, Prihoda TJ, Palomo T, Oscar-Berman M, Reinking J, Blum SH, DiNubile NA,
Liu HH, Blum K. Nutrigenomic targeting of carbohydrate craving behavior: can we manage
obesity and aberrant craving behaviors with neurochemical pathway manipulation by
Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS)
Map?Med Hypotheses. 2009 Sep;73(3):427-34.
Smith TL, Blum K, Callahan MF, DiNubile NA, Chen TJ, Waite RL. H-Wave induces
arteriolar vasodilation in rat striated muscle via nitric oxide-mediated mechanisms. J
Orthop Res. 2009 Sep;27(9):1248-51.
•
Blum K, Chen AL, Braverman ER, Comings DE, Chen TJ, Arcuri V, Blum SH, Downs BW,
Waite RL, Notaro A, Lubar J, Williams L, Prihoda TJ, Palomo T, Oscar-Berman M.
Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatric
Dis Treat. 2008 Oct;4(5):893-918.
•
Oben JE, Ngondi JL, Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on
adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and upregulation of the adiponectin gene. Lipids Health Dis. 2008 Nov 13;7:44.
•
Blum K, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW,
Waite RL, Williams L, Prihoda TJ, Kerner MM, Palomo T, Comings DE, Tung H, Rhoades
P, Oscar-Berman M. Activation instead of blocking mesolimbic dopaminergic reward
circuitry is a preferred modality in the long term treatment of reward deficiency syndrome
(RDS): a complmentary. Theor Biol Med Model. 2008 Nov 12;5:24
•
Chen AL, Chen TJ, Braverman ER, Acuri V, Kemer M, Varshavskiy M, Braverman D,
Downs WB, Blum SH, Cassel K, Blum K. Hypothesizing that marijuana smokers are at a
significantly lower risk of carcinogenicity relative to tobacco-non-marijuana smokers:
evidenced based on statistical reevaluation of current literature. J Psychoactive Drugs. 2008
Sep;40(3):263-72.
•
Chen AL, Chen TJ, Waite RL, Reinking J, Tung HL, Rhoades P, Downs BW, Braverman E,
Braverman D, Kerner M, Blum SH, DiNubile N, Smith D, Oscar-Berman M, Prihoda TJ,
Floyd JB, O'Brien D, Liu HH, Blum K. Hypothesizing that brain reward circuitry genes are
genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic
treatment targets for chronic pain conditions. Med Hypotheses. 2009 Jan;72(1):14-22. 2010.
•
Blum K, Chen AL, Chen TJ, Downs BW, Braverman ER, Kerner M, Savarimuthu S, Bajaj A,
Madigan M, Blum SH, Reinl G, Giordano J, Dinubile N. Healing enhancement of chronic
venous stasis ulcers utilizing H-WAVE(R) device therapy: a case series. Cases J. 2010 Feb
10;3:54.
•
Braverman ER, Bowirrat A, Damle UJ, Yeldandi S, Chen TJ, Madigan M, Kerner M, Huang
SX, Savarimuthu S, Blum K. Adult growth hormone deficiency treatment with a combination
of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulinlike growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case
report. J Med Case Reports. 2010 Sep 15;4(1):305
•
Miller DK, Bowirrat A, Manka M, Miller M, Stokes S, Manka D, Allen C, Gant C, Downs
BW, Smolen A, Stevens E, Yeldandi S,Blum K. Acute intravenous synaptamine complex
variant KB220™ "normalizes" neurological dysregulation in patients during protracted
abstinence from alcohol and opiates as observed using quantitative electroencephalographic
and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.
Postgrad Med. 2010
Nov;122(6):188-213. doi: 10.3810/pgm.2010.11.2236.
•
Blum K, Chen TJ, Morse S, Giordano J, Chen AL, Thompson J, Allen C, Smolen A, Lubar J,
Stice E, Downs BW, Waite RL, Madigan MA, Kerner M, Fornari F, Braverman ER.
Overcoming
"abnormalities and reward gene deficits during protracted abstinence in male
psychostimulant and polydrug abusers utilizing putative dopamine D. Postgrad Med. 2010
Nov;122(6):214-26. doi: 10.3810/pgm.2010.11.2237.
•
Blum K, Giordano J, Morse S, Liu Y, Tan J, Bowirrat A, Smolen A, Waite R, Downs W,
Madigan M, Kerner M, Fornari F, Stice E, Braverman, E, Miller D. Bailey J. Genetic
Addiction Risk Score (GARS) Analysis: Exploratory development of polymorphic risk
alleles in poly-drug addicted males. International J. Omics and Biotechnology 01/2010;
DOI:http://www.doaj.org/doaj
•
Bowirrat A, Chen TJ, Blum K, Madigan M, Bailey JA, Chuan Chen AL, Downs BW,
Braverman ER, Radi S, Waite RL, Kerner M, Giordano J, Morse S, Oscar-Berman M, Gold
M. Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress
Disorder: Unlocking the Mysteries of Resilience and Vulnerability. Curr Neuropharmacol.
2010 Dec;8(4):335-58. doi: 10.2174/157015910793358123.
•
Chen TJ, Blum K, Chen AL, Bowirrat A, Downs WB, Madigan MA, Waite RL, Bailey JA,
Kerner M, Yeldandi S, Majmundar N, Giordano J, Morse S, Miller D, Fornari F, Braverman
ER. Neurogenetics and clinical evidence for the putative activation of the brain reward
circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map. J
Psychoactive Drugs. 2011 Apr-Jun;43(2):108-27.
•
Braverman ER, Chen AL, Chen TJ, Schoolfield JD, Notaro A, Braverman D, Kerner M,
Blum SH, Arcuri V, Varshavskiy M, Damle U, Downs BW, Waite RL, Oscar-Berman M,
Giordano J, Blum K. Test of variables of attention (TOVA) as a predictor of early attention
complaints, an antecedent to dementia. Neuropsychiatr Dis Treat. 2010 Oct 15;6:681-90.
•
Blum K, Chen AL, Chen TJ, Downs BW, Braverman ER, Kerner M, Savarimuthu S, Bajaj A,
Madigan M, Blum SH, Reinl G, Giordano J, Dinubile N. Healing enhancement of chronic
venous stasis ulcers utilizing H-WAVE(R) device therapy: a case series. Cases J. 2010 Feb
10;3:54.
•
. Blum K, Chen TJ, Downs BW, Bowirrat A, Waite RL, Braverman ER, Madigan M, OscarBerman M, DiNubile N, Stice E, Giordano J, Morse S, Gold M. Neurogenetics of
dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse:
proposing "deprivation-amplification relapse therapy" (DART)Postgrad Med. 2009
Nov;121(6):176-96. Review.
•
Blum K, Chen TJ, Chen AL, Madigan M, Downs BW, Waite RL, Braverman ER, Kerner M,
Bowirrat A, Giordano J, Henshaw H, Gold MS. Do dopaminergic gene polymorphisms affect
mesolimbic reward activation of music listening response? Therapeutic impact on Reward
Deficiency Syndrome (RDS).Med Hypotheses. 2010 Mar;74(3):513-20.
•
Blum K, Giordano j, Morse S, Liu Y, Tain J, Bowirrat A, Smolen A, Waite R, Down B,
Madigan M, Kerner M, Fornari F, Barverman E, Miller D, Bailey J. Addiction Risk Score
(Gars) Analysis: Exploratory Development of Polymorphic risk Alleles in Polydrug addicted
males. IIOAB Vol1 (20 1-14.
•
Blum K, Giordano J, Morse S, Bowirrat A, Madigan M, Downs W, Waite R, Kerner M,
Damle U, Braverman ER, Bauer G, Femino J, Bailey J, Dinunile N, Miller D, Archer T,
Simpatico T. Understanding the high mind Humans are still evolving genetically. IIOABIndia 1(2);; 2010 1-14.
•
Kenneth Blum, John Giordano, Siobhan Morse, Arthur Anderson, Javier Carbajal, Roger
Waite, Bernarld Downs, Jaclyn Downs, Margaret Madigan, Debmalya Barh, Eric Braverman.
Hypothesizing Synergy between Acupuncture/ Auriculotherapy and Natural Activation of
Mesolimbic Dopaminergic Pathways: Putative Natural Treatment Modalities for the
Reduction of Drug Hunger and Relapse IIOAB Letters Vol 1, No 1 (2011)
•
Blum K, Fornari F, Downs BW, Waite RL, Giordano J, Smolen A, Lui Y, Tain J, Majmundr
N, Braverman ER. Chapter 19: Genetic Addiction Risk Score (GARS): Testing for
Polygentic Predisposition and Risk for Reward Deficiency Syndrome (RDS). in Gene
Therapy Applications (Ed. C King) pages 327-362.
•
Correlation of the Taq1 Dopamine D2 Receptor Gene and Percent Body Fat in Obese and
Screened Control Subjects: A Preliminary Report. Chen Alc, Blum K, Chen TJH, Giordano J,
Downs BW, Han D., Barh D., Braverman. Journal of Food & Function (J Royal Society of
Chemistry) .2012 3(1): 40-48.
•
Blum K, Chen TJ, Bailey J, Bowirrat A, Femino J, Chen AL, Simpatico T, Morse
S, Giordano J, Damle U,Kerner M, Braverman ER, Fornari F, Downs BW, Rector C, Barh
D, Oscar-Berman M. Can the chronic administration of the combination of buprenorphine
and naloxone block dopaminergic activity causing anti-reward and relapse potential? Mol
Neurobiol. 2011 Dec;44(3):250-68. doi: 10.1007/s12035-011-8206-0.
•
Westcott WL, Chen T, Neric FB, DiNubile N, Bowirrat A, Madigan M, Downs BW,
Giordano J, Morse S, LC Chen A, Bajaj A, Kerner M, Braverman E, Reinl G, Blakemore M,
Whitehead S, Sacks L, Blum K. The Marc ProTM Device Improves Muscle Performance and
Recovery from Concentric and Eccentric Exercise Induced Muscle Fatigue in Humans: A
Pilot Study. JEPonline 2011;14(2):55-67.
•
DiNubile N, Westcott W, Reinl G, Bajaj A, Braverman ER, Madigan MA, Giordano J, Blum
K. The MarcProTM Device is a Novel Paradigm Shift in Muscle Conditioning, Recovery
and Performance: Induction of Nitric Oxide (NO) Dependent Enhanced Microcirculation
Coupled with Angiogenesis Mechanisms. JEPonline 2011;14(5):10-19.
•
Westcott W, Varghesse J, Dinubile N, Moynih N, Loud RL, Whitehead S, Brothers S,
Giordano J, Morse S, Madigan M, Blum K. Exercise and Nutrition More Effective than
Exercise Alone for Increasing Lean Weight and Reducing Resting Blood Pressure. Exercise
and Nutrition More Effective than Exercise Alone for Increasing Lean Weight and Reducing
Resting Blood Pressure. JEPonline. 14 (3) 2011, 120133.
•
Blum K, Bailey J, Gonzalez AM, Oscar-Berman M, Liu Y, Giordano J, Braverman E, Gold
M. Neuro-Genetics of Reward Deficiency Syndrome (RDS) as the Root Cause of
"Addiction Transfer": A New Phenomenon Common after Bariatric Surgery. J Genet Syndr
Gene Ther. 2011 Dec 23;2012(1). pii: S2-001.
•
Blum K, Bailey J, Giordano J, Borsten J, Waite RL, Downs BW, Downs JM, Madigan M,
Fornarii F., Simpatico T, Jones D, Braverman, Barh D. Diagnosis and Healing in Veterans
Suspected of Suffering From Post-traumatic Stress Disorder (PTSD) Using Reward Gene
Testing and Reward Circuitry Natural Dopaminergic Activation. Omics Genetic Syndromes
& Gene Therapy 3 (3) 100116,2012.
•
Morse S, Giordano J, Perrine K, Downs BW, Waite RL, Madigan M, Bailey J, Braverman,
Damle U, Simpatico T, Moelelr MD, Blum K. Audio Therapy Significantly Attenuates
Aberrant Mood in Residential Patient Addiction Treatment: Putative Activation of
Dopaminergic Pathways in the Meso-Limbic Reward Circuitry of Humans. Journal of
Addiction Research & Therapy S3:001. doi:10.4172/2155-6105.S3- 001
•
Neuropsychiatric Genetics of Happiness, Friendships and Politics: Hypothesizing that “Birds
of a Feather (Homophily)” Flock Together as a Function of “Reward Gene (s)”
Polymorphisms.Blum K, Oscar-Berman M, Bowirrat A, Giordano J, Madigan M, Braverman
ER, Fornari F. Journal Genetic Syndromes & Gene Therapy 3(2) in press 2012
•
Neuropsychiatric Genetics of Happiness, Friendships and Politics: A new era in
understanding social interface. Blum, K, Oscar-Berman-M, Giordano J, Simpatico T,
Lohman R, Hauser M, Borsten J, Braverman ER. Genetic Syndromes & Gene Therapy 3(2)
1000e106,2012
•
. Blum K, Bowirrat A, Downs BW, Waite RL, Giordano J, Morse S, Madigan M, Downs JM,
Braverman ER, Polanin M, Fornari F, Simpatico T. Nutrigenomics of Neuradaptogen
Amino-Acid-Therapy (NAAT)™: Overcoming Carbohydrate Bingeing and Overeating
Through Neurometabolic Mechanisms Journal of Functional Food in Health and Chronic
Disease. 2011, 1(9):310-378
•
Bowirrat A, Amanda LCH, Madigan M, Chen TJH, Bailey J, Braverman ER, Kerner M,
Giordano J , Morse S, Downs BW, Waite RL, Oscar –Berman M, Blum K.
Neuropsychopharmacology and Neurogenetic Aspects of Executive Functioning: Are
Humans “Hard Wired” To Achieve Appropriate Goals? Molecular Neurobiology 2012
Apr;45(2):298-313.
•
Blum K, Chen ALCH, Chen TJH, Lubar J, White N, Lubar J, Bowirrat A, Braverman ER,
Scholfield J, Waite RL, Downs BW, Madigan M, Comings DE, Davis C Kerner M, Palomo T,
Stice E , Oscar-Berman M, Giordano J, Morse S, Bailey J. Generational association studies of
dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate
phenotypes for reward dependence behaviors. International Journal of environmental
Research and Public Health 8(2) 4425-4459, 2011.
•
Blum K Oscar-Berman, Femino J, Waite RL, Benya L, Giordano J, B.W. Downs, Braverman
Er, Loehmann R, Dushaj K, Simpatico T, Hauser M, Barh D, McLaughlin (2013) Withdrawal
from Buprenorphine/naloxone and Maintenance with a Natural Dopaminergic Agonist: a
Cautionary Note. J Addict Res Ther. 4: 146. Dol: 10.4172/2155-6105.1000146.
•
Archer T, Oscar-Berman M, Blum K. Epigenetics in Developmental Disorder: ADHD and
Endophenotypes J Genet Syndr Gene Ther. 2011 Jun 30;2(104). pii: 1000104.
•
Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, Gold M. Sex, Drugs and
Rock ‘N’ Roll: Hypothesizing Common mesolimbic activation as a function of reward gene
polymorphisms. Journal Psychoactive Drugs 44(1) 38-55,2012.
•
Blum K, Gardner E, Oscar-Berman M, Gold M. “Wanting” and “Liking” Linked to Reward
Deficiency Syndrome (RDS): Hypothesizing differential resposivity in brain reward circuitry
Cur Pharm Des. 2012;18(1):113-8.
•
Blum K, Bagchi D, Barh D, Giordano J, Morse S, Downs BW, Waite RL, Downs JM,
Madigan M , Ross –Coker C, Archer T, Braverman ER. Sugar craving a world epidemic: Is
there a nutrigenomic solution? Journal of Functional Foods. 2012 1(9) 310-378.
•
Braverman ER, Braverman D, Acuri V, Kerner K, Downs BW and Blum K. Sustainable
weight loss and muscle gain utilizing the Rainbow Diet, Diethypropion (Tenuate) [A
noradrenergic Agonist], Synaptamine Complex{Kb220} {a dopaminergic agonist], hormonal
deficiency repletion therapy and exercise. The Bariatrician : American journal of bariatric
medicine 2011
•
Blum K, Liu Y, Shriner R, Gold MS. Reward circuitry dopaminergic activation regulates
food and drug craving behavior. Curr Pharm Des. 2011;17(12):1158-67.
•
Blum K, Gold MS. Neuro-chemical activation of brain reward meso-limbic circuitry is
associated with relapse prevention and drug hunger: a hypothesis. Med Hypotheses.
2011
76(4):576-84.
•
Stice E, Yokum S, Blum K, Bohon C. Weight gain is associated with reduced
striatal response to palatable food. J Neurosci. 2010 29;30(39):13105-9..
•
Archer T, Oscar-Berman-M, Blum K, Gold M. Neurogenetics and Epigenetics in Impulsive
Behavior Impact in Reward Circuitry. Genetic Syndromes & Gene Therapy 3(3) 1000115,
2012.
•
Blum K, Giordano J, Borsten J, Downs BW, Hauser M, Simpatico T,Lohman R, Braverman
ER, Barh D. Translational research to uncover diagnostic & therapeutic gene targets
emerging in a genomic era: From bench to bedside. Journal of Genetic Disorders & Disease
Information. 1(1) 100e103 .2012.
•
Blum K, Chen AL, Giordano J, Borsten J, Chen TJ, Hauser M, Simpatico T, Femino J,
Braverman ER, Barh D. The addictive brain: all roads lead to dopamine. J Psychoactive
Drugs. 2012 Apr-Jun;44(2):134-43.
•
Miller M, Chen ALC, Stokes S, Silverman S, Bowirrat A, Manka M, Manka D, Miller D,
Perrine K, Chen TJH, Bailey J, Downs BW, Waite RL, Madigan M, Braverman ER, Damle
U, Kerner M, Giordano J, Morse S, Oscar-Berman M, Barh D, Blum K. Early intravenous
KB220V-Neuroadaptagen Amino-Acid Therapy (NAAT) improves behavioral outcomes in a
residential addiction treatment program: A pilot study. Journal Psychoactive Drugs 2012
Nov-Dec;44(5):398-409.
•
Oscar-Berman-M, Femino J, Blum K. Genes and Reward Dependence Circuitry: importance
of Dopamine. Chapter in Neurocognition and Neuroscience Book (in press). 2013
•
Blum K, Oscar-Berman M, Stuller E, Miller D, Giordano J, Morse S, McCormick L, Downs
BW, Wait RL, Barh D, Neal D, Braverman ER, Lohmann R, Borsten J, Hauser M, Han D,
Liu Y, Simpatico T. Neurogentics and Nutrigenomics of Neuro-Nutrient Therapy for Reward
Deficiency Syndrome (RDS): Clinical Ramifications as a function of Molecular
Neurobiological Mechanisms. Omics Journal of Addiction Research & Therapy 3:139.
doi:10.4172/2155-6105.1000139.
•
Blum K, Oscar-Berman, M, Giordano J, Downs BW, Simpatico T, Han D, Femino J.
Neurogenetic impairments of brain reward circuitry links to Reward Deficiency syndrome
(RDS): Potential Nutrigenomic Induced Dopaminergic Activation. Omics Journal of Genetic
Syndromes & Gene Therapy 2012, Oct 17;3(4).
•
Blum K (with J.Giordano, J Borsten, M Hauser, BW Downs, M Madigan, T. Simpatico, J
Femino and ER Braverman . The Addiction Gene: Why millions are inherently at risk ?
Colliers April 2012.
•
Braverman E, Oscar-Berman M, Lohmann R, Kennedy R, Kerner M, Dushaj K, Blum K.
Low and Normal IGF-1 Levels in Patients with Chronic Medical Disorders (CMD) is
Independent of Anterior Pituitary Hormone Deficiencies: Implications for Treating IGF-1
Abnormal Deficiencies with CMD. J Genet Syndr Gene Ther. 2013 Feb 9; 4(123). doi:pii:
1000123.
•
Archer T, Oscar-Berman M, Blum K, Gold M. Epigenetic Modulation of Mood Disorders. J
Genet Syndr Gene Ther. 2013 Feb 11;4(120).
•
Blum K, Oscar-Berman M, Barh D, Giordano J, Gold M. Dopamine Genetics and Function
in Food and Substance Abuse. J Genet Syndr Gene Ther. 2013 Feb 10;4(121).
•
Campbell H, Oscar-Berman M, Giordano J, Beley T, Barh D, Downs B, Blum K. Common
Phenotype in Patients with Both Food and Substance Dependence: Case Reports. J Genet
Syndr Gene Ther. 2013 Feb 6;4(122).
•
Braverman ER, Blum K, Damle UJ, Kerner M, Dushaj K, Oscar-Berman M. Evoked
Potentials and Neuropsychological Tests Validate Positron Emission Topography (PET)
Brain Metabolism in Cognitively Impaired Patients. PLoS One. 2013;8(3):e55398. doi:
10.1371/journal.pone.0055398.
•
Barh D, Barve N, Gupta K, Chandra S, Jain N, Tiwari S, Leon-Sicairos N, Canizalez-Roman
A, dos Santos AR, Hassan SS, Almeida S, Ramos RT, de Abreu VA, Carneiro AR, Soares
Sde C, Castro TL, Miyoshi A, Silva A, Kumar A, Misra AN, Blum K, Braverman ER,
Azevedo V. Exoproteome and secretome derived broad spectrum novel drug and vaccine
candidates in Vibrio cholerae targeted by Piper betel derived compounds. PLoS One.
2013;8(1):e52773. doi: 10.1371/journal.pone.0052773.
•
Blum K, Oscar-Berman M, Bowirrat A, Giordano J, Madigan M, Braverman ER, Barh D,
Hauser M, Borsten J, Simpatico T. Neuropsychiatric Genetics of Happiness, Friendships,
and Politics: Hypothesizing Homophily ("Birds of a Feather Flock Together") as a Function
of Reward Gene Polymorphisms.J Genet Syndr Gene Ther. 2012 Apr 13;3(112).
•
Barh D, Gupta K, Jain N, Khatri G, León-Sicairos N, Canizalez-Roman A, Tiwari S, Verma
A, Rahangdale S, Shah Hassan S, dos Santos AR, Ali A, Guimarães LC, Thiago Jucá Ramos
R, Devarapalli P, Barve N, Bakhtiar M, Kumavath R, Ghosh P, Miyoshi A, Silva A, Kumar
A, Misra AN, Blum K, Baumbach J, Azevedo V. Conserved host-pathogen PPIs. Globally
conserved inter-species bacterial PPIs based conserved host-pathogen interactome derived
novel target in C. pseudotuberculosis, C. diphtheriae, M. tuberculosis, C. ulcerans, Y. pestis,
and E. coli targeted by Piper betel compounds. Integr Biol (Camb). 2013 Mar;5(3):495-509.
•
Blum K, Giordano J, Oscar-Berman M, Bowirrat A, Simpatico T, Barh D. Diagnosis and
Healing In Veterans Suspected of Suffering from Post-Traumatic Stress Disorder (PTSD)
Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic Activation. J
Syndr Gene Ther. 2012 May 31;3(3):1000116.
Genet
•
Kerner M, Braverman ER, Rhoades P, Tung H. The H-Wave device is an effective and safe
non-pharmacological analgesic for chronic pain: a meta-analysis. Adv Ther. 2008
Jul;25(7):644-57. doi: 10.1007/s12325-008-0073-3.
•
Braverman ER, Chen TJ, Prihoda TJ, Sonntag W, Meshkin B, Downs BW, Mengucci JF,
Blum SH, Notaro A, Arcuri V, Varshavskiy M, Blum K. Plasma growth hormones, P300
event-related potential and test of variables of attention (TOVA) are important
neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence
supported by structural equation modeling (SEM) parameter estimates. Age (Dordr). 2007
Sep;29(2-3):55-67. doi: 10.1007/s11357-007-9030-3.
•
Blum K, Chen TJ, Meshkin B, Waite RL, Downs BW, Blum SH, Mengucci JF, Arcuri
V, Braverman ER, Palomo T. Manipulation of catechol-O-methyl-transferase (COMT)
activity to influence the attenuation of substance seeking behavior, a subtype of Reward
Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis.
Med
Hypotheses. 2007;69(5):1054-60.
•
Blum K, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mengucci JF, Braverman
ER, Arcuri V, Varshavskiy M, Deutsch R, Martinez-Pons M. Reward deficiency syndrome in
obesity: a preliminary cross-sectional trial with a Genotrim variant. Adv Ther. 2006 NovDec;23(6):1040-51.
•
Blum K, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mangucci JF, Braverman
ER, Arcuri V, Deutsch R, Pons MM. Genotrim, a DNA-customized nutrigenomic product,
targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation
demonstrating reward deficiency syndrome (RDS). Med Hypotheses. 2007;68(4):844-52.
•
Kerner M, Braverman ER, Rhoades P, Tung H. The H-Wave device is an effective and safe
non-pharmacological analgesic for chronic pain: a meta-analysis.
Adv Ther. 2008 Jul;25(7):644-57. doi: 10.1007/s12325-008-0073-3.
•
Blum K, Amanda Lin Chen, Thomas JH Chen, Thomas J Prihoda, Roger L Waite, Lonna
Williams, B. William Downs, Mallory Kerner, Eric R. Braverman. A Randomized, DoubleBlind, Placebo Controlled Investigation of the Anti-Anxiety Effects of Synapatmine
Complex™, A Putative Dopaminergic Activator: Hypothesizing a Targeted
Psychodermatological Nutraceutical to Reduce Stress and Improve Dermatologic
Conditions.J. Psychsocial Science (in preperation).
•
Blum, K., Noble, E.P., Sheridan, P.J., Montgomery, A., Ritchie, T., Highsmith, M., Cohn,
J.B., Wood, R. and Pritchett, D.B. and Braverman, ER. Allelic association of the serotonin
5HT2A receptor gene in alcoholism: a possible modifying gene. (In preparation).
•
Blum, K., Noble, E.P., Sheridan, P.J., Montgomery, A., Ritchie, T., Highsmith, M., Cohn,
J.B., Wood, R. and Pritchett, D.B. and Braverman, ER. Allelic association of the serotonin
5HT2A receptor gene in alcoholism: a possible modifying gene. (In preparation).
•
Blum, K., Braverman, E,R. Gill, J., Cull, J.G., Taub, M., Li, C., D.E. Comings, Sherman, M.,
and Eisenberg, A. Dopamine D2 Receptor gene polymorphisms and alcoholism: appropriate
use of "super" normals and "severe" probands (in preparation)
•
Blum, K., and Halikas, J.A. Confirmation of an association of DRD2A1 Allele and cocaine
dependence (In preparation).
•
Blum, K., Braverman, E.R., Wood, R.E., Gill, J. Taub, M., Chen, T.H.J. Enhanced frequency
of the Taq1A1 allele of the dopamine D2 receptor gene in psychiatrically-ill subjects with
comorbid substance use disorder (in preparation)
•
Holder, J., Duncan, R. and Blum, K., Subluxation-based chiropractic care in residential drug
treatment. (in preparation)
•
Holder, J., Blum, K., Duncan, R. Wood, R. Improvement of retention with auricular therapy
in residential drug treatment (in preparation)
•
Blum K, Chen T, Waite R., Dinublie N, Smith T, Callahan M, Prihoda T, Schoolfield J,
Downs W, Arcuri V, Braverman ER, Notaro A, Morrisette H, Mengucci J, Blum S, Payte J,
Palomo T, Kerner M, Floyd J, Williams L, and O'Brien D. ""Reward" Gene Polymorphisms
May Predict High Rates of Injury and Addiction in the Workforce: a Theoretical Review."
International Journal of Law & Psychiatry (in preparation)
•
Blum K, Gold MS. “Depressed Dopamine Function is Attention- Deficit/Hyperactivity
Disorder: Should Genotyping of Dopaminergic Polymorphisms Constitute Early Diagnosis in
Children?” Pediatrics, Postgradmed (in preparation).
•
Waite RL, Allen C, Giordano J, Morse S, Bowirrat A, Downs BW, Madigan M, Braverman
ER, Kerner M, Bailey J, Blum K. Quantitative Electroencephalography Analysis (qEEG) of
Neuro-Electro-Adaptive Therapy 12™ [NEAT12] Up-Regulates Cortical Potentials in an
Alcoholic During Protracted Abstinence: Putative Anti-Craving Implications
Neuromodulation (to be submitted)
•
Blum K, Schoenthaler SJ, Oscar-Berman M, Han D, Giordano J, Bruscino M, Alleyn K,
Beley T, Jones S, Hurley K, Campbell H, Simpatico T, Loehmann R, Dushaj D, B.W.
Downds, Madigan MA, Braverman ER. Relapse Rates as a Function of the Level of
Education in a Holistic Addiction Treatment Program: Is Dopamine a culprit? PLOSONE (to
be submitted)
•
H-Wave Device® Augments Healing by Inducing Cellular Mechanisms Responsible For
Increased Blood Flow and Loading of Injured Tissue: A hypothesis Having implications for
Clinical Practice. Blum k, Chen TJH, Reinl G, Chen ALCH, Dinubile N, Madigan M, Downs
BW, Bowirrat A, Bajaj A, Morse S, Giordano J, Westcott W, Smith L, Kerner M, Damle U,
Braverman ER, Sacks L. BMC-Theoretical Biology and Medical Modeling (to be submitted)
•
Braverman ER, Han D., Oscar-Berman M, Loehmann R, Dushaj D, Damle U, Blum K.
Multi-Hormonal Bio-identical Replacement Therapy Map (MHRT) in Menopause:
Significant Associations as a Function of Somatic and Neurological Symptom Clusters PLos
One ( to be submitted)
•
Braverman ER, Chen TJH, Waite Rl, Bowirrat A,Allen C, Yelandi S, Damle U, Madigan M,
Giordano J, Downs BW, Dinubile N, Polamo T, Archer T, Blum K. Neuroquantum Theories
of Psychiatric Genetics: Can Weak Forces Induce Epigentic Influence on Future Genomes.
Journal of Neuroquantology ( in process )
•
Yarnell S, Oscar-Berman M, Avena NM, Gold MS. Pharmacotherapies for Overeating &
Obesity. J Genet Syndr Gene Ther 4: 131. Dol 104172/157-7412.1000131
•
Kushner S, Han D, Oscar-Berman, B.W Downs, Madigan MA, Giordano J, Barh D,
Simpatico T, Braverman ER, Loehmann R, K Dushaj , Schoenthaler S. Jones S, Blum K.
Declinol a complex containing Kudzu, Bitter Herbs (Gentian, Tangerine Peel) and
Bupleurum, significantly reduced Alcohol Use Disorder (AUD) Scores in moderate to heavy
drinkers: A pilot study. Journal Addict Res Ther (to be submitted).
•
Schoenthaler S, Giordano J, B W Downs, Blum K. Hypothesizing neurochemical
mechanisms of nutrient induced positive brain function and attenuation of aberrant behaviors.
Med Hyp (in preparation)
•
Blum K, Han D, Oscar-Berman M, Reinl G, DiNubile,N, Madigan MA, Bajaj A, Dows BW,
Giordano J, Westcott W, Smith L, Braverman Er, Dushaj, Loehmann R, Hauser M, Simpatico
T, McLaughlin T, Beley t, Borsten J, Barh D. Iatrogenic Opioid Dependence is Endemic and
Legal: Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy as a new
paradigm shift in pain relief programs. Omics –Pain & Relief.
•
Blum K, Braverman E., Wood R., Sheridan P., Comings D., “DRD2 A1 Allele and P300
Abnormalities in Obesity.” American Society of Human Genetics, Montreal Canada, October
18, 1994.
•
Braverman, ER, Miller, D.S., Holland, R., Johnson, D., and Blum, K. “Myers-Briggs type
indicator relationships with the Millon Clinical Multiaxial Inventory Version II, ” presented
at the 149th Annual Meeting of the American Psychiatric Association, May 7, 1996, NY.
Abstract # NR, pp 145, 1996.
•
Braverman E., Blum K., “Comorbid Psychiatric Disorders In a Holistic Health Clinic,” APA
Meeting, May 7-8, 1996.
•
Braverman E, Stone-Miller D., Blum K., “Myers-Briggs Type Indicator Relationships with
the Millon Clinical Multiaxial Inventory Version II,” APA Meeting, May 7-8, 1996.
•
Braverman E, Blum K. “Comorbid Disorders in an Obese Population,” APA Meeting, May
7-8, 1996.
•
Braverman E and Blum K., “Amino Acids in Clinical Medicine and Neuropsychiatry,”
APA Meeting, May 7-8, 1996.
•
Blum K., Schnautz N., Braverman E, Matthews D., Fischer L., Williamson B., Eisenberg A.,
Sherman J., Cull J., Seals J., Wood R., Chen TH, Walsh W., Comings D. “Association
Studies of Polymorphism of the Dopamine D2 Receptor (DRD2), Dopamine Transporter
(DAT1), and the Dopamine Hydroxylase (DxH) Genes with Impulsive-Aggressive-Violent
and Schizoid/Avoidant Behaviors in Adolescent and Adult Probands,” APA Meeting, May 78, 1996.
•
Blum K, Kaats G, Davis K, Eisenberg M, Sherman M, Cull J, Woods R, Bucci L, Chen THJ,
Braverman E. “Chromium Picolinate Induces Changes in Body Composition as a Function
of TAQ 1 Dopamine D2 Receptor A2 Alleles,” American College of Nutrition, October
1998.
•
Braverman E., Blum K., Lubar J., Comings D.E., “Genetic Dopaminergic Clinical Correlates
to Schizoid/Avoidant Personality, ADHD Probands, Pathological Violence, P500 Event
Related Potential and TOVA Attention Test,” Molecular Psychiatry, February 2001.
•
Blum K., Braverman E., “Reward Deficiency Syndrome: an emerging concept,” Molecular
Psychiatry, February 2001.
•
Braverman E.,Blum K, Smith D., “A medical model for ‘Reward Deficiency Syndrome’:
clinical significance of genetic dopamine deficiencies,” Molecular Psychiatry, February 2001.
•
Braverman, E. & Blum, K., “P300 and Wechsler Memory Scores on an Aging Large
Population of Patients,” Clinical EEG, September 11, 2002.
•
Braverman, E & Blum K. “P300 Latency (An Established Marker of Brain Processing
Speed) Correlates with Sex Hormones and Insulin Growth Factors (IGF-1 and 3)” The
abstract has been accepted for Poster Presentation at ENDO 2005, The Endocrine Society’s
87th Annual Meeting, June 4 – 7 in San Diego, California
•
Braverman, E & Blum, K. “P300 (Latency) Event-Related Potential: An Accurate Predictor
of Memory Impairment: Hormonal Correlates,” Accepted into Alzheimer’s Conference on
Prevention of Dementia for June 18-21, 2005 in Washington, DC; Published Alzheimer’s &
Dementia, Vol 1, issue 1, Suppl 1, July 2005.
•
Braverman, E. and Blum, K., American Academy of Anti-Aging Medicine, 10th International
Conference, December 2002. Poster Session: Adult Growth Hormone Deficiency: A Higher
Compliance Delivery System.
•
Smith Tl, Blum K, Waite RL, Heaney WL, Callahan M. The musculoskeletal and
hemodynamic mechanisms for therapeutic actions of H-wave muscle stimulation. Abstract
presented at 66th Combined Meeting of the Orthopedic Research Societies. October 21, 2007.
Honolulu Hi. Abstract 83.
•
Blum k, Meshkin, B, Prihoda TJ, Downs BW., Waite RL, Braverman ER, White L. DNA –
customized Genotrim induces significant reduction in weight, appetite and sugar cravings in
D.I.E.T. study: Polymorphic correlates involving five candidatr genes in Obesity, a clinical
subtype of Reward Deficiency Syndrome (RDS). Presented at the Natural Products
Association Scientific Session ( Bronze Medal Winner) 2007, July21, Las Vegas , NV
(poster).
•
K. Blum, L. Williams B., R.L. Waite, T. Huntington, L. White, T. Prihoda, E. Braverman.
First Report of Genotrim® to significantly reduce Body Mass Index ( BMI) as a function of
five candidate (DRD2, MTHFR, 5-HT2a, PPAR-Gamma -2, OB) gene polymorphisms
American Dietetic Association, Meeting, 2008.
•
Kenneth Blum, Eric Stice, B. William Downs, B.Sc., Roger L. Waite, Eric R. Braverman,
Mallory Kerner, and Marlene Oscar-Berman” Dopamine Resistance” in Brain Reward
Circuitry as a Function of DRD 2gene Polymorphisms in Reward Deficiency
syndrome(RDS): Synaptamine Complex Variant Induced “Dopamine Sensitivity” and
Enhancement of Happiness. XV11 World Congress, San Diego, California.. November,2009.
•
Kenneth Blum and B. W. Downs ” Dopamine Resistance” in Brain Reward Circuitry as a
Function of DRD 2gene Polymorphisms in Reward Deficiency syndrome(RDS):
Synaptamine Complex Variant Induced “Dopamine Sensitivity” Symposia American
College of Neuropsychopharmacology. Part of an invited Symposia. Hollywood , Florida
December 2009. .
•
ER Braverman, K Blum, M Kerner, R Kennedy, M Dispensa, S Kern, T Prihoda Low
Normal IGF-1-Levels in Patients with Chronic Medical Disorders (CMD) Is Independent of
Anterior Pituitary Deficiencies of LH, FSH and TSH: Implications for Treating CMD Using
IGF-1 as a Diagnostic Marker. POSTER SESSION: BASIC/TRANSLATIONAL - Insulin
Like Growth Factors & IGF Binding Proteins. Endocrine Society Meeting, June 12, 2009.
PS-136.
•
Blum K, Oscar-Berman M, Gardner E, Simpatico T, Gold MS. Neurogenetics and
Neurobiology of Dopamine in Anhedonia. Chapter in Anhedonia Book, (ed M.Ristner)
Frontiers of Neuroscience , 3013
•
Blum K, Olive MF, Wang KW, Macelo F, Borsten J, Giordano J, Hauser M, Gold MS.
Hypothesizing that designer drugs containing Cathinones (“Bath Salts”) have profound
neuro-inflammatory effects and dangerous neurotoxic response following human
consumption. Med Hyp (in press)
•
Blum K , Han D, Madigan M, Loehmann R, Dushaj K, Braverman ER.“Cold” X5 Hairlaser™
used to treat male androgenic alopecia: Preliminary report trends significant hair
growth.BMC-Research Notes ( in review)
•
Blum K, Han D, Femino J, Smith DE, Saunders S, Simpatico T, Oscar-Berman M.
Psychoactive Drug Misuse and Non-Compliance to Prescribed Treatment Medications in
Chemical Dependence Programs: Evidence from the Comprehensive Analysis of Reported
Drugs (CARD. PLOSONE (to be submitted)
•
Hill, E, Han D, Dumouchel P, Dehak N, Quatieri T, Moehs C, Oscar-Berman M, Giordano J,
Simpatico T, Blum K. Long Term Suboxone? Emotional Reactivity As Measured by
Automatic Detection in Speech.PLOSONE (Revision submitted)
•
Blum K, Femino J, Teitlebaum S, Giordano J, Oscar-Berman M. Molecular Neurobiology of
Addiction recovery : 12 step program & Fellowship. SpringerNeuroscienceBrief ( May
publication) 2013.
Others at various stages
Legal Expertise
Expert Witness- Dr. Blum has served as an expert witness in the fields of pharmacology and drug
and alcohol intoxication matters on Texas and a number of other domiciles ( New York, Denver,
Chicago, Las Vegas, Las Angeles) in both State and Federal courts for both the prosecution and
defense having a very high success rate.
INVITATIONS TO INTERNATIONAL SYMPOSIA: (A sampling)
1976
Seminar presented to faculty of Pharmacology, University of
Western Ontario Ontario, London, Canada.
June, 1978
Paper presentation, Fourth Biennial Symposium on Biomedical Research
on Alcoholism Zurich, Switzerland.
June, 1979
Invited Communication, International Conference Animal Models in
Alcohol Research Helsinki, Finland.
Sept, 1979
Keynote Speaker, International Congress on Neurotoxicology, Alcohol
Session Pavia, Italy.
1980
Guest Lecturer, Department of Psychiatry, University of Madrid,
Madrid, Spain.
1980
Special Scientific Presenter, FIDIA Research Laboratories,
Alano, Terne, Italy.
1980
Paper presentation, Fifth Biennial Symposium on Biomedical
Research on Alcoholism Cardiff, Wales.
Nov, 1980
Introductory lecture, Italian Ministry of Health, Traffic Medicine
Symposium (sponsored by the World Health Organization), Catholic
University Rome, Italy.
Nov, 1980
Special press conference with National Association of Italian Scientific
Journalists (sponsored by the Italian Association for the Fight Against
the Distribution of Dangerous Drugs) - Milano, Italy.
Jan, 1983
World
Psychiatric
Association
International
Symposium,
"Psychobiology of Alcoholism," Lecture on Central Nervous System
Peptides Los Angeles, CA.
Aug, 1984
Scientific Leader, "Addictions," U.S. Professional Seminars
(Russia).
Sept, 1985
Invited symposia participant, Fourth World Congress on Biological
Psychiatry Philadelphia, PA.
Mar., 1986
Scientific Leader, "Biological Psychiatry and Addictive Behavior."
China Association on Science and Technology Peoples Republic of
China.
May, 1987
Invited Main Lecture
Turino, Italy.
Aug, 1988
Major
Symposium
Speaker
Collegium
Internationale
Neuropsychopharma-cologium XVIth Congress
München, Federal
Republic of Germany.
Mar, 1989
Plenary Speaker
Moscow, Russia.
May 1990
Keynote speaker, International Addictions Conference, Oxnard, Canada.
June, 1990
Invited speaker, 4th Congress of Fachverband Such E.V., Heidelberg,
Germany.
June, 1990
Invited Symposium Cochairman and Speaker Fifth World Congress on
International Conference on
USSR
Neurotoxicology
First SovietAmerican Conference on Alcoholism
Biological Psychiatry, Florence, Italy.
June, 1992
Major Symposium Speaker C.I.N.P. XVII Nice, France.
July, 1992
Invited Speaker Alcohol Conference Rome, Italy.
May, 1993
Invited Speaker Menniger Clinic.
June, 1993
9th World Congress of Psychiatry. Plenary Lecture: Molecular Genetics
of Compulsive Disease Rio de Janeiro.
December 2009 American College of Neuropsycopharmacolgy Meeting, Hollywood,
Florida ,
December 2009
January 21 2010Psychiatry Grand Rounds , University of Vermont College of
Medicine , Burlington Vermont
February 2013- Keynote Conference on Behavioral Addictions , Hungry, Budapest.
Many others
FUNDING AND SUPPORT:
RESEARCH:
National
"Consequences of Methadone Maintenance During Gestation", Principal Investigator: K.
Blum, NIMH, Drug Abuse Study Sect., June, 1973 May, 1974, $5,000
Career Teacher Award in Drug Addiction, A.H. Briggs, M.D., Chairman, Department of
Pharmacology, UTHSCSA, accepted on Dr. Blum's behalf.
NIDA, July, 1974 June, 1977, $139,239, Alcohol Opiate Grant, Principal Investigator:
K. Blum
NIDA, Approved, 1977, but not funded, $5,000, "Blood Withdrawal Transfer Studies",
Principal Investigator: K. Blum
NIAAA Grant, 1979 1980, $6,000, "Biochemistry and Pharmacology of Cocaine",
CoPrincipal Investigator: J.E. Wallace, Ph.D., Pathology, UTHSCSA
PNIMN, Drug Abuse Study Sect., June, 1973 May, 1975, $80,000, Renewal, 1976,
"Analysis of Polyaromatic Psychosedative Drugs in Serum", CoPrincipal Investigator:
J.E. Wallace, Ph.D., Pathology, UTHSCSA
NIMH, NIGMS, January, 1975
December, 1978, $190,000, "Marijuana and
Reproduction in the Female", CoPrincipal Investigator:
Carol Smith, Ph.D.,
Pharmacology, UTHSCSA
NIDA, 1976 1978, $45,043 ($135,129), "Psychogenetics of Drug Seeking Behavior",
Principal Investigator: K. Blum
NIAAA, Submitted Nov. 1, 1981, $141,206, Approved not funded
State
Texas Commission on Alcoholism, Principal Investigator: K. Blum, 1980, $7,600
University
"Experimental Analysis of Ethanol Dependence in Rodents", Principal Investigator: K.
Blum, December, 1971 November, 1972, $2,000
"The Role of the Pineal Gland in Alcoholism", Principal Investigator:
November, 1972 August, 1973, $2,000
K. Blum,
"Biogenic Amines and Experimental Alcoholism", Principal Investigator: K. Blum, May,
1974 February, 1975, $1,900
Other
"Psychopharmacological Evaluation of Tetrahydrocannabinol: Biochemical Correlation
of Behavior", Pharmaceutical Manufacturers Assoc., Starter Grant, December, 1972
November, 1973, $5,000
"Help Communities Help Themselves." National Regional Drug Abuse Resource Center,
Southwest, United States Office of Education, Cowritten by Dr. K. Blum, Trinity
University, 1973, $345,000
"Skills Training Improvement Program" Subcontract to Job Power Now, Young Adult
Career Training Program. Cowritten by Dr. K. Blum, United States Dept. Labor, 1978,
$110,000
"Psychogenetics of AlcoholSeeking Behavior", Raleigh Hills Foundation, 1982, $3,000
"Searching for the Hibernation Factor", Southwest Research Institute, 1983, $25,000
"Morphological Identification of Steroid Receptors in Breast Cancer" Investigators: P.J.
Sheridan, K. Blum, W. Hall, Southwest Research Institute, September 1, 1985 August
30, 1987, First year, $87,118. Total $167,531
"Molecular Genetics of Alcoholism" Investigators: K. Blum and P.J. Sheridan, Seaver
Institute, July 1, 1988 June 30, 1990, $180,000
"Molecular Genetics of Alcoholism" Investigators: K. Blum, and P.J. Sheridan, Wacker
Foundation, June 30, 1989 Aug 1990, $15,000
"Effect of Soluble Fiber Supplement on Cholesterol Levels" Investigators: K. Blum and
G. Kaats, Nanci Corporation, February 1, 1991 December 30, 1991, $27,126
"Molecular Genetics of Compulsive Disease" Investigator: K. Blum, NeuroGenesis Inc.,
January 1, 1984 present, $10,000 annually
"Alcogene Test" Investigators: K. Blum and P.J. Sheridan, Pharmavene, Inc., June 30,
1991, $30,000
Seaver Foundation $500,000 Finding a genetic link to Alcoholism- 1987-1991.
Life Extension Grant Funded $29,000 to Path Research Foundation on Hormones and
Menopause (May 2009).
Patents Awarded, Pending
Us patents issued include 6,132724, 6,9558873 and others. European patents include
EP0979092
and
others.
Patents
pending
include
RDS
patentsUS11/250,355;US61/154,501, two Pain patent applications (provisional) #’s
61074629, 61074630 and US patent issued H-Wave device. The total number of patents
in the US and abroad amount to north of 20.
BIO
In 1995 Dr. Blum retired from the University of Texas Health Science Center giving up tenure to
enter the world of business and biotechnology. In the second year, acting as manager of 1899
Limited Liability Corporation, his first weight management product grossed in excess of 60
million retail. His company Cyberpharm has launched a weight loss system with
Rexall/Showcase which was launched early 1999. Dr. Blum continues to publish research articles,
writes books (twelve), lectures, and is actively applying for numerous patents in the field of
molecular genetics & nutrition. Dr. Blum is very active as Scientific Director of the Path Medical
Foundation and former co-founder and Vice President of the American College of Addictionology
and Compulsive Disorders. Dr. Blum is co-founder and Chairman& CSO of LifeGen. His
concept of Reward Deficiency Syndrome is being embraced by world leaders in science and the
DRD2 gene discovery has been confirmed in over 3,000 publications from laboratories all over
the world. He serves as Editor –in-Chief Omics Journal of Genetic Syndromes &Gene Therapy
and is currently serving on twelve other prestigious journal’s editorial Boards. Currently he has
been named Volunteer Full Professor of the Department of Psychiatry & McKnight Brain
Institute University of Florida College of Medicine, Gainesville, Florida and Adjunct Research
Professor, Global Integrated Services Unit University of Vermont Center for Clinical &
Translational Science, College of Medicine, Burlington, VT. He currently serves as neuroscience
advisor for Dominion Diagnostics, LLC North Kingstown Rhode Island; G &G Holistic
Addiction Treatment center, North Miami Beach Florida and Malibu Beach Recovery Center,
Malibu Beach, California. Many consider him as the “Father of Psychiatric Genetics” and “Father
of Neuro Nutrient Therapy”. Dr. Blum received the Life Time Achievement Award from the
National Institute of Holistic Addiction Studies 2011, the Scientific Achievement Award in a
Gala Celebrity Event, Miami Beach Florida and Best Abstract Award from the American
Society of Anesthesiology and Pain. He and Mark Gold recently signed with Springer as Series
editor for Neuroscience of Addiction: A Reference Work which includes four volumes to be
published in 2015. Dr. Blum has been notified by Research Gate that is Reputation Score is
higher than 97.5% of all scientists in the network to date scoring 39.58 out 40. He has also
accepted a distinguished appointment of Scientific Advisory Board of NVP's newly formed and
funded portfolio company.
LUMINEC CORPORATION
Steven Hanna, Esq.
Director and Corporate Attorney
Steven Michael Hanna, Esq.
Orange County, California
Phone: (714) 323 - 9031  E-Mail: [email protected]
Education
Seoul Foreign School, Korea. 1966 – 1969.
California State University Northridge, California. Graduated 1974. B.S. Business Administration.
University of West Los Angeles School of Law, California. Graduated 1980. Juris Doctorate.
Orange County Bar Association College of Trial Advocacy (Civil), Certificate of Completion 1993
Professional Experience
1985 - Present.
Patterson, Hanna & Associates, LLP. Southern California.
Co-Founder and Managing Partner; Attorney at Law.
Aside from managing partner’s responsibilities of eight man law firm and
supporting staff, serves as head of firm's General Litigation and Personal Injury
Departments, and litigates cases to conclusion before judge and jury in a broad
spectrum of matters including personal injury cases (representing primarily
plaintiffs), business and contract disputes, probate matters, partnership disputes,
corporation disputes, professional liability claims, and real estate disputes. In
addition, represents clients in private arbitration, mediation, and other alternative
dispute resolution forums.
In addition to the aforementioned, heads firm's Business and Transactional Law
Department. Applies a background in the banking and insurance industries in
addition to practical experience in real estate acquisitions, financing and
development. This experience has been invaluable working with a wide range of
clientele in both business and real estate transactions.
1982 – 1985.
Sole Practitioner, Southern California. Attorney at Law.
Began a general private legal practice in both business transactional work, as
well as civil litigation. Further, developed areas of expertise in probate, trusts, and
associated dispute and litigation issues.
1980 – 1982.
Christian Law Center, Southern California. Attorney at Law.
Associate Attorney.
Principle duties handling general business and civil litigation, family law and
probate matters. Also, responsible for general office management.
1978 – 1980. Pacific Reinsurance Company/Buffalo Reinsurance Company, Los Angeles, California.
Treaty Underwriter.
Underwrote insurance companies books of business in the areas of property and
casualty, primarily US domiciled insurance companies.
Steven Michael Hanna
Page 2
1976 – 1978.
Con Surfboards. Santa Monica, California.
Retail Manager.
Managed and operated the retail store. Responsible for all aspects of retail sales
inclusive of management supervision of employees. Also handled business
development, marketing and public relations.
1975 – 1976.
New City Bank of Beverly Hills, California.
Loan Officer.
General banking and lending responsibilities.
1973 – 1975.
Security Pacific National Bank, Los Angeles, California.
Operations Manager.
Managed more than 25 employees, both tellers and other bank support staff.
Supervised the operational functions at the branch level of the Bank.
Real Estate Development Experience
2005 – 2011.
H & S Coastal Development LLC, Founder/Manager.
Property acquisition, management, entitlements, development, marketing,
financing and sales. Managed three properties, developed one to completion and sale.
2005-2010
North Pacific LLC. President and Project Manager.
Property acquisition, management, entitlements, development, marketing,
financing and sale of 16382 and 19386 North Pacific Avenue, Sunset Beach, CA,
90742. Each unit sold for $1,900,000.
1985-Present
Various Personal Real Estate Projects.
• Acquired, entitled, and sold real property developed for four custom
condominiums located at 8th Street, Sunset Beach, CA, 90742. (2001-2005)
• Acquired property, developed and sold a more than 5,600 square foot custom
single family residence in the gated community of Oak Tree Downs on Village
Drive, Chino Hills, CA, 90710. (1989-1999)
• Acquired, restored and sold vintage 1927 property located on West Brookdale
Place, Fullerton, CA, 92832. (1999-2010)
• Acquired, restored and currently manage vintage 1925 beach cottage located in
the gated community of Surfside Colony, CA, 90743. (2004-present)
• Acquired, restored and sold vintage mid-1920’s property located on North Ross
Street, Santa Ana, CA, 92706. (1985-1989)
• Acquired, restored and currently manage vintage 1920’s 4-plex located on 15th
Street, Sunset Beach, CA, 90742. (2005-present)
• Acquired, restored and currently manage historic civil war home built in 1865.
Located in New Bremen, Ohio. (1999-present)
Steven Michael Hanna
Page 3
Affiliations/Memberships
• California State Bar Association
1980 - Present
• Orange County Bar Association
• State Courts of California
1980 - Present
1980 - Present
• The United States of America Central District of California
1980 - Present
• Fullerton Chamber of Commerce
• United States Tax Court
1985 - Present
1998 - Present
• Association of Trial Lawyers of America
2000 - Present
• Directorship in Luminec Corporation
Experience
•
•
•
•
•
•
•
•
•
•
•
Litigation experience: Business/Civil/Tort/Real Property/Trusts/Estates
Fraud Investigations: Corporate/Real Property/Civil
Mergers/Acquisitions/Sales
Formation of businesses/Corporate Council
Banking operations/lending
Insurance underwriting/risk assessment
Land and Construction Financing
Construction and Land Defects
Land Entitlements/Zoning
Mediation/Alternative Dispute Resolution
Trusts and Estates (Asset Protection)
Interests and Activities
• Competitive drive and dedication to accomplishing goals extends to personal activities, such as golf,
surfing, skiing, hiking, boating, camping and other family activities.
• Happily married for more than 25 years. Blessed with a son, two daughters and two grandsons.
• Active member of Hacienda Golf Club, La Habra Heights, California.
• Lived in Seoul, Korea from 1966 to 1969. Attended high school and travelled with and shared in my
father’s medical ministry.
• Involved in Boy Scouts of America and other various organized sports organizations, both as a coach
and director.
LUMINEC CORPORATION
Daniel C. Masters, Esquire
Director
Finance and Corporate Securities
LUMINEC CORPORATION
Thomas J. Kenan, Esquire
Founder
LUMINEC CORPORATION
Dr. Robert Weinacker
Director, Business Development and Health Care - Military
LUMINEC CORPORATION
Thomas E. Beatrous, M.D.
Founder, Director Scientific Development Human Health Care
LUMINEC CORPORATION
William LoBell
Executive VP Sales and Development
U.S. and International
LUMINEC CORPORATION
Preston Brawn
COO Amnion Bio Technologies Corporation
Director International Product and Development
LUMINEC CORPORATION
Bruno Buckner
CEO Luminec Dante Group. Ltd.
LUMINEC CORPORATION
Gary N. Sater
Chief Financial Officer
LUMINEC CORPORATION
Albrecht W. Meyer
Founder, Director International Banking (Germany)
LUMINEC CORPORATION
Frank Zhang, Esq.
Founder, Director Product Distribution – all of Asia
Senior Partner Longan Law Firm, Beijing, China
LUMINEC CORPORATION
Denis Schinck
Founder, Director International Development
and Advisor Formulations
LUMINEC CORPORATION
Lord Michael Sandberg, CBE, OBE
Founder, International Advisor World Banking
LUMINEC CORPORATION
Lord Michael Sandberg, Jr.
Sandberg Family Directorship
TIMOTHY J. VIANCOURT
4014 Fox Meadow Drive, Medina, Ohio 44256
(330) 416-2459 (cell)
[email protected]
SUMMARY OF QUALIFICATIONS
Dynamic senior sales executive with a successful 25+ year history of sales and sales management in CPG
industry. Exceeds expectations through a high energy/high impact management style. Creates multifunctional teamwork, ongoing organizational development and consistent execution. Uninterrupted sales
growth with emphasis on customer development via account penetration, training and effective selling
techniques. A passionate leader able to coach, mentor, focus and inspire direct and indirect sales teams
with an entrepreneurial spirit.
US and International Sales Management
Direct Sales Force Effectiveness Planning
Promotional Program & Budget Development
Trade Marketing Development
Integration & Restructuring of Acquisitions
Business Development/Growth Strategies
Key Account Development in Consolidating Industry
Contract Negotiation/Strategic Partnerships
PROFESSIONAL EXPERIENCE
OurPet’s Company
2011-Present
OurPet’s (OPCO) founded in 1995 by current CEO Dr. Steve Tsengas focusing on the development of
propriety differentiated hard good pet products. OPCO is driven by innovative product development in
three key strategic dog and cat categories; 1) Feeding Solutions 2) Interactive Toys 3) Waste
Management
Vice President of Global Sales
2013-Present
Direct report to Founder & CEO: Responsible, for all sales functions globally across all channels of distribution
(Food, Drug, Mass, Pet Specialty, Club Stores, Military, E-Commerce, Home Shopping Network). Organization
consists of Direct Sales Force of four National Account Managers, International Sales Manager, Customer Service
Representative, National Broker Network and Independent Manufacturers Representatives across all channels
• Develop, manage and direct all sales personnel, sales plans, P&L and forecasting
• As a officer in the company, responsible for working with executive management team to develop and
execute the 5 year plan and annual strategy
• Play a key role in developing and launching our brand strategy by channel
• Work closely with product development and marketing to ensure we have a pipe line of new products to
launch annually
• Responsible for developing and maintaining top to top customer relationships across all channels with our
top 10 customers
OurPet’s Company Continued
National Sales Manager
2011- 2013
Direct report to President/COO: Develop, manage and direct the pet specialty sales organization consisting of
Regional Sales Managers, Customer Service Representative, National Broker Network and Independent
Manufacturers Representatives.
• Achieved double digit growth in 2011 and 2012 by creating buy-in at all levels of our key customers.
Established and executed fully integrated programs, including new products both custom branded & private
label, including promotional plans creating differentiation. Drove sales growth with key distributors, key
national accounts and regional chain retailers such as PetSmart, Petco, Pet Supermarket, Pet Supply Plus,
Pet Food Express, Pet People Phillips Feed, Central Garden & Pet, Bradley Caldwell Inc., Animal Supply
Company, Spartan, Wakefern, Wegmans, and Fred Meyer.
• As part of the management team drove the development and execution of the corporate channel strategy
creating differentiation between grocery, drug, mass, and pet specialty.
• Manage and directed trade development programs with national accounts, regional chains and distributors.
• Established process//hiring criteria for direct regional sales managers & a national broker network.
Fire-Dex, LLC.
2010 – 2011
Fire-Dex is a 28 year old privately held company and one of the largest producers and suppliers of PPE
apparel for the fire service market in North America.
Director of Sales Domestic and International, Medina, OH
Direct report to President/CEO. Key member of the senior management team. Responsible for driving the strategic
sales direction of the total sales organization. Manage and direct domestic/international sales team consisting of a
National Product Specialist, seven RSM’s, three customer service representatives and a network of over 300
distributor partners.
! Consistently exceed sales plans driving sales growth +28% YTD in a category where the top competitors are
down over 30%.
! Realigned sales organization adding a new region resulting in over 53% growth in the respective markets.
! Instituted new bonus program that resulted in 71% of the sales team exceeding plan and achieving double digit
revenue growth.
! As part of the senior management team, responsibilities encompass participating in the development of the
corporate annual operating and three year strategic plan. These include: new product introductions, new
market rollouts, international growth & development, and strategic market planning/implementation.
Responsible for relationship development at all levels with new key accounts including Greater New York Hospital
Association, Grainger Industrial Supply, top 25 distributors and key metro accounts.
Bil-Jac Foods (Kelly Food Corporation)
1996 –2010
Family owned/operated privately held super premium dry and frozen pet food/treat manufacturer for 63 years.
Bil-Jac Foods Vice President of Sales - USA/Canada, Medina, OH
2006 – 2010
Direct report to ownership. Managed and directed the pet specialty sales organization consisting of a National Sales
Manager, National Accounts Manager, and two Regional Sales managers, 25 Field Sales Managers, National Demo
Team and National Broker/Merchandising Team.
• Tripled size of pet specialty business in highly competitive dog food and dog treat market.
• Instituted key account development plans/strategies (PetSmart, Petco, Pet Supplies Plus, Regional Chains
and Independent/Pet Food Distributors) resulting in ongoing double-digit growth.
• Responsible for relationship development at all levels with key specialty accounts at leading Pet Specialty
accounts that represent 75% of the industry’s premium specialty food sales resulting in:
•
•
" PetSmart growth of nearly 5 times during my tenure
" Petco growth of nearly 10 times during my tenure.
Helped drive strategic direction of company as part of senior management team including new products,
new packaging, grass roots marketing, direct to consumer marketing and breeder development.
" Launched 9 new food products now accounting for 39% of brand sales,
" Launched 6 new treat products now accounting for 45% of brand sales.
Pioneered Broker/Merchandising Training Program resulting in:
" 98% of PetSmart and Petco stores being merchandised a minimum of once per month leading to
consistent 97% in stock rate at store level.
" Reduced out of stocks by 5% resulting in incremental sales and minimizing brand defection.
" Reduced outdated product 2% resulting in significant savings on returns and salesman time.
Bil-Jac Foods National Sales Manager - USA/Canada, Medina, OH
1996 – 2006
Direct report to ownership. Responsible for driving pet specialty growth through a player coach approach with key
customers along with managing, mentoring, motivating and developing the sales organization. Created and initiated
sales process/procedures including hiring standards, performance evaluation, and planning process, budgeting and
designing of bonus programs.
•
•
•
•
•
To meet company objectives, completed national launch of Bil-Jac products in key pet specialty retailers,
PetSmart and Petco, resulting in company’s move from regional to national brand.
Directed Demo Sales Team initiative. Increased weekly in store product demos from 25% to over 50% of
stores in 6 months. This resulted in increased rate of sales up to 10 times in demo stores vs. non demo
stores. This program was a key driver in overall double-digit sales increase.
Instituted DVD and script training for Field Sales Managers and Demo Team for all programs.
Recruited and negotiated contract for national broker/merchandise team creating a hybrid sales
organization consisting of a national broker/direct sales force. This resulted in reducing field sales
overhead by 50%, while increasing account penetration and supporting double- digit sales growth.
Developed seminar training program for Field Sales Managers resulting in all major retailers’ participation
with in-store seminars supporting word of mouth grass roots marketing strategy.
The J.M. Smucker Co.
1980 – 1996
$3.8 billion leading manufacturer of fruit spreads, frozen pies, ice cream toppings, beverages, natural peanut butter
and other food products.
Mrs. Smith’s Bakeries Inc. – A Division of JM Smucker Co/Flowers Industries
$150 million leading manufacturer in frozen pie category, founded in 1920’s.
VP Sales-National Sales Manager, Pottstown, PA
1993 –1996
Reported directly to the President of the company. Directed multi chain-channel team of two regional and ten sales
managers,
In- Store Bakery/Military Manager, and national network of food brokers. Responsible for $150 Million in gross
sales.
• Developed strategic relationships for fall seasonal planning events with key accounts including Walmart,
Safeway, Kroger, Publix, Wegmans, Wakefern, A&P and Albertsons resulting in Mrs. Smith’s achieving
number 1 top featured fall season brand and a 14% increase in sales.
• Introduced 11 new products in 18 months resulting in achieving an average ACV of over 60 %.
• Performed key role in transforming company strategic planning process and merging dual corporate
cultures.
• Successfully implemented cross-functional go-to-market strategy, achieving an integrated approach to
business building, and increased profitability.
• Led industry by creating a marketing paradigm shift for the critical Fall season pumpkin pie business by
increasing the retail price point from $1.99 to 2/ $5.00 resulting in market share growth from 47% to over
50%.
• Implemented a sales leadership program and transformed sales accounting/reporting analysis from general
marketing funds to customer specific funds, driving internal accountability for spending vs. results.
The J.M. Smucker Co. – Consumer Group Division
Eastern Regional Sales Manager, Orrville, OH
1986– 1993
Directed Broker and District Sales Managers. Recruited, trained and coached District Sales Managers and direct
sales force. Received Company’s “Big Apple” achievement award for excellence.
• Led the Firm’s largest region broker managers/direct sales force ($75m).
• Attained target goals in seven of eight years resulting in ongoing increased market share.
• Responsible for implementing all sales training programs including negotiation and effective selling
techniques.
Southern California District Sales Manager, Los Angeles, CA
1985 – 1986
Achieved 110% of plan ($18M) and managed Key Accounts & company’s largest broker resulting in turnaround of
declining market in one year.
Southwest District Sales Manager, Dallas, TX
1982 – 1985
Exceeded 100% of sales target yearly ($14 Million). Managed Key Accounts/multiple broker networks.
Ohio Direct Sales Supervisor/Key Account Manager, Orrville, OH
1981 – 1982
Ohio Direct Sales Representative, Orrville, OH
1980 – 1981
TIMOTHY J. VIANCOURT
4014 Fox Meadow Drive, Medina, Ohio 44256
(330) 416-2459 (cell)
[email protected]
EDUCATION AND TRAINING
Bachelor of Arts, Cleveland State University
Graduate of Cornell Food Executive Program
Kepner Tregoe Problem Solving &
Decision Making Process
Neo Development Trade Negotiations Course
PERSONAL/INTERESTS
Married 28 years, two children
Active outdoorsman: Golf, skiing, sporting events
Volunteer: Medina Lacrosse, Youth football/ basketball coach
Operation Support Our Troops
References are available upon request.
LUMINEC CORPORATION
__________________________________________
Amnion Animal Sciences Corp. / Luminec Life Sciences Corp. / Bio Veritas Cosmetics Corp.
Luminec Life Sciences Health & Wellness Clinics / Amnion Animal Heath & Wellness Clinics
THE FUTURE OF HEALING
Tri-AminoTM and TAFA 4ooTM from the Luminec Corporation
Introducing a new era of health and wellness for
humans and animals around the world

luminec corporation - Luminec Life Sciences

Transcription

Similar documents

Book Launch: Reflections of Amma: Devotees in a Global Embrace

Northmont Today - Northmont City Schools

Hinge Replacement Instructions

Paranormal Press_September.pub

Special Announcement: Meetings will no longer be held at Tragara`s!!!

CLIP top BLUMOTION

METABOX with BLUMOTION

Make-Believe: Parafiction and Plausibility